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ABSTRACT  
 
BACKGROUND 
Streptococcus pneumoniae is a leading cause of severe invasive bacterial infections globally; 
estimated to cause over 300,000 deaths in children <5 years in 2015. Pneumococcal 
conjugate vaccine (PCV) introduction in South Africa has been associated with changes in 
invasive pneumococcal disease (IPD) risk groups and emerging serotypes. Serotype 1 
pneumococcal disease is highly invasive, fluctuates annually but tends to have lower 
mortality and antibiotic-resistance than other serotypes. Paediatric antiretroviral treatment 
(ART) and HIV prevention of mother-to-child transmission programme improvements in 
South Africa have resulted in a growing number of HIV-exposed-uninfected (HEU) children 
who have higher rates of infectious diseases than unexposed children. It is important to 
identify risk groups changes with new interventions and define IPD burden pre- and post-
PCV introduction in developing countries.  
 
OBJECTIVES  
In South Africa we aimed to estimate severe pneumococcal disease burden in the pre- (2005-
2008) and post-PCV era (2013) amongst HIV-infected (HI) and HIV-uninfected (HU) 
children <5 years of age; describe the epidemiology of serotype 1 IPD in all age groups from 
2003 to 2013; describe the epidemiology of IPD in HEU children <1 year of age  from 2009 
to 2013 and the risk factors related to IPD in HI and HU children post-PCV introduction 
(2010 to 2012). All analyses included PCV introduction impact. 
 
METHODS  
A model using national laboratory-based IPD surveillance data as the baseline was used to 
determine the total burden of severe hospitalised pneumococcal disease and related mortality 
in South Africa in children aged <5 years. Adjustments were made for specimen-taking 
practices and care seeking differences. Vaccine probe studies were used to calculate non-
bacteraemic pneumococcal pneumonia case numbers. Observed case fatality ratios were 
applied to estimated case numbers to determine pneumococcal death numbers.  
All patients with laboratory-confirmed IPD were included in the serotype 1 analysis. We 
calculated incidence rates, determined factors associated with serotype 1 disease and 
conducted a space-time analysis using SaTScan with a Bernoulli model for comparison. 
Maps to visualise serotype 1 clusters were generated using ArcGIS.   
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Surveillance data was used to compare IPD incidence and mortality in HEU, HIV-
unexposed-uninfected (HUU) and HI infants. Factors associated with HIV status were 
compared using a multinomial regression model and logistic regression for mortality factors.  
A matched case-control study nested within the surveillance programme was used to 
determine risk factors associated with IPD in HU and HI children aged <5 years. Data was 
analysed using conditional logistic regression.   
 
RESULTS 
In the pre-vaccine era (2005-2008) in South Africa, roughly 196,100 (148,000-251,000) cases 
of severe pneumococcal disease were estimated annually in children aged <5 years, an 
incidence of 3799/100,000; the rate was reduced by 67% in 2013, likely due to PCV and 
other interventions. In addition 8600 (7000-10220) pneumococcal-related annual deaths were 
estimated pre-vaccine and 3600 in 2013, a rate difference of 99/100,000 child-years.  
Over an 11-year period two clusters (2003-2004 and 2008-2012) of serotype 1 infection were 
detected in all age groups with reductions in incidence noted in 2013. Among children aged 
<5 years, those with serotype 1 IPD had shorter hospital stays, fewer penicillin-
nonsusceptible cases (adjusted odds ratio (aOR) 0.02, 95% confidence interval (CI) 0.01–
0.05), lower HIV prevalence (aOR 0.19, 95% CI 0.12–0.31) and lower in-hospital death rates 
(aOR 0.38, 95% CI 0.19–0.76) than children with non-serotype 1 IPD.   
The incidence of IPD was greatest in HI infants (272-654/100,000), then HEU infants (33-
88/100,000) and HUU infants (18-28/100,000). Young HEU infants (37% [59/175]) were 
more likely to die than HUU infants (32% [51/228]; adjusted relative risk ratio, 1.76, 95% CI 
1.09–2.85]). On case-control analysis a number of factors were shown to be associated with 
an increased risk of IPD in the post-PCV period. In HU children these factors included 
underlying medical conditions (aOR = 1.99, 95% CI 1.22–3.22), attending day care (aOR = 
1.58, 95% CI 1.01–2.47) or having been exposed to HIV perinatally (aOR = 1.62, 95% CI 
1.10–2.37), while PCV vaccination reduced the odds of IPD (aOR = 0.67, 95% CI 0.46–
0.99). Predisposing factors in HI children included malnutrition (aOR = 2.68, 95% CI 1.40–
5.14) and recent tuberculosis (aOR = 5.12, 95% CI 1.69–15.50), while current ART reduced 
the odds of IPD (aOR = 0.13, 95% CI 0.05–0.38). 
 
CONCLUSION 
Pneumococcal disease represents a major public health burden in young children in South 
Africa. PCV and other HIV-associated interventions resulted in a significant reduction in 
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both invasive disease and non-bacteraemic pneumonia. Serotype 1 IPD has distinctive 
clinical features with temporal decreases noted post-PCV13 introduction. With improvements 
in interventions to prevent and treat HIV, a resultant growing HEU infant population has 
been observed with an increased risk of IPD compared with HUU children. Risk factors 
related to socio-economic conditions and intense exposure to infection continues to be 
important causes of IPD in children. A full understanding of PCV impact on pneumococcal 
disease burden is needed to support ongoing national policy decisions on PCV use.  
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ABBREVIATIONS 
PCV: Pneumococcal conjugate vaccine  
IPD: invasive pneumococcal disease  
ART: antiretroviral treatment  
HIV: human immunodeficiency virus  
HEU: HIV-exposed-uninfected  
HI: HIV-infected  
HU: HIV-uninfected   
HUU: HIV-unexposed-uninfected  
CI: confidence interval  
VT-IPD: vaccine type invasive pneumococcal disease  
NPNM: non-pneumonia non-meningitis  
ARTI: acute respiratory tract infections   
CXR: chest radiograph  
PPSV23: 23-valent polysaccharide vaccine  
PCV7: 7-valent pneumococcal conjugate vaccine  
PCV10: 10-valent pneumococcal conjugate vaccine  
PCV13: 13-valent pneumococcal conjugate vaccine  
CSF: cerebrospinal fluid  
Hib: Haemophilus influenzae type b 
NVT-IPD: non-vaccine type invasive pneumococcal disease  
PMTCT: prevention of mother-to-child transmission 
PCV9: 9-valent pneumococcal conjugate vaccine  
VE: vaccine efficacy  
VT: vaccine type  
NVT: non-vaccine type  
EPI-SA: Expanded Programme on Immunisation in South Africa   
GERMS-SA: Group for Enteric, Respiratory and Meningeal Disease Surveillance in South 
Africa 
DALYs: disability-adjusted life years  
QALYs: quality-adjusted life years 
ST1: Serotype 1  
GIS: Geographic Information System   
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BACKGROUND 
 
INTRODUCTION 
 
Streptococcus pneumoniae has long been recognised as a significant disease-causing 
pathogen. It was first identified as pathogenic in 1881 when two microbiologists, Louis 
Pasteur and George Sternberg, each individually injected human saliva into rabbits and 
isolated this bacterium 1. As early as 1918 Sir William Osler referred to the pneumococcus as 
the “captain of the men of death” as it killed young adults in the “prime of their lives” 2. It 
was finally given its current name in 1974 3. 
S. pneumoniae is a small gram-positive diplococcus that affects children and adults 
worldwide. At least 93 different serotypes have been described. The pneumococcus causes 
severe disease such as bacterial pneumonia, meningitis and sepsis, but is also a common 
coloniser. Colonising rates can vary between different age groups and settings: 5-10% in 
adults and 10-50% in children in developing countries, but up to 86% in children in some 
African countries 4. Much of the virulence of S. pneumoniae originates from its 
polysaccharide capsule which can prevent phagocytosis 5. Despite a number of therapeutic 
strategies, such as antibiotics and vaccines, S. pneumoniae continues to kill individuals of all 
ages till the present day. It has been treated with antibacterial drugs since the late 1930s but 
widespread overuse of antibiotics in recent years has led to the creation of penicillin-resistant 
strains of S. pneumoniae. 
Studies from South Africa have shown an increased risk of invasive pneumococcal 
disease (IPD) in HIV-infected (HI) adults and children 6-11. Following the widespread 
introduction of antiretrovirals in 2004, a significant reduction in IPD was noted in children 12, 
but not in adults 13.  
 
BURDEN OF PNEUMOCOCCAL DISEASE 
 
In developing countries pneumonia is a serious disease in both adults and children. 
Pneumonia accounts for almost one in seven deaths in young children with nearly a million 
deaths annually, 50% of which are in sub-Saharan Africa according to the World Health 
Organization 14. In South Africa the incidence of severe pneumococcal disease in children <5 
years of age was estimated as having been approximately 3000 per 100,000 and the death rate 
as around 100 per 100,000 population in the year 2000 15.  
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Annual estimates for pneumonia in children <5 years of age in South Africa in 2010, 
derived from a Global Action Plan for Pneumonia and Diarrhoea model, were reported as 
705,554 cases for all acute respiratory tract infections (ARTI) and 33,436 new episodes of S. 
pneumoniae pneumonia; severe disease was a proportion of this, namely 78,749 cases for all 
severe ARTI and 10,052 severe new episodes of S. pneumoniae pneumonia 16. This 
manuscript reported country level estimates of the model. The estimates were modelled based 
on the prevalence of five main risk factors for childhood pneumonia obtained from country-
based demographic health or cluster surveys. A meta-analysis assessed the size of the risk 
factor effect on pneumonia incidence 16. The portion of pneumonia deaths attributable to S. 
pneumoniae was derived from the meta–analysis of pneumococcal conjugate vaccine (PCV) 
vaccine efficacy against chest radiograph (CXR) confirmed pneumonia 15; it was assumed 
that the etiologic fraction of S. pneumoniae (33%) among cases was similar to that among the 
deaths 15.  
Baseline data from a national pneumococcal surveillance programme pre-PCV 
introduction (2003-2008) demonstrated that IPD rates were 6-fold higher in the <1 year age 
group compared with children 1–4 years of age, and HI infants had a 21-fold greater risk of 
disease than HU infants <5 years of age 17. Even though PCV had lower efficacy amongst HI 
children 18,19, these children had a higher burden of IPD than HU children resulting in a 
projected 18-fold greater reduction in the absolute burden of IPD in HI compared to HU 
children if PCV were introduced 20,21.  
Bacteraemia is approximately four-fold more common in HI compared to HU children 
with pneumococcal pneumonia 20. Disease among HI children is more likely to be caused by 
vaccine serotypes than among HU children 22 and there is also an increased prevalence of 
paediatric serotypes in HI adults 6. Higher single drug 23 and multidrug 22 antibiotic resistance 
has been reported in children and HI individuals 6,8. HI individuals with a lower CD4 count 
tend to have a higher mortality from bacteraemic pneumococcal pneumonia than individuals 
with a higher CD4 24.  
Three methods, some of which have been touched on above, have been proposed to 
estimate the burden of different pneumococcal syndromes 15. Firstly, a proportional approach 
using a mortality or morbidity envelope for the relevant clinical syndrome with allocation of 
cases or deaths attributable to S. pneumoniae; secondly, an incidence-based approach using 
clinical disease incidence to derive cause specific cases, and then case-fatality ratios to 
estimate the number of deaths; or lastly “triangulation” which compares the relative 
occurrence of one syndrome relative to another. All three methods were used to determine 
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case and death numbers in a pneumococcal global burden paper 15. To estimate the proportion 
of pneumonia attributable to S. pneumoniae the vaccine efficacy against a specific pneumonia 
endpoint was first divided by the overall efficacy against vaccine type invasive pneumococcal 
disease (VT-IPD) and then by the proportion of VT-IPD in the population where the study 
was conducted. An adjustment was also made for the effect of Haemophilus influenzae 
serotype b vaccination in the relevant study population. The estimated proportion of each 
pneumonia endpoint attributed to S. pneumoniae was based on a meta-analysis 25-27 of 
vaccine efficacy trial results 20,21,28-32. Pneumonia deaths numbers were estimated by applying 
the proportion of pneumonia deaths attributable to S. pneumoniae to overall estimates of 
pneumonia deaths in children 1-59 months of age. For meningitis, an incidence-based 
approach was used in countries where S. pneumoniae incidence and case fatality rates were 
available. Estimates were also combined using meta-analysis results 25-27. The burden of non-
pneumonia non-meningitis (NPNM) invasive disease was based on the ratio of NPNM to 
meningitis cases multiplied by the estimated number of meningitis cases for each country. 
The number of deaths caused by NPNM was calculated by multiplying the severe NPNM 
cases by an appropriate case fatality rate 15. Global pneumonia death models often split case 
and death rates by aetiological agent. The Rudan, et. al. paper 16 used  previous determined 
proportionate estimates for S. pneumoniae and accounted for vaccine use.  
Although the number of countries in the African region, who have introduced PCV 
since it first became available in 2000, has increased exponentially, the availability of 
published pre-vaccine and post-vaccine data is limited to a small number of countries. South 
Africa was the first African country to introduced PCV into its public National Immunisation 
Programme in April 2009 and is one of the few African countries to have robust pre-vaccine 
pneumococcal surveillance data. South African impact data will help to inform vaccine 
introduction into other low- and middle-income countries in terms of vaccine type, schedule, 
duration of protection, replacement and risk groups in the post-PCV era.  
 
PNEUMOCOCCAL SEROTYPES AND VACCINES  
 
Polysaccharide antigens are large molecules which interact directly with B cells and 
induce T-independent antigens 33. Due to the absence of T-cell reactions polysaccharide 
vaccines fail to induce significant and sustained antibody responses in young children less 
than 18 months of age. Even in older children and adults, antibody responses are relatively 
short lived and booster response cannot be produced by repeated exposure. By conjugating 
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the polysaccharide to a protein carrier, a T-cell response can be induced 33. T cells stimulate a 
more vigorous immune response and also promote a more rapid and long-lasting 
immunologic memory. Conjugate vaccines are immunogenic in very young children, prime 
for memory responses and also provide "herd immunity" 34.  
In 1983 the 23-valent polysaccharide vaccine (PPSV23) was released and included 
serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 
22F, 23F and 33F, covering 90% of serotypes found in pneumococcal bacteraemia. This 
vaccine should only be used in children older than two years of age due to poor antibody 
responses in younger children 35. When healthy adults are vaccinated antibody levels persist 
for at least 5 years, but may be shorter in adults with underlying illnesses.  
In February 2000, the heptavalent pneumococcal conjugate vaccine (PCV7; serotypes 
4, 9V, 14, 19F, 23F, 18C, and 6B) was licensed in the US and this vaccine included several 
serotypes that were resistant to antibiotics. In addition, it was highly effective in children <2 
years of age. Higher valency vaccines, such as the 10-valent PCV (PCV10), which includes 
additional serotypes 1, 5, 7F, and 13-valent PCV (PCV13), which includes additional 
serotypes 1, 3, 5, 6A, 7F, 19A, later replaced PCV7. The 10 most common pneumococcal 
serotypes account for about 62% of invasive disease worldwide. The serotypes in PCV7 
cause the highest incidence of IPD in the first 2 years of life and then decrease over the next 
few years of life 36.  
Serotypes differ by age (6B, 9V, 14, 19F, are most common in young children) and by 
disease syndrome (serogroups 6, 10 and 23 are more frequently isolated from cerebrospinal 
fluid (CSF) than from blood, while serotypes 1, 4, and 14 are more frequently isolated from 
blood) 36. Serotypes 1 and 7F are more likely to be invasive than carried, whereas other types 
are mainly involved in carriage. Carriage duration varies by age and is generally longer in 
children 36.  
 
OUTBREAK PNEUMOCOCCAL SEROTYPES 
 
Most of the historical pneumococcal outbreaks in the early part of the 20th century 
were caused by serotypes 1, 2, and 5 37. A reduction in outbreaks has been noted with very 
few reported in the present day 38. Reasons for the reduction in outbreaks may be related to 
the availability of antibiotics which has changed transmission dynamics and colonisation, 
improvements in socioeconomic conditions and an increase in vaccine serotypes in recent 
years 39. Viral respiratory infections in defined populations have been implicated in a 
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predisposition to pneumococcal pneumonia outbreaks with the predominant strains carried in 
that population 40-43.  
Pneumococcal outbreaks usually occur in closed communities. Pre-2006 a systematic 
review of 42 outbreaks identified serotype 14 as the most common cause 44, but most studies 
included patients with underlying medical conditions in hospitals or care facilities and often 
included asymptomatic carriers 45. When outbreaks were limited to non-hospitalised poor 
young adults and a single serotype, three out of the five studies were due to serotype 1. Two 
serotype 1 outbreaks were in homeless shelters and one in a military training facility 46,47.  
Serotype 1 has been shown to cause outbreaks in Africa 48. The African meningitis 
belt is a region of sub-Saharan Africa, extending from Senegal to Ethiopia that is 
characterised by hyperendemic seasonal peaks of acute bacterial meningitis and sporadic 
epidemics 49. It is not clear why pneumococcal meningitis in the meningitis belt is seasonal 
and usually presents with one predominating serotype. Even though climatic factors increase 
the incidence of meningitis in the meningitis belt, these factors do not explain the increase in 
serotype 1 above other pneumococcal serotypes. In addition other socio-economic and 
underlying conditions predisposing to IPD are similar between other African countries and 
the meningitis belt.  
A study comparing opsonophagocytic activity against pneumococcal disease in 
Burkina Faso and the United Kingdom (UK) showed that even though functional activity was 
generally low in both groups, a higher serotype 1 activity was observed during childhood in 
Burkina Faso, with similar levels during adolescence and adulthood in both populations 50. 
Despite this disease incidence in the UK was much lower. The low level of functional 
antibodies was consistent with infrequent carriage of serotype 1 51-53 and reduced natural 
immunity compared with other serotypes. A general defect in humoral immunity amongst the 
Burkina Faso population was ruled out. Climatic factors have been shown to play a key role 
in predisposing people in the meningitis belt to meningitis 53-55. These environmental factors 
were thought to increase the incidence of serotype 1 in Burkina Faso 50 even though both the 
UK and Burkina Faso populations had low natural immunity to serotype 1.  
 
Serotype 1 epidemiology  
 
Serotype 1 is commonly isolated in IPD but rarely causes asymptomatic 
nasopharyngeal colonization 37,56. Serotype 1 pneumococci have been isolated from swabs 
taken from ill patients with pneumonia 57 or close contacts of patients with serotype 1 IPD 58. 
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A meta-analysis demonstrated the difference in carriage duration between serotypes; with a 
shorter duration in serotype 1, which has a high attack rate, compared with other 
pneumococcal serotypes 59.  
Serotype 1 has been shown to have lower antibiotic resistance than serotypes that are 
more commonly carried asymptomatically (e.g. 6B and 23F) 60,61. Prior antibiotic use may 
clear susceptible serotype 1 pneumococci, making it less likely to be grown on culture 48. 
Serotype 1 shows substantial year-to-year variability that is more marked than other serotypes 
62. In terms of the influence of vaccination on serotype 1, although it can’t be excluded, there 
was data that showed that serotype 1 increased prior to PCV introduction in some countries 
63,64 and had no correlation in others 61, likely due to the epidemic nature of serotype 1. 
Serotype 1 was found to be an important cause of disease among older children and 
among HU children in the pre-PCV era in South Africa 17.  Serotype 1 IPD tends to occur in 
patients who are younger and healthier than IPD caused by other serotypes 65. Serotype 1 is 
found across all age groups 36 and the age differences in reported rates may be due to relative 
differences in other serotypes. Compared to other serotypes, serotype 1 has lower morbidity 
and mortality 65,66 and frequently causes uncommon presentations of IPD, including 
empyema 67 and peritonitis 68. 
The serotype 1 capsule contains zwitterionic polysaccharides which have sections of 
opposing charges, allowing it to elicit a T‑cell dependent immune response 48. This is in 
contrast to the capsular polysaccharides of other serotypes that function as T‑cell independent 
antigens. The serotype 1 capsule has been shown to be more resistant to opsonisation and 
complement deposition than other serotypes, except for serotype 5 69; as such it is thought 
that the serotype 1 capsule may function in a different way to other serotypes resulting in a 
difference in virulence. There were also differences in pneumolysin in some serotype 1 
isolates, which also impacts colonisation and virulence 48. The zwitterionic polysaccharide 
capsule has been found to be related to abscess formation in animal models and thus cause 
empyema 48.  
Serotype 1 is contained in both the PCV10 and PCV13 vaccines. This thesis focusses 
on the effects and impact of PCV13 only as this is the vaccine that replaced PCV7 in the 
routine national immunisation programme in South Africa. 
 
RISK FACTORS OTHER THAN HIV-EXPOSED UNINFECTED CHILDREN  
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It is important to establish risk factors for pneumococcal disease in different settings 
and following different interventions such as antiretroviral treatment (ART)  or PCV, to 
establish priority groups for public health interventions. Prior to the introduction of PCV 
there was limited data on risk factors for IPD in South Africa. Local studies showed a 
significant higher risk of IPD in HIV-infected children (41-fold) with “paediatric” 
pneumococcal serotypes, than –uninfected children 11. HIV-infected children in this study 
had high rates of malnutrition and underlying tuberculosis.  Other studies from the US also 
showed that a higher risk of pneumococcal disease with HIV was in the pre-ART era 70. In 
contrast in HIV-uninfected children with IPD in South Africa had underlying infections, like 
chronic liver and renal disease in the pre-vaccine era 11. Young children (<2 years of age) and 
the elderly are most at risk of invasive disease caused by the pneumococcus, as are males 71. 
Other risk factors include alcoholism, smoking 72, day care for children and asplenia 73.  
Also in the pre-vaccine era a case-control study in children <5 years of age in The 
Gambia showed lack of maternal income, exposure of the child to indoor smoke from 
cooking or cigarette smoke, poor weight gain and serious illness in the child in the last few 
months as risk factors associated with pneumococcal disease 74. Another case-control study 
conducted in the US prior to the introduction of PCV7 identified a number of risk factors for 
IPD 75. Cases of IPD were identified from a laboratory-based surveillance programme and 
controls from the community. On multivariable analysis recent day care attendance was 
associated with an increased risk in all age groups. In infants 2-11 months old IPD was 
associated with a decreased likelihood of current breastfeeding, in 12-23 month olds with 
recent antibiotic use and in older children (24-59 months) with crowding 75.  
Following the introduction of PCV7 in the US in 2000 another case-control study 
(2001-2004) assessed the changes in risk factors associated with IPD 76. In children who had 
received at least one PCV7 dose, the strongest risk factor for cases with vaccine-type IPD 
was an underlying medical condition; other factors included male gender, having no health 
insurance and been less likely to be up-to-date for Haemophilus influenzae type b (Hib) 
vaccination. Unvaccinated cases with VT-IPD had additional risk factors similar to those 
seen in the pre-PCV period, namely day care attendance and black race which was not seen in 
vaccinated children. Risk factors for NVT-IPD included children with underlying conditions 
(in households with smokers), day care attendance among black children, children from low-
income households, male gender, history of asthma, low birth weight or grommets. Cases 
were less likely than controls to be up-to-date with Hib vaccination or to live in households 
with children younger than 18 years. 
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In the post-PCV period prior to our study, there was no data exploring the changes in 
risk groups for pneumococcal disease in South Africa. A case-control study in South Africa 
in the post-PCV era and published after our risk factor paper, assessed risk factors for 
presumed bacterial pneumonia hospitalisations in young HIV-uninfected children 77. This 
study reported black race, malnutrition with (OR 3.30, 95% CI 2.28-4.79) and without 
crowding (OR 6.68, 95% CI 4.74-9.42), crowding among well-nourished children (OR 2.29, 
95% CI 1.89-2.78), previous pneumonia hospitalisation (OR 2.35, 95%CI 1.65 to 3.35) and 
smoking by the primary caregiver (OR 5.15, 95%CI 2.94 to 9.03) as risk factors. 
Risk factors for antibiotic non-susceptible disease have been shown to include 
previous hospital admissions due to antibiotic exposure, day care attendance due to crowding 
and highly likelihood of transmission, HIV infection and malnutrition possibly due to 
previous admissions and antibiotic therapy 78. Female sex 79, probably due to transmission 
from children and pneumococcal serotypes commonly found in children (‘paediatric 
serotypes’), due to prolonged carriage 80, are also associated with higher antibiotic resistance.  
 
HIV-EXPOSED UNINFECTED CHILDREN   
 
Groups of particular interest in South Africa are HI and HEU (HIV-exposed-
uninfected) children in view of the fact that around a third of all pregnant women test positive 
for HIV at antenatal clinics nationally in the country 81. An improvement in treatment to 
prevent the transmission of HIV from pregnant women to their babies has resulted in an 
increasing number of exposed but uninfected infants. Prior to our study, HIV exposure was 
shown to be associated with an increased risk of lower respiratory tract infections and 
bacterial infections, but had not been described as a specific risk factor for IPD. 
A review article by Evans, et. al. highlighted the challenges when reviewing studies 
including HEU children 82. The difficulties in reviewing these studies included that earlier 
studies did not include HIV testing in infants, follow-up testing was often not done for HIV-
uninfected mothers and infants, HIV-unexposed groups were often not included for 
comparison, breast feeding practices differed between groups and HIV and ART exposures 
were often not described.  Despite these limitations mortality in young HI and HEU children 
<2 years of age has been shown to be higher than that of HIV-unexposed-uninfected (HUU) 
children. Factors such as maternal CD4 count and health status impact the outcome in the 
HEU group 83. A number of factors have been proposed to contribute to the poor health and 
nutrition among HEU children: lack of parental care, infant feeding practices, immune 
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abnormalities, exposure to other infections and antiretroviral drugs 84. HEU children have 
been shown to have a significantly higher all-cause outpatient consultation rate and LRTI-
associated visit rate in infants <6 months of age 85. In South Africa, HEU infants hospitalised 
with pneumonia tended to have higher treatment failure rates than HUU infants 86; HEU 
infants were prone to higher infectious morbidity 87 and were at higher risk for more severe 
infections requiring hospitalisation 88. Data from high-income countries also showed a 
correlation between the risk of serious bacterial infections among HEU infants and maternal 
CD4 values during pregnancy 89. 
A small cohort of 27 HEU and 28 HUU infants from South Africa in 2009 showed a 
non-significant three-fold increase in hospitalisations for infections in HEU compared with 
HUU children in the first year of life 88. Most infections were respiratory tract infections. The 
HEU infants did not have more reported infectious events or higher rates of malnutrition. No 
comparison could be made with regards to the role of breastfeeding as only one HEU infant 
was breastfed.  
In South Africa a case-control study which assessed risk factors for presumed 
bacterial pneumonia hospitalisations in HIV-uninfected children 77 identified that maternal 
HIV infection was a risk factor for pneumonia in infants who were exclusively breastfed (OR 
2.33, 95% CI 1.53 to 3.55). These results differed from another study in Kenya which showed 
a decreased risk of pneumonia in breastfed HEU infants 90. The authors of the South African 
study suggested that the inconsistent association between breastfeeding and pneumonia in 
their study may have been due to unmeasured confounding.  
A pooled analysis which included a number of HIV prevention of mother-to-child 
transmission (PMTCT) studies demonstrated that risk factors for death among young HEU 
children included having a mother with a low CD4 count or who died 83. In Tanzania low 
birth-weight was also a risk factor for death among HEU infants 91, while in Zimbabwe, 
mortality within the first 2 years of life was significantly higher amongst HEU than HUU 
children 92. Other studies also showed advanced maternal disease to be a risk factor for 
mortality 89,93. Additional risk factors for death among HEU children included low birth 
weight, male sex, maternal death, malnutrition 92, severe maternal anaemia, single mother and 
low household income. Mortality was highest in HEU infants <6 months of age mainly 
associated with lower respiratory tract infections 92. 
A cohort study from 3 African countries showed differential mortality after 12 months 
of follow-up amongst HI (42%), HEU (7.2%) and HUU (4.8%) infants.  Infants were more 
likely to die if their mother experienced a severe adverse event or died; and in HI mothers 
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with low CD4 counts or high viral loads 94. In Zambia a cohort of 620 HEU infants were 
followed up to 4 months of age. Overall infant mortality was 4.6% and those whose mothers 
had low CD4 cell counts (≤350 cells/mL) were almost three times more likely to die or be 
hospitalised after adjusting for other factors. The most common cause of infant death and 
hospitalisation was pneumonia and/or sepsis 95. 
 
General immunological responses in HIV-exposed-uninfected children  
 
HEU children have been reported to have a number of distinct immunological 
differences from HUU children 96. The magnitude of cytotoxic lymphocyte activity, CD4 
helper T cell responses and natural killer cells responses in HEU infants have all been found 
to be associated with whether the infant is infected perinatally with HIV or not 97-99. 
Transplacental transfer of specific maternal antibodies, including tetanus and measles 
antibodies, are reduced in HEU infants compared to HUU infants 100-103. This reduction may 
be related to impaired B cell function, less efficient IgG placental transfer and myeloid 
dendritic cells activity 104. Absolute CD4 and naive CD8 T cells have been found to be 
reduced in HEU children and some studies have shown thymic function disruption in HEU 
infants 105,106. These immunological changes may have a negative impact on the HEU child’s 
response to infection and to immunisation in early life. Their immune response to S. 
pneumoniae and other encapsulated bacteria, which requires functional antibodies, may also 
be reduced 96. 
A number of metabolic and haematological changes have been reported in HEU 
infants exposed to ART during PMTCT 96. Metabolic changes are likely caused by 
mitochondrial toxicity which can result in mitochondrial dysfunction with neuropathy, 
development of lactic acidosis, cardiac growth and functional abnormalities 107-109. 
Haemoglobin levels, platelets, total lymphocytes, neutrophils, CD4 and CD8 T cell counts 
may all be reduced 110-112. Further studies are required to determine the extent to which ART 
directly alters immune responses and to assess the functional significance of the changes in 
haematological parameters.  
 
Impact of breastfeeding in HIV-exposed-uninfected children  
 
Another explanation for a higher mortality in HEU compared with HUU infants is that HIV-
infected mothers chose not to breastfeed or are unable to breastfeed due to advanced HIV 
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disease. Breast milk contains a number of different immune-related compounds including 
IgA, leukocytes, lysozyme, lactoferrin, interferon-ɣ and cytokines 113. Some compounds 
prevent adherence of pathogens to the upper respiratory tract and gastrointestinal tract 
mucosa in the infant providing passive protection against invasive infections. Breast milk 
may also stimulate the child’s own immune system. In developing countries breastfeeding 
reduces mortality from acute respiratory infection and diarrhoea 114, with a 6 times higher 
odds of mortality reported in non-breast-fed infants <2 months of age. Even in developed 
countries, studies have shown a protective effect of breastfeeding against acute infections 
115,116.  
 
VACCINE EFFICACY OF PNEUMOCOCCAL CONJUGATE VACCINES IN 
CLINICAL TRIALS  
 
Vaccine probe studies can be used to estimate the total burden of pneumococcal 
disease incidence that is preventable by PCV by calculating the difference in disease 
incidence between vaccinated and unvaccinated people 117. Estimates can be calculated 
separately for different disease syndromes. Vaccine probe studies can gauge the contribution 
of the pneumococcus to different clinical syndromes and explore causality in disease 
pathogenesis. Vaccine probe studies can use either a randomised or non-randomised design to 
measure the incidence of IPD pre- or post-PCV introduction and be incorporated into the 
design of a vaccine efficacy study or be applied retrospectively 117. 
A Cochrane review exploring PCV effect on IPD and CXR pneumonia included 
eleven publications from 6 randomised control trials conducted in 5 different countries (South 
Africa, The Gambia, the USA, Philippines and Finland) 118. These trials included 113,044 
children <2 years of age; 57,015 who received PCV and 56,029 who received a placebo or 
another vaccine. The evidence on PCV efficacy against IPD was considered high quality 
while the evidence against pneumonia was of moderate quality. Of the 5 trials that included 
all-cause mortality data, none had sufficient numbers to explore this outcome and only 2 
trials had data on all-cause admissions. The pooled vaccine efficacy (VE) for vaccine type 
IPD (VT-IPD) in HU children was 80% (95% confidence interval (CI): 58-90) while the VE 
for all serotype IPD was 58% (95% CI: 29-75) and the all-cause mortality VE was 11% (95% 
CI: -1-21%). The findings for HI children were similar although point estimates were slightly 
lower than in HU children 118.  
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Vaccine efficacy of pneumococcal vaccines in developed countries  
 
A Kaiser Permanente trial was conducted in Northern California (NCKP study) from 
October 1995 to April 1999 to evaluate PCV7 efficacy 28. The final analysis included 40 fully 
vaccinated IPD VT-IPD cases, 39 of which were controls, translating into a VE of 97.4% 
(95% CI: 82.7 to 99.9%). There was an 89.1% (95% CI: 73.7 to 95.8%) reduction in all-
serotype IPD in children who had received ≥1 dose of PCV7. Another trial which used a 
group-randomised design to recruit Native American children ≤2 years of age demonstrated a 
per-protocol VE of 76.8% (95% CI: –9.4-95.1) 119. None of the non-vaccine type (NVT) 
results were statistical significance.   
 
Vaccine efficacy of pneumococcal vaccines in developing countries 
 
Two clinical randomised, placebo-controlled, double-blind vaccine efficacy trials 
were conducted using a 9-valent PCV (PCV9) in Africa 21,29. This vaccine included additional 
serotypes 1 and 5 which were not included in the PCV7 vaccine that was ultimately licensed. 
In the South African VE trial, a total of 39,836 children were included, 19,922 in the PCV9 
group and 19,914 in the placebo group 21. In the per-protocol analysis, the VE was 85% (95% 
CI: 32-98) for HU children and 65% (95% CI: 24-86) against VT-IPD (the primary endpoint) 
in HI children. In the Gambian trial 17,437 children were randomised of those screened, 8718 
into the vaccine group and 8719 into the placebo group 29. The original primary endpoint was 
all-cause childhood mortality, but this was changed to radiologically confirmed pneumonia 
due to concerns that the original study endpoint would not be met. Efficacy against a 
secondary endpoint of the study, VT-IPD was 77% (95% CI: 51–90).  
 
VACCINE EFFECTIVENESS OF PNEUMOCOCCAL CONJUGATE VACCINES 
FROM CASE-CONTROL STUDIES 
 
Vaccine effectiveness of pneumococcal vaccines in developed countries  
 
In the US, a matched case-control study was conducted from 2001-2004 to assess the 
effectiveness of PCV7 against IPD following the introduction of this vaccine in 2000 120. 
Cases were identified using the Active Bacterial Core Surveillance programme and 
community controls from birth registers; matching was by age and zip code. Vaccines were 
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administered at 2, 4, 6 and 12–15 months of age. The study showed a high vaccine 
effectiveness against VT-IPD with ≥1 dose of PCV7 in healthy children (96% [95% CI: 93–
98]) as well as good efficacy against penicillin non-susceptible disease (76% [95%CI: 63–
85]) and multidrug-resistant strains (77% [95%CI: 62–86]).  
A paper from the UK using enhanced surveillance data utilised the indirect cohort 
method to assess the vaccine effectiveness of PCV7 against VT-IPD and individual serotypes 
121. The analysis included all first episode IPD cases aged ≥5 months from November 2006 to 
May 2010. In children <14 months of age, the adjusted vaccine effectiveness for 1 dose was 
56% (95% CI: -7-82) and for 2 doses was 83% (95% CI: 60-93); the vaccine effectiveness for 
2 doses in children ≥14 months was 93% (95% CI: 70-98).  The authors concluded that their 
vaccine effectiveness estimates were lower than in the US study possibly due to residual 
confounding.  
 
Vaccine effectiveness of pneumococcal vaccines in South Africa   
 
In South Africa, a matched case-control study was conducted to assess the 
effectiveness of PCV7 against IPD 122. Cases of IPD were identified through a national 
laboratory-based surveillance programme while controls were enrolled from wards or 
outpatient departments at the same hospital as their case. Cases and controls were also 
matched by age and HIV status. The study was able to show that ≥2 PCV7 doses were 
effective against VT-IPD amongst HU children (74% [95% CI: 25–91]), but not against HI 
children ≥16 weeks of age (−12% [95% CI: −449-77]). Among HIV-exposed-uninfected 
(HEU) children, the vaccine effectiveness of ≥2 doses was 92% (95% CI: 47–99) against VT-
IPD, while that against all-serotype multidrug-resistant IPD was 96% (95% CI: 62–100) 
among HU children. A single dose of PCV7 given at about 6 weeks provided no protection 
against VT-IPD, unlike the effectiveness shown in the USA 122.  
A later analysis from the same South African case-control study determined PCV13 
effectiveness (Cheryl Cohen, submitted). Amongst HU children the vaccine effectiveness of 
≥2 PCV13 doses against PCV13-serotype IPD was 85% (95% CI: 37-96), 92% (95% CI: 40-
99) against the 6 additional PCV13 serotypes and 52% (95% CI: -12-79) against all serotype 
IPD. When the data from both children who received PCV7 or PCV13 was combined the 
vaccine effectiveness against PCV7-serotype IPD was 87% (95% CI: 38-97) in HEU children 
and 90% (95% CI: 53-98) in HU malnourished children. Significant effectiveness could still 
not be shown for ≥2 doses amongst HI children (91% [95% CI: -35-100]) against PCV13-
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serotype IPD or against the 6 additional PCV-13 serotypes (82% [95% CI: -155-100]) even 
though the point estimate was higher than that shown in the PCV7 study.        
 
PNEUMOCOCCAL CONJUGATE VACCINE IMPACT  
 
When using surveillance systems to monitor the impact of PCV it is important to 
remember the inherent biases associated with trend data 123. There may be natural fluctuations 
in serotypes and changes in specimen-taking practices following vaccine introduction 124,125. 
Post-vaccine introduction less blood cultures may be taken due to clinicians expecting less 
disease, resulting in an inflation of the change in VT disease and a reduction in NVT disease 
detection. Increases in trends may also be reported 126,127. These changes in specimen-taking 
practices may be more marked in outpatient departments than hospitalised children. It is 
important to ensure that there is stability in the pre-vaccine years used for the baseline 
calculation of rates and sufficient post-vaccine years to determine the actual change in 
disease incidence and the extent of replacement disease 123. Incomplete case ascertainment 
can make the establishment of a stable baseline for subsequent comparison difficult. In 
ecological studies changes in disease incidence following vaccine introduction cannot always 
be causally attributed to vaccine introduction. PCV effectiveness and impact data is now 
available from more than 50 countries (http://view-hub.org/viz/). Only a few of these studies 
are discussed in detail below.  
 
Pneumococcal conjugate vaccine impact on invasive pneumococcal disease in developed 
countries  
 
A meta-analysis of 21 datasets from different surveillance systems showed a 
reduction in all IPD and VT-IPD in children <5 years of age by 1 year after introduction of 
PCV7 and which continued till 7 years post-introduction 128. Most sites showed an increase in 
NVT-IPD in at least one post-introduction year. In adults, VT-IPD decreased significantly by 
the second year following PCV7 introduction and was more gradual when compared to 
children. Only adults aged ≥50 years showed significant increases in NVT-IPD post-PCV 
introduction. The impact of PCV7 on VT-IPD has shown consistent results in high-income 
countries, with reductions in incidence ranging from 79% to 100% 129-137. However the 
overall reduction in incidence of all serotype IPD showed more variation across studies (37-
80%), likely due to differences in serotype distributions 129-139.   
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In the UK, PCV7 was introduced in 2006 and replaced by PCV13 in 2010. Comparing 
IPD incidence rates from 2004-2006 to those in 2009-2010, in children <2 years of age, there 
was a 46% reduction in all IPD, 97% reduction in VT disease and an 81% increase in NVT 
disease 136. In the elderly (≥65 years) there was a 13% reduction in all IPD, 79% reduction in 
VT disease and a 48% increase in NVT disease. After PCV13 introduction, IPD incidence 
decreased by 32% across all ages by 2013-14 140. The incidence of PCV7 VT disease 
continued to decline in all age groups and the additional six serotypes in PCV13 also showed 
a significant decrease of 69%. Compared with the pre-PCV7 baseline years the overall 
incidence of IPD in 2013-14 was reduced by 56% and the incidence of PCV7 VT disease by 
97%; the incidence of non-PCV13 IPD, compared with the pre-PCV baseline, increased by 
28%.  
In the USA, PCV7 was introduced in 2000 and replaced by PCV13 in 2010. In 2001 
in children <2 years of age, compared with 1998-1999, the incidence of PCV7 VT disease 
was reduced by 78%, while all vaccine-related IPD (6A, 9A, 19A) was reduced by 50% and 
NVT disease increased by 27%; the latter was not significant 141. Following PCV13 
introduction, time series models were used to compare what would have been seen in the 
absence of PCV13 with what was actually observed 142. In children <5 years of age in 2012-
2013 there was a reduction of 64% in all IPD, 93% reduction in the additional 6 PCV13 
serotypes and no evidence of replacement disease. In adults ≥65 years of age, there was a 
12% reduction in all IPD and a 58% reduction in the additional 6 PCV13 serotypes. There 
was also no significant increase in NVT disease in this age group.   
 
Pneumococcal conjugate vaccine impact on pneumonia and hospitalisation in developed 
countries  
 
A number of studies have reported the impact of PCV7 on pneumonia-associated 
hospitalisation. Reported reductions in all-cause pneumonia hospitalisations in children post-
PCV7 introduction range from 13% to 65% after introduction of PCV-7 139,143,144. It was 
suggested that the range of reductions was possibly due to differences between countries in 
the common serotypes causing pneumonia, the aetiology of pneumonia and differential 
duration of time since PCV7 introduction 145. In the United States it was estimated that 
41,000 all-cause pneumonia hospitalisations were avoided in children <2 years of age 
through the introduction of PCV7, a 39% (22-52%) reduction 143; by the end of 2004, there 
was a 65% (47-77%) reduction in the rate of pneumococcal pneumonia admissions in 
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children <2 years of age and a 21% (6-34%) reduction in all age groups. The control group of 
dehydration admission rates showed no change in young children.  
In Canada PCV7 was first introduced as part of the national immunisation programme 
in 2002. A review of data from 2004 to 2010 showed an overall decrease in the incidence of 
all-cause and pneumococcal pneumonia 146. This was driven primarily by decreases in 
incidence in children <5 years and the elderly (≥65 years). In all age groups the incidence of 
all-cause pneumonia declined from 361 (359-364) per 100,000 in 2004-2005 to 347 (345-
349) per 100,000 in 2009-2010 and for pneumococcal pneumonia from 6.40 (6.09-6.73) per 
100,000 to 5.08 (4.81-5.36) per 100,000 in the same years.  
 
Pneumococcal conjugate vaccine impact on invasive pneumococcal disease and carriage in 
developing countries  
 
Studies on the impact of PCV on IPD are currently been conducted in at least 21 
developing countries and impact on nasopharyngeal carriage in 18 countries (http://view-
hub.org/viz/). 
The KEMRI Wellcome Trust Research Programme in Kenya launched a study of 
PCV10 effectiveness in the routine childhood immunisation schedule in Kenya. The study 
endpoints included invasive pneumococcal disease, radiologically proven pneumonia and all-
cause hospital admissions pre- and post-PCV10 introduction. Routine immunisation of 
children <12 months of age began in January 2011. The surveillance programme showed a 
significant reduction in VT and all serotype IPD by 2012 (http://www.kemri-wellcome.org). 
In 2012 PCV10 effectiveness was estimated to be 72% (95% CI 34–88) against VT-IPD in 
children <5 years of age. In terms of nasopharyngeal carriage, vaccine effectiveness for VT 
disease was 64% (95% CI 49–74) in children <5 years of age and 66% (38–82) in individuals 
≥5 years of age 147. There was a significant increase in NVT carriage in children <5 years of 
age 37% (95% CI 13–65); however overall there was a slight decline in pneumococcal 
carriage prevalence because the magnitude of the decline in VT carriage was greater than 
NVT increase 147. 
 To investigate the impact of PCV7 on pneumococcal nasopharyngeal carriage, a 
cluster-randomised trial was conducted in 21 villages in The Gambia over a 5 year period 
(December 2003 to June 2008) 148. PCV7 was given to children <30 months of age in all the 
villages, while older children and adults were randomised to receive either one dose of PCV7 
(11 vaccinated villages) or meningococcal serogroup C conjugate vaccine (10 control 
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villages). Nasopharyngeal swabs were collected in cross-sectional surveys before vaccination 
and at 3 points after vaccination. A time trend analysis demonstrated a reduction in VT 
pneumococcal carriage prevalence in all age groups in both villages following vaccination, 
showing both direct and indirect vaccine effects. The herd effect was shown from 6 months 
after vaccination and persisted for at least the next 2 years. Only small differences were noted 
in NVT pneumococcal carriage prevalence between the different villages 148.  
A population-based surveillance system in the Gambia compared the incidence of 
baseline IPD rates pre-PCV13 (May 2008-May 2010) and rates post-PCV13 (Jan 2013-Dec 
2014) introduction 149. A total of 320 cases of IPD were identified over the 7 year period. In 
children 2-23 months of age there was a 55% (95% CI 30-71%) reduction in the incidence of 
all IPD and an 82% (95% CI 44-91%) reduction in the incidence of PCV13 serotypes. 
Similarly in children 2-4 years of age there was a 56% (95% CI 25-75%) reduction in the 
incidence of all IPD and a 68% (95% CI 39-83%) reduction in the incidence of PCV13 
serotypes. Reductions in other age groups were not significant, as were the increases in non-
vaccine type disease.   
In South Africa a national, laboratory-based surveillance programme for IPD 
demonstrated a reduction in the incidence of disease, when rates were compared between four 
pre-vaccine (baseline) years (average of 2005 through 2008) and two different post-vaccine 
years (2011 and 2012) 150. In children <2 years of age (vaccinated group), the incidence rates 
for all pneumococcal serotypes decreased from 54.8 to 17.0 cases per 100,000 person-years 
(69% reduction) between these 2 periods, while PCV7 serotypes showed an 89% reduction 
(32.1 to 3.4 cases per 100,000 person-years). The additional 5 serotypes (excluding 6A) in 
PCV13 and not in PCV7 also showed a significant 57% reduction by 2012. Among HU 
children, PCV7 VT disease decreased by 85%, whereas disease caused by non-PCV13 
serotypes increased by 33%. Similarly in HI children PCV7 VT disease decreased by 86%, 
although the overall rate of disease was more than 20 fold greater than in HU children, and 
there was no significant change in non-PCV13 serotype disease. The absolute difference in 
HI children between VT and NVT disease was 55%. Among adults 25 to 44 years of age, 
there was evidence of herd immunity with the rate of PCV7 VT disease declining by 57%, 
and all serotype disease by 34% 150. This surveillance programme does not capture outpatient 
or non-invasive disease.  
 
Pneumococcal conjugate vaccine impact on pneumonia and hospitalisation in developing 
countries  
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There is limited data on PCV impact on pneumonia and hospitalisations from low and middle 
income countries. Various studies on the impact of PCV on pneumonia are ongoing in a 
number of developing countries (http://view-hub.org/viz/). Post–PCV7 introduction a study 
from Poland reported a 65% reduction in pneumonia hospitalisations 151 and a study from 
Uruguay showed a 56% reduction in CXR confirmed pneumonia 152. A later study from 
Uruguay showed a continued reduction in hospitalisations for non-consolidated pneumonia 
(46.4%) in the post-vaccine era and an overall decrease in consolidated pneumonia (27.3%) 
despite an slight increase in numbers in 2012 153. The authors investigated possible causes for 
this increase including changes in the diagnosis or hospitalisation of patients with suspected 
pneumonia, but could find none. They suspected an increase in other bacterial aetiologies. In 
Brazil, soon after the introduction of PCV10, an interrupted time-series analysis measured the 
rates of hospitalisation for pneumonia and non-respiratory causes among children in 5 cities 
154. During the post-vaccination period there was a significant difference in the reductions of 
pneumonia hospitalisation rates and non-respiratory hospitalisation rates in 3 of the cities.  
 
REPLACEMENT PNEUMOCOCCAL DISEASE  
 
With the expanded use of PCV globally it is important to estimate the scale of serotype 
replacement to determine the net decline in disease and the overall benefit of vaccination. 
The magnitude of the increase in non-vaccine serotypes varies between different settings and 
is depended on host and S.pneumoniae population level characteristics 123.     
Randomised-controlled clinical trials are unable to demonstrate indirect effects or 
replacement disease due to the fact that only a limited number of individuals are vaccinated 
155-157. Data on the extent of replacement disease is mainly being derived from observational 
studies which are subject to various biases. Replacement is more marked in well-vaccinated 
populations 158.  
Vaccination with conjugate vaccines has resulted in a change in pneumococci 
colonising the nasopharynx, from mainly VT serotypes to predominantly NVT serotypes with 
little or no net change in the bacterial carriage prevalence 21,123,159,160. The increase in NVT 
carriage may partially be due to the artefact known as “unmasking” 161 in which the reduction 
in prevalence of VT serotypes has made it easier to detect the presence of NVT serotypes in 
the population. Other contributing factors may be the increase in acquisition of new serotypes 
162 and a higher NVT colonisation density in vaccinated individuals 163.  
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NVT-IPD incidence has also increased 123. In the USA, 10 years after PCV7 
introduction, the surveillance system showed a decrease in VT disease and increase in NVT 
disease especially serotype 19A. The increase was most apparent among hospitalised cases. 
The incidence of NVT disease in children <5 years of age increased from 16·8 per 100 000 
population in 1998–99 to 22·1 per 100 000 population in 2006–7 (32%); however the overall 
rate of IPD in the paediatric population was still significantly lower than in the pre-vaccine 
era 137.  
The increase in NVT infections in England and Wales post-PCV7 introduction was 
greater than that reported in the USA 136. This may be as most children in the UK programme 
were hospitalised, whereas the US surveillance system also included non-hospitalised 
children (68% of <5 year olds in 1998–99) 137 resulting in a substantially higher prevalence of 
IPD in the USA compared with England and Wales. For pneumococcal meningitis the 
increase in NVT cases in children <5 years in the USA and England/Wales was similar at 
over 70% 136,137. The increase in NVT disease in individuals aged 65 years or older in the 
USA was 32% by 2006–07 137 compared with 48% in England and Wales by 2009–10 136. 
Serotypes 17F and 19A were major causes of replacement pre-PCV13 introduction 123,136, 
while data regarding serotype 1 was contradictory 21,29. In 2013-14, post-PCV13 introduction, 
non-PCV13 serotypes increased significantly in children <5 years and adults ≥45 years, 
compared with the pre-PCV13 baseline across all age groups. For children <5 years, the 
increase in non-PCV13 IPD compared with the pre-PCV13 baseline was most marked in 
2013-14 and at this point the overall IPD incidence was higher than 2012-13 140.  
Increases in NVT disease are likely due to a number of factors; however vaccination 
probable provides the strongest pressure for this increase. Other contributing factors may 
include antibiotic use and resistance and long-term secular trends 164-166.  
A meta-analysis, including 19 datasets in children <5 years, showed a significant 
increase in NVT-IPD rates by 2 years post-PCV introduction, which increased through 5 
years, with some plateauing till year 7 128. 
There is a possibility that serotype replacement could substantially reduce the impact 
and benefits of vaccines. Replacement serotypes could be associated with resistance, even 
multidrug resistance. The amount of replacement thus far, especially with PCV13 use (which 
covers serotype 19A) is small in comparison to the overall reduction in disease. However 
there is a need for broader valency vaccines, universal vaccines and adequate surveillance 128.  
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JUSTIFICATION AND OBJECTIVES 
 
There are limited data on the epidemiology of pneumococcal disease from Africa and 
other developing countries. As PCV is gradually introduced into developing countries, it is 
important to have good data regarding pneumococcal disease and the impact of the vaccine. 
As South Africa was the first African country to introduce PCV into its routine national 
immunisation programme and there is a long-standing national pneumococcal surveillance 
programme with good baseline data, it is a good platform to describe the changes in 
pneumococcal serotypes and the overall impact of PCV on disease burden. We used the IPD 
surveillance data to build a burden model to describe the overall burden of hospitalisations 
and deaths in the pre- and post-PCV period. We also calculated the proportion of disease 
averted as all these components are important for health policy.  
Serotype 1 pneumococcal disease has been shown to have distinctive clinical and 
microbiological characteristics in other studies and is an important cause of disease in low 
and middle income countries. Although it has been shown to cause outbreaks in the African 
meningitis belt the epidemiology of serotype 1 is likely different in South Africa a high HIV 
prevalence setting. Serotype 1 is contained in the PCV13 vaccine and it is important to 
describe its epidemiology in the post-vaccine era. There is conflicting data regarding whether 
PCV13 will result in a reduction in serotype 1 disease and in view of its epidemic nature 
ongoing surveillance is important.       
Risk factors for pneumococcal disease in South Africa are anticipated to differ 
somewhat from those traditionally reported from developed countries as there are high rates 
of HIV and malnutrition and lower socioeconomic conditions in certain communities. HIV-
infected children have been shown to have an increased risk of IPD but data are limited on 
other risk factors for IPD in South Africa. It is important to describe the change in risk in 
these children the era of PCV and paediatric HIV treatment and care. In HIV-uninfected 
children it is important to describe the risk factors for ongoing disease in the era of PCV. The 
identification of risk groups guides policy makers with regards to allocation of resources and 
clinical management by alerting clinicians to who may present with pneumococcal disease 
and who to treat empirically. 
With improvements in prevention of mother-to-child HIV transmission (PMTCT) 
programmes and high maternal antenatal HIV prevalence rates, there has been a reduction in 
HIV-infected children but an increasing number of HEU infants. There were no published 
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data exploring the risk of IPD-associated hospitalization or mortality amongst HEU children 
at the time of conceptualisation of this PhD.  
This thesis aimed to assess the public health impact of introducing the pneumococcal 
conjugate vaccine into the Expanded Programme on Immunisation in South Africa (EPI-SA), 
including the changes in disease burden and risk factor groups in the country as well as trends 
in disease caused by specific important serotypes. It is hoped that the findings from this thesis 
will be useful in guiding future pneumococcal vaccination policies and development in South 
Africa and other developing countries. The thesis focused predominantly on children <5 
years of age where the greatest effects of PCV were observed. For the serotype 1 analysis all 
age groups were included to provide a complete picture of disease clustering for this 
serotype.  
The primary objectives for this thesis were:  
1. To estimate the burden of hospitalised pneumococcal cases and in-hospital deaths caused 
by severe pneumococcal clinical syndromes (meningitis, bacteraemic and non-bacteraemic 
pneumonia, and non-pneumonia non-meningitis invasive disease), among HI and HU 
children <5 years in South Africa, in the pre-vaccine (2005-2008) and post-vaccine (2013) 
era (Paper I). 
2. To describe the epidemiology of IPD due to serotype 1 in all age groups in South Africa 
from 2003 to 2013, including the impact of PCV (Paper I). 
3. To describe the epidemiology of IPD in HEU children <1 year of age, compared with 
HUU and HI children in South Africa from 2009 through 2013 and include changes over this 
time period due to PCV and paediatric antiretroviral treatment introduction (Paper III). 
4. To describe the risk factors related to IPD in HI and HU South African children eligible to 
receive PCV7 through the EPI-SA and the changes in risk factors associated with vaccination 
between 2010 and 2012 (Paper IV). 
  
22 
 
METHODS 
 
STUDY SETTING 
 
In 2015, South Africa had a total population of around 54,96 million people with an 
annual birth rate of 22,7 per 1000 and an infant mortality rate of 34,4 per 1000 live births. 
The HIV prevalence rate was approximately 11.2% in the general South African population 
in 2015 167, as compared with 18.8% in 2008 168. The antenatal HIV prevalence rate remained 
stable at around 30% from 2004 81, while the HIV prevalence in children <5 years of age 
decreased over time from 4.4% in 2006 to 3.5% by 2013 due to marked improvements in the 
PMTCT programme; the estimated perinatal HIV transmission rate decreased from 16.4% in 
2006 to 2.4% in 2012 169,170. The number of HI infants identified under the age of 2 months, 
fell by 46% between 2008 and 2012 170. Access to ART has gradually improved since its 
introduction in the public sector in South Africa in 2004, and the overall estimated coverage 
in HI children requiring treatment was 63% in 2012 171,172. The number of women newly 
infected with HIV declined by 21% from 2009 to 2012 in South Africa. 
PCV7 was available in the private sector and limited areas of the public health sector 
in South Africa from 2008. The vaccine was introduced into the EPI-SA in April 2009. It was 
replaced by PCV13 from May 2011. PCV is administered in the EPI as 2 primary doses (6 
and 14 weeks) with a booster dose at 9 months. This differs from the schedule that was used 
in the vaccine efficacy trial (6, 10 and 14 weeks) conducted in South Africa with PCV9 21.  
There are a number of different estimates of vaccination coverage rates for PCV in 
South Africa, all of which have limitations 173. According to WHO-UNICEF estimates, 
vaccination coverage for the third dose of PCV increased from 10% in 2009 to 65% in 2014, 
while official administrative country estimates reported 94% in 2014.  
 
STUDY DESIGN  
 
Data from a number of studies was utilised in order to address the objectives of this 
thesis. Descriptions of the study methods and statistical analyses are discussed in detail 
within the methods sections of each paper. A brief description of methods as well as some 
additional issues related to different study designs is discussed below. 
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Burden models 
 
Burden of disease models usually combine multiple data sources to calculate the 
number of cases and deaths from defined diseases in a certain population. For our burden 
model we used a robust active laboratory-based surveillance programme for the baseline case 
numbers for meningitis, bacteraemic pneumonia and non-meningitis non-pneumonia 
syndromes, adjusting for differences in specimen taking practices. We calculated non-
bacteraemic pneumonia cases using data from a vaccine probe study 20. We applied observed 
case fatality ratios from hospitalised cases to calculate death rates. This approach differed 
from previous estimates as it used a bottom-up approach.  
We conducted one-way sensitivity analyses adjusting one variable at a time using 
different assumptions. Adjusted variables included community HIV prevalence, deaths in the 
community, a specimen-taking practice adjustment based on IPD incidence rates from a 
clinical trial conducted in South Africa, different adjustment rates for HIV-infected and –
uninfected children and a lower vaccine attributable reduction ratio for chest X-ray confirmed 
pneumonia instead of clinical pneumonia, compared to bacteraemic pneumonia. For death 
rates we also explored different case fatality ratios. Tornado diagrams were used to depict the 
sensitivity of the case and death estimates to changes in selected variables. These diagrams 
show the effect on the base rate by varying each input variable one at a time, while keeping 
all the other input variables at their initial base value. High and low values may be chosen for 
each input. The results are displayed as a bar graph with the variation for each variable from 
the base rate. 
To account for uncertainty in our estimates and calculate confidence intervals we used 
bootstrapping. It is usually not feasible to sample repeatedly from the same population so the 
best estimate is to resample randomly from a sample. Every resample has the same number of 
observations as the original sample, so the bootstrap method models the impact of the actual 
sample size 174. Bootstrapping allows measures of accuracy to be assigned to sample 
estimates, verifies replicability of results and allows inferences to be made regarding key 
parameters. The simulated samples were used to calculate an estimated population 
distribution.  
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Spatial-temporal analysis for detection of IPD clusters 
 
Outbreaks or clusters of serotype 1 pneumococcal disease have not been previously 
described in South Africa despite a long standing surveillance programme, but this may have 
simply been due to the fact that they were missed. To determine whether any serotype 1 
clusters occurred within an 11 year period (2003-2013) we conducted a space-time scan 
analysis using a Bernoulli model 175,176 to compare cases (serotype 1 IPD cases) to controls 
(non-serotype 1 IPD cases) rather than a rate (Poisson) model. The space-time analysis was 
implemented using SatScanTM version 9.3.1 (http://www.satscan.org/) 177. SatScanTM is 
able to detect spatial, temporal or spatio-temporal disease clusters and determine whether 
they are random and whether they are significant or not. For Bernoulli models SaTScan uses 
a shifting window of varying proportions to evaluate clusters. The area of search varies in 
size, shape and direction. At each point SaTScan calculates the number of observed and 
expected observations and the likelihood function. 
 A Poisson-based model can be used when events in a geographical area are Poisson-
distributed and assumed to be independent with a known underlying population at risk. The 
dependent variable is a count of the number of cases that occur over a follow-up period. One 
can estimate a rate ratio associated with a given predictor or exposure. A Bernoulli model is a 
discrete-time stochastic model that takes only two values, 0 (controls) and 1 (cases) and 
determines whether there is a significant difference in clustering of cases versus that of 
controls. The SaTScan Bernoulli model uses a likelihood ratio test of the probability of a 
group of patients within a potential cluster being a case versus a control 178. SaTScan uses 
elliptical windows to identify potential cluster boundaries and this may not be a realistic 
representation of the population at risk.  
We chose to use a Bernoulli as opposed to a Poisson model for a number of reasons. 
Firstly we felt that the comparison of cases to controls from the same geographical area and 
time period would minimise biases potentially introduced by temporal and geographical 
differences in specimen-taking practices, healthcare seeking behaviour or improvements of 
the surveillance system over time. Secondly the Bernoulli model is independent of the 
underlying population distribution. Following the introduction of PCV7 from 2009 there was 
a reduction in control numbers; to account for this we adjusted positively by the percent 
reduction from the pre-vaccine period 150. We obtained average monthly estimated reductions 
in control numbers (from 2009 to 2013) assuming that there was no PCV introduction. 
Monthly adjustment factors were also differentiated by province as PCV7 uptake was 
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assumed to differ by geographical area. It was necessary to adjust controls to obtain a stable 
baseline by essentially removing the impact of PCV7 on serotypes in this group; this allowed 
for true increases in cases to be identified and not just relative case changes.  
 
Surveillance data for monitoring trends in IPD  
 
A number of countries have population-based surveillance programmes for 
monitoring infectious diseases. In South Africa, surveillance for IPD started in 1999 179 and 
the programme was expanded into a more comprehensive national active laboratory-based 
surveillance system, called GERMS-SA (Group for Enteric, Respiratory and Meningeal 
Disease Surveillance in South Africa) in 2003. This robust surveillance system provided us 
with good baseline data pre-PCV introduction to show trends post-PCV introduction 150.  
Cases of IPD were considered as hospitalized individuals with S. pneumoniae cultured from 
normally sterile site specimens. The GERMS-SA programme includes over 200 
microbiological laboratories (“non-enhanced” sites) which submit isolates and basic 
demographic information (age, gender, date of specimen collection, and body fluid source of 
isolate). Trained surveillance officers at 24 sentinel hospitals (“enhanced” sites) located in all 
nine provinces collect additional data including HIV status, discharge diagnosis and outcome. 
A number of factors can influence trend data besides the exposure of interest, in this 
case PCV. There was an improvement in healthcare services, ART for adults and children 
and HIV PMTCT programmes over the same period which also would have impacted trend 
data and needed to be accounted for in interpretation of PCV impact data 150. 
Surveillance data was used in three of the manuscripts included in this PhD. Firstly it 
was used for the baseline rates of the pneumococcal burden model for the different invasive 
clinical syndromes in both the pre- (2005-2008) and post-PCV (2013) period. In addition to 
the introduction of PCV, other interventions were instituted in South Africa between these 
two periods. We attempted to account for these other changes by using adjusted denominators 
stratified by HIV status, and using actual case numbers with altered HIV prevalence rates. 
Secondly it was used to calculate IPD incidence rates in HEU, HUU and HI infants in one 
year pre- (2009) and post-PCV (2013) introduction using adjusted denominators as before. 
Lastly we also used surveillance data in all age groups to demonstrate changes in serotype 1 
pneumococcal trends over an 11 year period using pre- (2003-2008) and post-PCV (2013) 
time points.    
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Case-control study  
 
A case-control study design was used to explore risk factors for pneumococcal disease 
in children; this was a secondary objective of the study, the primary being vaccine 
effectiveness. In our case-control study 122 which enrolled cases with IPD from 24 sentinel 
hospitals, there was only one group of controls. Controls were children hospitalised in wards 
or attending outpatient departments at the same hospital as the case. This group of controls 
were chosen based on convenience and the fact that we did not have mechanisms in place to 
enrol community controls e.g. through registers or telephone lists. We matched for age, as 
vaccination status is integrally linked to age; HIV status, as PCV efficacy differed in HU and 
HI children in the South African clinical trial; and hospital site as access to care differs 
between different provinces of South Africa. We explored risk factors associated with all-
serotype, VT, NVT and penicillin nonsusceptible IPD. We also determined the change in risk 
factors associated with PCV introduction by stratifying by vaccination status.  
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RESULTS AND DISCUSSION 
 
Detailed study results are presented in full within the results sections of each paper. Here we 
discuss some of the main issues arising from the results. 
Surveillance data was used as the baseline for most of our studies. There are inherent 
limitations in the use of surveillance data. Our laboratory-based surveillance programme 
underestimates the full burden of pneumococcal disease as it only includes patients who 
present to healthcare facilities and have samples taken; we aimed to address this in our 
burden model (paper I). There is often missing data associated with the use of surveillance 
programmes; we assumed that data were missing at random and imputed values for serotype 
for trend analyses. Interventions other than vaccination, for example PMTCT and ART, 
impact IPD disease trends. It is often difficult to tease out the proportional contribution of all 
these strategies on disease reduction using surveillance data.  
 
BURDEN OF POTENTIALLY VACCINE-PREVENTABLE PNEUMOCOCCAL 
DISEASE IN CHILDREN  
 
Summary of results and comparison with other burden models    
 
The estimates from our burden model demonstrated that approximately 196,100 
(178,500-210,400) total cases of severe hospitalised pneumococcal disease occurred annually 
in the pre-vaccine era. In 2013, 5 years after PCV introduction, only 67,300 total cases were 
estimated, a rate reduction of 2528 cases per 100,000 child-years. In terms of deaths 
approximately 8600 (7000-10200) pneumococcal-related annual deaths were estimated in the 
pre-vaccine period and 3600 in 2013, a rate difference of 99 per 100,000 child-years. These 
changes were assumed to be due to PCV as well as HIV-related interventions.  
Prior to our study, the only available burden estimates for pneumococcal disease for 
South Africa were derived from global pneumococcal models which included data on South 
Africa using a proportional mortality top down approach to calculate burden of disease.   
Most national disease burden estimates for pneumococcal disease are derived from 
models that use country specific inputs with a pneumonia component which is calculated 
from randomised control trial data. Data is then aggregated in a meta-analysis at the global 
level.  In contrast we used country-specific surveillance data on IPD as the input data for 
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building our burden model, a bottom up approach, and adjusted for underestimation in case 
ascertainment. Our model differed from the global model of O’Brien et al. in its conceptual 
approach and in terms of several input parameters; it allowed us to assess the degree to which 
the models calculated similar or different disease rates. Death rates for South Africa reported 
by the pre-PCV era global model 15 were 101 (72-140) per 100,000 py for total pneumococcal 
death rates, 9 (6-25) per 100,000 py for meningitis and 82 per 100,000 (60-90) py for 
pneumonia in the <5 year old age group in 2000. Rates from our model for the pre-vaccine 
period (2005-2008) were similar: 166 (87-261), 7 (6-8) and 139 (59-243) per 100,000 py in 
these respective groups, but our rates in 2013 were lower than an updated model 180 which 
reported 203 (164-241) per 100,000 py for total pneumococcal death rates, 19 (16-23) per 
100,000 py for meningitis and 166 (133-198) per 100,000 py for pneumonia in the <5 year 
old age group.  
As mentioned the pneumococcal global burden paper used three different methods for 
determining incidence and death rates for different pneumococcal syndromes 15. Both this 
model and our model used an incidence based approach for meningitis. We were able to use 
this approach as we had actual meningitis case numbers and appropriate case fatality rates. 
The O’Brien model adjusted case fatality rates for access to care, while we adjusted our 
meningitis estimates for specimen taking practices, resulting in similar estimates. The global 
model used a proportional approach for pneumonia using vaccine efficacy trial results 20,21,28-
32 for WHO-defined clinical pneumonia to determine the proportion of cases attributable to S. 
pneumoniae and WHO-defined CXR positive pneumonia for deaths. For pneumonia we used 
actual case numbers and CFRs for bacteraemic pneumonia and used vaccine efficacy trial 
results 20 to estimate non-bacteraemic pneumonia numbers. There are limitations in using the 
vaccine probe approach for allocating aetiological fractions; clinical definitions err on the 
side of higher sensitivity but low specificity in detecting pneumococcal pneumonia. The 
global model used triangulation to determine the burden of NPNM invasive disease from 
meningitis cases while our model used actual non-meningitis non-pneumonia cases. Lastly 
the global model calculated numbers of HIV-infected children by using HIV prevalence rates 
while our model used HIV data from the surveillance programme. 
Burden of disease models usually combine multiple data sources to calculate the 
number of cases and deaths from defined diseases in a certain population. Disease burden 
may be reported as incidence rates as described in our model; however disability-adjusted life 
years (DALYs) or quality-adjusted life years (QALYs) measurements may also be used 181. 
Death rates are used to compare mortality in different regions of the world and vital 
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registration systems are often used. These registration systems usually underestimate the true 
number of deaths 182. In our model we used death rates observed in hospitalised cases 
captured through our surveillance programme.  
 
Considerations for interpreting burden model results 
 
Burden models are often particular to the setting in which they were calculated as they 
usually use locally specific data. The choice of potential covariates and structure of the model 
introduces uncertainty and variability into the model. It is important to account for model 
uncertainty otherwise standard error calculations will underestimate the overall equivocality 
of the results. Bayesian model averaging or stratification of data may be used to deal with the 
variability 183.  
A pathogen-based incidence approach like our burden model usually uses data 
acquired from different surveillance sources, including notification or lab surveillance data 
for symptomatic cases, hospital data for hospitalised cases and vital registration systems for 
death rates. Data from these routine surveillance sources need to be adjusted when estimating 
disease burden to correct for underreporting (misdiagnosis) and under-ascertainment (cases 
who never seek health care). The multiplication factors used to adjust the data should be age-
specific and disease-specific at minimum 184.  
As previously mentioned, in South Africa in the post-PCV period a number of other 
interventions, including improvements in PMTCT and paediatric ARTs changed the profile 
of pneumococcal disease in HIV-infected children. Data was not available for all adjustment 
parameters in the post-PCV era resulting in some pre-PCV parameters been used for these 
calculations. This may have overestimated the contribution of HIV to pneumococcal disease 
in 2013 and inflated our calculation of case numbers and deaths. In 2013, the estimated 
number of deaths in children <5 years of age for South Africa was 44000 (35000-55000), 
40% during the neonatal period and 15% due to pneumonia 185. Our model estimated that 
approximately 8% (3600) of these deaths were still due to severe pneumococcal disease, 
mostly pneumonia. This has important implications for management guidelines for 
pneumonia including choice of antibiotics and taking of blood cultures. In addition continued 
surveillance to monitor changes in pneumococcal disease especially replacement serotypes is 
important. 
 
Generalisability of results and accounting for variability  
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Our burden model was based on national laboratory-based surveillance data which 
included isolates from both urban and rural sites. It is likely that representivity differed 
between these sites, however our model adjusted for differences in specimen taking practices 
assuming that urban sites and certain provinces with more academic facilities were more 
likely to take specimens. This adjustment was also assumed to account for access to care and 
deaths prior to reaching facilities (which is likely higher in rural areas).  
We considered alternative parameters and adjustment factors by conducting one-way 
sensitivity analyses by changing a single variable at a time. We explored changing the HIV 
prevalence (community versus hospitalised patients), using different specimen-taking 
estimates and lower vaccine attributable reduction ratios which all lowered our case 
estimates. Using alternative non-bacteraemic pneumonia estimates and adding community 
deaths increased our estimates  
To account for variability and uncertainty around our estimates we used 
bootstrapping, a robust statistical method, to calculate confidence intervals. Bootstrapping 
relies on fewer assumptions than more traditional statistical approaches but is often more 
accurate in certain circumstances, requires smaller sample sizes and is easier to implement for 
complicated statistics. Bootstrapping assumes that each sample is identically and 
independently distributed. It draws many more sub-samples than other methods and provides 
less biased and more consistent results than the Jackknife method for example 186.  
 
Remaining gaps and implications following our study   
 
Our burden model only estimated the burden of severe pneumococcal disease in 
children <5 years of age in a middle income country. Pneumococcal burden estimates are still 
required for older children and adults as well as for non-invasive pneumococcal disease, for 
example otitis media, in order to build the complete burden pyramid. In addition the cost of 
pneumococcal disease in our setting and the cost-effectiveness of PCV in South Africa would 
be important to determine.  
We were not able to accurately estimate the individual contribution of PCV and HIV 
interventions (ART and PMTCT) to the reduction in IPD observed in 2013. Based on 
findings from the surveillance programme which showed the reduction in IPD between 2005-
2008 and 2012 150 we made some assumptions regarding the impact of PCV. We assumed 
that all reductions in PCV7 serotypes (85%) in HIV-uninfected children <2 years of age were 
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due to PCV7, while in HIV-infected children <2 years of age the impact of PCV (55%) was 
assumed to be the difference between changes in the PCV7 serotype rates (86%) and NVT 
serotype rates (31%), the latter assumed to be due to the effect of ART.  
In our study we noted differential changes in PCV13 and non-PCV13 serotypes in 
2013 in HIV-infected and HIV-uninfected children by syndrome. In HIV-infected meningitis 
cases aged <5 years, there was a reduction in both PCV13 (90%) and non-PCV13 (22%) 
serotypes; while in contrast PCV13 serotypes were reduced (90%) in HIV-uninfected 
children, but non-PCV13 serotypes increased by 27%. A similar picture was seen with non-
pneumonia non-meningitis rates. For incidence rates in bacteraemic and non-bacteraemic 
pneumonia cases, there was a decrease in PCV13 serotypes in HIV-infected (89%) and –
uninfected (83%) children, while non-PCV13 serotypes increased in both groups (1.1 fold in 
HIV-infected and 1.9 fold in HIV-uninfected children). For all syndromes combined for 
children aged <5 years there was a 85% reduction in PCV13 serotypes in HIV-infected 
children with a 75% increase in non-PCV13 serotypes; in HIV-uninfected children there was 
an 83% reduction and a 98% increase, respectively. The increases in non-PCV13 serotypes 
are indicative of replacement disease which has been observed in surveillance data for 
children <5 years of age from the UK 187, but not in the US 188.  
 
EPIDEMIOLOGY OF SEROTYPE 1 INVASIVE PNEUMOCOCCAL DISEASE  
 
Summary of results and comparison with other serotype 1 studies  
 
Serotype 1 (ST1) IPD has been described to have a number of distinct characteristics 
when compared to other pneumococcal serotypes. In our study we demonstrated that over 11 
years of surveillance (2003-2013), the incidence of serotype 1 (ST1) IPD fluctuated 
significantly with two clusters of ST1 IPD from May 2003 to December 2004 and September 
2008 to April 2012. ST1 is amongst the most frequently isolated IPD serotype and has been 
shown in other studies to fluctuate year-on-year and cause outbreaks 189,190. 
When we explored factors associated with ST1 IPD, compared with all other 
serotypes, in children <5 years of age we found that older children (1-4 years) were more 
likely to have ST1 IPD than the youngest group (<1 year). In the <5 year olds, the most 
common serotypes prior to PCV introduction (2003-2008) were 14, 6B, 6A, 19F, 23F and 
19A; while in the post-PCV era (2010-2013) in the same group, serotypes 19A, 6A, 8, 23F, 
6B, 19F and 35B had the highest numbers. ST1 IPD differed by province and year 
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demonstrating its epidemic-prone nature. Young children with ST1 IPD were hospitalised for 
shorter periods, were less likely to have HIV or die or have resistant disease compared with 
children with non-ST1 IPD. Other studies have shown that ST1 has low mortality and rarely 
causes antibiotic resistance. ST1 has a short duration of carriage which allows reduced 
opportunity for recombination, genetic diversity and antibiotic resistance 48. 
Serotype 1 was the most common serotype in older children and adults (≥5 years) in 
the pre-vaccine era and the post-vaccine era. These older individuals with ST1 IPD had lower 
rates of hospitalisation and were hospitalised for shorter periods when compared to 
individuals with non-ST1 IPD. HIV and resistance rates were also lower and pneumonia was 
more common than meningitis in ST1 IPD. ST1 tends to affect young adults without 
underlying conditions and frequently causes uncommon clinical manifestations of 
pneumococcal disease such as empyema and peritonitis 48. When ST1 is associated with 
pneumonia it is usually bacteraemic pneumonia 191. When we analysed factors associated 
with in-hospital deaths in patients with ST1 IPD, the extremely young (<1 year), those with 
underlying conditions and those with meningitis were more likely to die. In older individuals 
the elderly and extremely ill were also more likely to die. Our findings regarding ST1 
disease, i.e. syndrome, age and underlying conditions, were similar to a study from Israel 
(2000-2009) 192.  
 
Considerations for interpreting cluster results 
 
Spatial epidemiology has been described as the “study of spatial variation in disease 
risk or incidence” 193 and it can be used to advise public health decision making 194. Our 
spatio-temporal analysis identified two large serotype 1 clusters, which were not recognised 
prospectively, due to the limitations of laboratory-based surveillance data. There is a delay in 
the processing and serotyping of samples from laboratory-based surveillance which hinders 
the ability to identify community-wide clusters in real time. In addition clusters were over 
prolonged periods and across a number of provinces which complicated identification. A 
cluster is considered as a number of health events (in our study serotype 1 pneumococcal 
cases) situated in close proximity in space and/or time. Clusters may be detected using a 
number of different techniques which are based on cell counts, or on adjacent high cell 
counts, or on distance between events 195. A large cluster may engulf surrounding regions 
which don’t have an elevated risk of disease 196. 
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 We explored clustering of other epidemic serotypes, i.e. serotypes 5 and 8, over the 
study period to assist in the interpretation of the two ST1 clusters. These serotypes fluctuated 
at low levels with small numbers. When we modelled serotype 5 changes in children <5 years 
of age, we ascertained that compared with 2005, which was considered the baseline, there 
were no significant increases in case numbers. Most years showed a decrease in numbers, 
especially 2013. Similar findings were found in individuals ≥5 years of age. When we 
modelled serotype 8 changes in children <5 years of age, compared with 2005, there were 
increasing trends in case numbers from 2011-2013 but none were significant. In persons ≥5 
years of age, there were non-significant increases in 2006-2008 and 2012-2013. 
We used a Geographic Information System (GIS) to analyse and present our serotype 
1 cluster data spatially-referenced data. GIS is able to handle large volumes of data with 
repetitive tasks and compare spatial data from various sources and different spatial areas. 
However, GIS data does not always adequately represent spatial-temporal information as it 
usually represents static points in time 195. We were able to demonstrate two clusters of 
serotype 1 by district level during May 2003 to December 2004 (Gauteng, Mpumalanga, 
Limpopo and North-West Provinces) and September 2008 to April 2012 (KwaZulu-Natal, 
Free State, Gauteng, North-West, Mpumalanga and Eastern Cape Provinces). We were only 
able to map ST1 IPD incidence for all age groups at district level, so minor changes in 
incidence and clusters at the individual healthcare facility level may have been missed.  
 
Generalisability of results  
 
Only patients who had relevant samples taken were identified as IPD cases and 
included in our surveillance programme. This means that more severe cases that potentially 
did not reach a health facility or died soon after admission would not be represented by the 
surveillance programme. Most of our enhanced sites were urban or peri-urban sites which 
may not be completely reflective of rural sites.  
 
Remaining gaps and other considerations following our study   
 
The PCV13 vaccine has been found to induce antibodies against the serotype 1 
capsule in children; however in two clinical trials from The Gambia and South Africa using 
PCV9, protection could not be demonstrated against serotype 1 clinical disease, although case 
numbers were small 197,198. In addition these two trials, which used three infant vaccine doses 
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only, showed that serotype 1 vaccine failures occurred after 12 months of age 199. It was 
suggested that a booster dose may be necessary for protection against this serotype. As 
mentioned the serotype 1 capsular polysaccharide is particularly resistant to opsonisation and 
it is uncertain whether protein-conjugate vaccination will be as effective against serotype 1 
disease as against other serotypes.  
In the United Kingdom PCV13 was introduced in April 2010 in a 2+1 schedule. 
Annual serotype specific incidence rates showed a significant reduction in serotype 1 rates 
between 2008-2010 and 2013-2014 in all age groups 140. An indirect cohort study, including 
data up to 3.5 years after PCV13 introduction, showed protection against serotype 1 with a 
vaccine effectiveness of 84% (95% CI 54-95) 200.  
In South Africa a case control study demonstrated a high vaccine effectiveness point 
estimate against serotype 1 (89% [95% CI -82-100]) although the results were not statistically 
significant (Cohen 2016, submitted). In the USA no reductions in serotype 1 incidence rates 
were shown, but case numbers were small 142.  
As ST1 is an outbreak serotype with fluctuating annual cases it is important for 
surveillance programmes to monitor for increasing case numbers. The main aim of 
monitoring for outbreaks would be to determine if there are any modifiable risk factors or 
public health changes which could be made to stop the spread of the outbreak. In addition it is 
important to determine if new serotype 1 clones are emerging as these may have different 
characteristics in terms of antibiotic resistance. 
Following the introduction of PCV13 it is assumed that serotype 1 case numbers will 
decrease although previous studies  showed differing results. Our study only included data on 
ST1 up to 2 years post-PCV13 introduction. It is important to continue to monitor trends in 
outbreak prone serotypes included in PCV13 to document whether there is indeed a sustained 
reduction in these serotypes.  
 
INCREASED INVASIVE PNEUMOCOCCAL DISEASE RISK AND MORTALITY IN 
HIV-EXPOSED BUT UNINFECTED INFANTS  
 
Comparison with other studies including HIV-exposed-uninfected children  
 
The PMTCT programme for HIV in South Africa has improved significantly over the 
last decade. Mother-to-child HIV transmission rates decreased from 16.4% in 2006 to 2.4% 
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in 2012 170, despite an antenatal HIV prevalence of around 30% over the same period. This 
resulted in an increasing population of HEU children and less HI children. 
To explore the risk of disease and mortality associated with IPD in HEU children we 
included cross-sectional data from a surveillance programme as well as data from a nested 
case-control study. We were able to use the cohort data to determine incidence of HEU to 
HUU and HI children while the case-control data allowed us to explore risk factors for IPD 
associated with being HIV exposed but uninfected.  
Our case-control study showed that the single risk factor which remained significant 
in all the subgroup analyses for IPD in HU children was been exposed to HIV. For all-
serotype IPD and NVT-IPD, HEU children had a two times higher odds of IPD [OR 1.62 
(95% CI=1.10–2.37) and OR 1.96 (95% CI=1.25–3.07), respectively]. The increased risk was 
more marked for VT-IPD [OR 3.05 (95% CI=1.10–2.37)], especially in unvaccinated 
children [OR 8.80 (95% CI=1.23–62.94)]. Prior to our study, HIV exposure had not been 
described as a specific risk factor for IPD; it had however been shown to be associated with 
an increased risk of lower respiratory tract infections and bacterial infections. 
 All-cause hospitalisation rates and complicated hospital admissions are more frequent 
in HEU than in HUU infants 86,88. Some infectious diseases, including respiratory tract 
infections 201, are more common and often more severe among HEU than HUU children. 
HEU children tend to have more severe infections, for example persistent diarrhoea 202, 
complicated acute malaria 203 and higher treatment failure rates with pneumonia 86. In our 
study we showed that HEU children were more likely to have pneumococcal pneumonia than 
other syndromes when compared with HUU children..  
A pooled analysis of three longitudinal community studies from Uganda, Tanzania 
and Malawi found that both maternal HIV infection and maternal death increased the risk of 
childhood death 204. In Botswana discontinuation of breastfeeding increased the risk of death 
in HEU compared with HUU children 205. In our dataset we only had breastfeeding data for 
17-35% of cases across all years and could therefore not make definite conclusions regarding 
the contribution of breastfeeding as a risk factor in our population. Not accounting for 
breastfeeding in our study may have resulted in confounding in our comparison of HEU, 
HUU and HI children as breastfeeding practices possibly differed between these groups.  
We established that the incidence of IPD was three-fold higher in HEU infants <6 
months of age when compared with HUU infants. It is possible that breastfeeding differed 
between HEU and HUU children in our study. Breastfeeding is protective against IPD and 
mortality which may have resulted in residual confounding in our risk factor and mortality 
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analyses. A number of studies could not show a significant difference in mortality between 
HEU and HUU children 206-209. In our study we demonstrated that HEU infants less than 6 
months of age with IPD were more likely to die than HUU infants likely due to differences in 
breastfeeding practices. This increased risk was not shown in the older infants.  
In our study HI infants were at higher risk of malnutrition, previous hospital 
admissions, non-susceptible pneumococcal disease and death than HEU infants. In addition 
children who were malnourished and who had pneumococcal meningitis were also more 
likely to die. A study in Tanzania (1995-1997) enrolled 474 HU and 69 HI children and 
followed them up until 12 months of age. CD4 counts were measured in children every 3 
months and they decreased linearly among HI children and increased linearly among HEU 
children. Predictors of IPD in HI and HEU children included malnutrition and advanced 
maternal HIV 210. As shown in the literature, for HI infants, we found that those who had a 
low CD4 count (CD4 percent <30) were 2-3 times more likely to die [infants <6 months (OR 
2.43, 95% CI = 1.12-5.28) and >6-<12 months (OR 2.73, 95% CI = 1.16-6.41) then those 
with a higher CD4 count. CD4 T-cell depletion rates in HI children are predictive of mortality 
and poor clinical outcome. A prospective cohort study in South Africa in 848 mother–child 
pairs determined that the main causes of infant morbidity were gastrointestinal and 
respiratory infections. The mortality rate among HI infants was eight times higher than 
among HU infants 93.  
 
Considerations for interpreting surveillance data results 
 
Surveillance data is used to monitor population health to develop and direct public 
health strategies, for example to target specific high risk and underserved groups. It allows 
large-scale between-country comparisons. Surveillance data may be limited by under-
reporting and misclassification, trend changes due to logistic and operational reasons, 
changes in case definitions or testing strategies and multiple interventions. In our surveillance 
programme decreasing trends in IPD rates were demonstrated after the introduction of PCV. 
Some of the reductions in HI individuals were also attributed to improvements in HIV care. 
To account for the impact of HIV interventions in HI individuals when exploring trend data, 
it was assumed that reductions in non-vaccine type disease was due to HIV interventions 
while vaccine-type disease was mainly influenced by PCV introduction; the difference in rate 
reductions between VT-IPD and NVT-IPD were then assumed to be due to PCV introduction 
150. This assumption is not entirely accurate as HIV-interventions also reduce VT-IPD; it is 
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however difficult to tease out the differential impact of PCV and HIV-interventions on 
disease. To ensure that changes in laboratory testing did not influence trend rates, PCR results 
were excluded from reported trends. The number of hospitals and laboratories covered by the 
surveillance programme increased between 2005 and 2012 from 126 to 459 hospitals (and 
109 to 215 laboratories);  however, 94% (32,922/35,192) of cases were reported from 150 
hospitals, and more than 70% of these hospitals reported cases for the full period 150. 
 
Generalisability and implications of results  
 
As mentioned only certain patients with IPD would have been captured by our 
surveillance programme. In addition only patients with clinical data were included in some 
analyses, which may have limited the generalisability of some of our findings to certain 
groups. However we used national data for incidence calculations and had large numbers of 
children <1 year of age in our dataset which would likely make our results applicable to other 
low/middle income countries with high HIV prevalence. In addition our findings were similar 
those from other studies 83,208.      
With increasing numbers of HEU children who have a higher risk of IPD when 
compared to HUU children, it is important to ensure that HIV-infected pregnant women 
receive ART to optimise the outcome of the infant and reduce HIV transmission. It is also 
important recognise these children to ensure that they receive appropriate doses of PCV to 
reduce their risk of IPD and its negative health outcomes, including death. 
 
CHANGING RISK FACTORS FOR INVASIVE PNEUMOCOCCAL DISEASE IN 
YOUNG CHILDREN IN A HIGH HIV PREVALENCE SETTING 
 
As part of a nested case-control study we explored the risk factors predisposing 
children to IPD in South Africa. In HU children, besides from being HIV-exposed other risk 
factors in this group included having siblings <5 years old, underlying medical conditions, 
preceding upper respiratory tract infections and day care attendance, while been vaccinated 
with PCV7 was protective.  
In HI children, advanced HIV disease was more common in cases than controls; being 
recently diagnosed with tuberculosis and malnutrition increase the odds of IPD in cases 
versus controls, while use of ART was protective.  
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Comparison with other risk factor studies   
 
We described risk factors in HU children which were in line with conventional 
pneumococcal risk factors. In our study these risk factors included, day care attendance 
which may increase IPD risk due to crowding which aids in transmission of pneumococci and 
higher pneumococcal loads, mixing of children with different pneumococci and possible 
cessation of breastfeeding 75; living with siblings less than 5 years of age due to high rates of 
pneumococcal carriage 211, underlying medical conditions 75, poor socioeconomic conditions 
which are often associated with crowding and different odds in different race groups and by 
sex. Vaccination with the conjugate pneumococcal vaccine reduced the odds of disease in HU 
children 120. 
A number of factors increased the risk of antibiotic-resistant IPD. In HU children we 
found that black race, a recent hospital admission, been HIV exposed and attending day care 
was associated with penicillin-nonsusceptible disease. In HI children, being malnourished, 
recent tuberculosis or a respiratory tract infection increased the odds of disease, while ART 
use reduced the odds of penicillin-non-susceptible disease. Upper respiratory tract infections 
may increase vulnerability to bacterial infections by causing changes in the respiratory 
epithelium which promote bacterial invasion 212. Previous studies and reviews 78 have showed 
a positive association between day care attendance and resistant disease, likely due to 
crowding, lack of hygiene and a higher use of antibiotics as children often have recurrent 
respiratory tract infections. Previous admissions and respiratory tract infections are associated 
with antibiotic use which in turn results in increased resistance, especially if antibiotics are 
used inappropriately.  
A case-control study nested in the US Active Bacterial Core surveillance programme 
76 explored risk factors associated with IPD in the PCV7 era and demonstrated that cases and 
controls differed in terms of race, gender, history of breastfeeding, smoke exposure in the 
home, day care attendance, caregiver education level, presence of underlying illnesses, 
household income and healthcare coverage. This study showed a reduction in risk among 
traditional risk groups following PCV introduction, while children with underlying conditions 
still remained at risk of IPD 76; similarly in our study children with underlying medical 
conditions remained at risk of IPD.  
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Considerations for interpreting case-control study results 
  
Prior to introduction of PCV into the EPI-SA, a randomised controlled trial showed 
good efficacy of this vaccine in a high HIV prevalence setting 21. Post-PCV introduction into 
routine use, other study designs need to be used to evaluate vaccine effectiveness as placebo 
controlled trials are no longer ethically acceptable. One option is a case-control study design 
213,214. Case-control studies can be used for rare diseases, such as IPD, and are less costly and 
time-consuming then randomised trials or cohort studies. Case-control studies are however 
subject to bias and confounding. There are a number of strategies to minimise bias 215: 
attention must be given to the choice of cases and controls, for example having a clear case 
definition for cases, random selection of controls, matching of cases and controls; ensuring 
that there are no confounding associations between detection of disease and risk factor 
exposure and use of statistical techniques, such as stratification or logistic regression. In 
addition use of “sham” outcomes and exposures can be used to determine whether bias 
affected the results of the study 215.  
Choosing the correct control group is vital to the conduct of a case-control study and 
when considering differences in risk factors between cases and controls. Differences may 
occur if cases are compared to hospital or community controls 216,217. In our study we 
included hospitalised controls or those seen at the hospital outpatient department due to ease 
of access. Hospitalised controls may not be representative of children in the community from 
which the case originated as they may have different vaccination and disease risk factor status 
with different IPD risk factors. For example, if controls were hospitalised with gastroenteritis 
many risk conditions would be elevated in these children resulting in some risk factors been 
potentially missed or underestimated when compared with IPD cases. However, there are 
advantages to using hospital controls; besides for the convenience of enrolment, their health-
seeking behaviour is likely similar to hospitalised IPD cases. We had to take these differences 
into account when we analysed risk factors for cases with IPD.  
Matching is an important strategy to control for known confounders and ensure that 
there are enough controls in each subgroup 218,219. However, as in our study, some cases were 
excluded in the analysis when no matched controls could be found, and especially in the HI 
group, enrolment of eligible HI controls often took months as it was difficult to find controls 
who met the eligibility criteria. An enrolment algorithm was followed if sufficient controls 
were not identified within a prescribed period and cases were often closed with one or two 
controls.   
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Generalisability of results  
 
The public health impact of pneumococcal vaccines as well as the risk factors 
associated with IPD may differ between and within countries.  We analysed risk factors by 
province as we had national data and risk factors were not statistically different across 
provinces. However, enhanced sites that collected risk factor data were predominantly urban 
or peri-urban sites and our results may therefore not be generalisable to more rural areas of 
South Africa. It is likely that our results may be generalisable to other developing countries 
with a high HIV prevalence.  
Pre-PCV introduction in the USA, age (<2 years of age) and race (black) were risk 
factors for pneumococcal disease. Following PCV introduction, rates in black children 
decreased by 83% to similar rates to those in white children. In addition there was a reduction 
in the proportional difference in antibiotic non-susceptible disease in young children 220. In 
our study we showed a higher risk of IPD in HU children of black race, especially antibiotic 
resistant disease.  
 Another study from South Africa 88 showed that similar to our study, young infants 
who were HIV-exposed but uninfected were shown to have an increased risk of severe 
disease.   
 
Remaining gaps and implications following our studies   
 
Even though there were limitations in our choice of control group which may have 
resulted in some risk factors been missed, our risk factors were comparable to previous 
studies. We only had breastfeeding data for <40% of all cases and could therefore not make 
definite conclusions regarding its role as a risk factor in our population. In other studies, 
however, breastfeeding has been shown to be protective against IPD and mortality and should 
be advocated for to improve child health. HI infants who were malnourished were more 
likely to die from IPD. Improving the nutritional status of HI infants and ensuring they 
receive appropriate ART is a key part of management. It is important to continue to document 
changes in risk factors for IPD with continued use of PCV, especially higher valency 
vaccines, and ongoing decreases in HIV rates in children. It is important to identify risk 
factors in order to prioritise interventions to reduce pneumococcal disease.   
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CONCLUSION 
 
This doctoral thesis has demonstrated that even in the post-PCV era, S. pneumoniae is 
still an important cause of invasive disease in young children in South Africa and represents a 
major public health burden and potential cost. There has been a reduction in HIV infection 
rates in young infants due to improvements in the PMTCT programme and an improvement 
in paediatric ART with an 18-fold greater reduction in the absolute burden of IPD in HI 
children. However there are increasing numbers of HEU children who we have shown to be 
more likely to be hospitalised with IPD. HEU infants <6 months of age were more likely to 
die from IPD than HUU children. From a public health point of view it important to continue 
targeting HEU children for PCV vaccination and ensure that IPD is diagnosed promptly 
especially in the very young to minimise mortality. In HU children, traditional risk factors 
such as poor socio-economic conditions and intense exposure to infection need to be 
addressed to reduce the burden of disease in these children. 
It is important to continue with robust ongoing surveillance to show reductions or 
increases in different serotypes in the post-vaccine era. We demonstrated that serotype 1 IPD 
had marked temporal variability with two large clusters observed between 2003 and 2012 and 
apparent reductions within two years of PCV13 introduction; however an extended period is 
needed to better define this change.  
Laboratory-based IPD surveillance should continue unchanged to allow for 
measurement against the baseline. In addition documentation of nasopharyngeal carriage at 
defined points in time may assist with prediction of which serotypes will become most 
prominent in the post-PCV13 period. Although vaccine-serotypes continue to decrease 
globally following PCV13 introduction, some increases in non-vaccine serotypes have been 
observed. There is a limit on the number of serotypes that can be conjugated in one vaccine 
and replacement non-PCV13 serotypes vary across different countries. New universal 
protein-based vaccines are therefore in development. A complete picture of the impact of 
PCV on pneumococcal disease burden is needed to support ongoing national policy decisions 
related to PCV use.  
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Abstract  
 
Introduction 
Streptococcus pneumoniae is a leading cause of severe bacterial infections globally. A full 
understanding of pneumococcal conjugate vaccine (PCV) impact on pneumococcal disease 
burden, following its introduction in 2009 in South Africa, can support the ongoing national 
policy on PCV use and assist with policy decisions elsewhere. 
 
Methods 
We developed a model to estimate national burden of severe pneumococcal disease pre- 
(average 2005-2008) and post-PCV introduction (2013) in children aged 0-59 months in 
South Africa. We estimated case numbers for invasive pneumococcal disease using data from 
national laboratory-based surveillance, adjusted for specimen-taking practices. We estimated 
non-bacteraemic pneumococcal pneumonia case numbers using vaccine probe study data. To 
estimate pneumococcal deaths, we applied observed case fatality ratios to estimated case 
numbers. Estimates were stratified by HIV status to account for the impact of PCV and HIV-
related interventions. We assessed how different assumptions affected estimates using a 
sensitivity analysis. Bootstrapping created confidence intervals.  
 
Results 
In the pre-vaccine era a total of approximately 196,100 (148,000-251,000) cases of severe 
hospitalised pneumococcal disease were estimated annually. In 2013, 5 years after 
introduction of PCV, 67,300 (49,000-95,000) cases were estimated, a rate reduction of 2528 
cases per 100,000 child-years. Approximately 8600 (4500-13,500) pneumococcal-related 
annual deaths were estimated in the pre-vaccine period and 3600 (1000-6800) in 2013, a rate 
difference of 99 per 100,000 child-years.  
  
Conclusions 
A reduction in the burden of pneumococcal-associated hospitalisations and deaths, 
temporally associated with PCV introduction, was noted in children aged <5 years in South 
Africa. The impact of other interventions such as improvements in HIV care can’t be 
excluded.  
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Introduction 
 
Streptococcus pneumoniae is a leading cause of bacterial pneumonia, meningitis, and sepsis, 
and was estimated to cause 335,000 (240,000-460,000) deaths in children <5 years in 2015 
globally (1). In 2008, immediately before the introduction of the pneumococcal conjugate 
vaccine (PCV)  in low income countries, the estimated number of deaths was 541,000 
(376,000- 594,000) (2). In South Africa HIV-infected children, as well as HIV-exposed-
uninfected children, had a higher incidence of all acute lower respiratory tract infections 
(LRTIs) than HIV-unexposed-uninfected children, even in the post-PCV era (3). In addition 
the incidence of pneumococcus-associated LRTIs still remained higher in HIV-infected than 
–uninfected children, although the rate ratio was not significant.  
 
Prevention of pneumococcal disease by PCV use has been documented through effectiveness 
and impact data from more than 50 countries (http://view-hub.org/viz/). In South Africa, the 
7-valent pneumococcal conjugate vaccine (PCV7) was introduced nationally in April 2009 
and replaced by PCV13 in June 2011.  National surveillance data for invasive pneumococcal 
disease (IPD) from South Africa showed a 69% (95% confidence interval [CI]: 65-72%) 
reduction in the incidence of all-serotype IPD among children aged <2 years by 2012, with 
contributions by PCV and HIV-associated interventions (4). 
  
The burden of pneumococcal disease has been described in young children in the African 
region (5) with epidemiological studies in a number of countries including The Gambia (6, 
7), Kenya (8) and South Africa (9). World Health Organization (WHO) country specific 
estimates of disease burden (1, 5, 10) generate summed regional and global estimates using 
country specific inputs for syndromic mortality (pneumonia and meningitis) along with other 
country specific parameters (e.g. pathogen specific case fatality ratios, HIV prevalence, 
population size, vaccine coverage).  However, these models do not include the observed 
incidence of IPD.  South Africa has excellent surveillance to measure IPD incidence and thus 
allows for an alternative model to estimate national cases and deaths from pneumococcal 
disease, anchoring on this observed value. The model can be updated over time to track 
improvements in health and be compared to other estimates.   
 
We aimed to estimate the national burden of severe hospitalised pneumococcal disease 
(meningitis, bacteraemic and non-bacteraemic pneumonia, and non-pneumonia non-
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meningitis invasive disease) among HIV-infected and HIV-uninfected children aged 0-59 
months in South Africa in two periods: 2005-2008, before PCV was introduced, and 2013, 
after PCV was introduced. Estimates were based on the observed IPD incidence measures 
from our surveillance system, as an alternative approach to that used by the WHO.  
 
Methods 
 
Model overview 
We developed a conceptual model to estimate the national burden of pneumococcal cases, 
deaths, incidence and mortality rates, in children 0-59 months in South Africa for the pre-
vaccine (average 2005-2008) era and one year (2013) of the post-vaccine era (Figure 1 and 
supplementary figures 1a and 1b). Cases and deaths averted were calculated as the difference 
between these two periods, i.e. over 5 years. We used the observed cases of IPD 
hospitalisations from the GERMS-SA surveillance programme at both time points, stratified 
by disease syndrome (meningitis, pneumonia and non-pneumonia non-meningitis) and by age 
(<1 year of age, 1-4 years of age) as the base rate and adjusted for incomplete specimen 
collection based on Corporate Data Warehouse (CDW) data numbers by province among 
hospitalised children. Gauteng province was used as the reference province for this 
adjustment because of its systematic testing practices. We stratified all estimates by HIV 
status which has previously been documented to affect burden of disease (9). Model 
parameters are given in Table 1a and calculations are explained further below as well as 
shown in Figure 1 (and Supplementary Figures 1a and 1b). All reported case numbers were 
rounded to the closest 100, except when counts were less than a 100. Incidence rates were 
calculated from the estimated cases using denominators from Statistics South Africa (11); 
incidence rates were reported to the lowest case number per 100,000 population. 
 
Estimated number of cases and incidence rates by clinical syndrome   
IPD case numbers were estimated from national laboratory-based surveillance (described 
below) and divided into fractions attributable to meningitis, bacteraemic pneumonia and non-
pneumonia non-meningitis cases on the basis of GERMS-SA clinical data. IPD case numbers 
were adjusted for sensitivity of blood culture among truly bacteraemic cases and CSF culture 
among those with pneumococcal meningitis, and incomplete specimen-taking practices 
among those with IPD. To estimate the number of cases of non-bacteraemic pneumococcal 
pneumonia, we extrapolated data from PCV probe studies in South Africa (12) by using the 
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PCV9 vaccine attributable reduction (VAR) ratio of clinical pneumonia to bacteraemic 
pneumococcal  pneumonia (11:1). An additional adjustment was made for the presumed 
underestimation of vaccine efficacy (VE) for non-bacteraemic pneumococcal pneumonia in 
this study. This assumption was based on a study which showed a higher pneumococcal 
detection rate using urine antigen testing in non-bacteraemic pneumonia in the elderly (13). 
The adjustment value (1.89) was based on the ratio of the original and inflated VE from the 
different studies (see Supplementary Material for detailed methods). 
 
Estimated number of deaths and mortality rates  
Pneumococcal death estimates for each syndrome were calculated by multiplying case 
estimates (as calculated above) by observed syndrome specific case fatality ratios (CFRs) 
(from GERMS-SA enhanced sites) for IPD cases by age group and HIV status. For non-
bacteraemic pneumococcal pneumonia we used the ratio of CFR (5:1) among all-cause 
community-acquired bacteraemia (28.2%) to all-cause non-bacteraemic hospital admissions 
(5.7%) reported in the literature from Kenya (14, 15) to calculate the non-bacteraemic 
pneumonia CFR. This CFR ratio was intermediate between those reported by two other trials 
(16, 17). Clinical trial data from The Gambia showed a death risk ratio of 4 times for end-
point pneumonia (3.0%) compared to ‘other infiltrates/abnormalities’ pneumonia (0.8%) (16) 
and a CFR of 6.6% in a study comparing cases with bacteraemic pneumonia to a non-
pneumonia control group (17). Mortality rates were calculated by dividing the estimated 
pneumococcal deaths by mid-year age-specific population denominators.  
 
Data sources   
GERMS-SA IPD surveillance programme 
GERMS-SA is an active, national, laboratory-based surveillance programme for IPD and 
other invasive organisms. All public health sector microbiology laboratories (>200) are 
encouraged to submit isolates to the National Institute for Communicable Diseases (NICD) in 
Johannesburg. The public sector serves 84% of the South African population without private 
medical aid coverage (18). Some private sector laboratories also submit isolates. Of the 
public sector facilities, 24 sites have dedicated surveillance officers who collect clinical 
information on identified patients thereby defining them as enhanced sites.  Laboratory-based 
surveillance for IPD in South Africa began in 1999 (19) and completeness of case reporting 
stabilised by 2005 (20). Cases of IPD were defined as illnesses in patients with S. 
pneumoniae cultured from normally sterile-body sites (e.g. cerebrospinal fluid (CSF) or 
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blood) or polymerase chain reaction (PCR) confirmation of culture-negative cases. 
Information on specimen type and age of cases is available from all sites; clinical diagnosis is 
reported only from cases that occurred at enhanced sites. Severe pneumococcal disease was 
considered as disease resulting in hospitalisation.  
 
National Health Laboratory Service (NHLS) Corporate Data Warehouse (CDW)  
The CDW is managed by the NHLS, the sole laboratory service provider for all public health 
facilities in South Africa. The CDW is a repository which contains archived data on all 
laboratory tests requested and results from public laboratories from 2003. 
 
Additional input parameters for model  
Values for input parameters of the model were derived from a number of sources. For 
estimates of non-bacteraemic pneumococcal pneumonia cases and adjustments for expected 
burden in presence of systematic blood culturing practices we used published data from a 
South African PCV9 vaccine clinical trial (12, 21). Published data was also used to derive the 
CFR for non-bacteraemic pneumococcal pneumonia (14, 15).  
 
Population denominators 
Annual age-specific population denominators used to calculate incidence and mortality rates 
were obtained from Statistics South Africa (11). The Thembisa model (22) was used to 
estimate population denominators by HIV status; these denominators accounted for the 
changes in mother-to-child HIV transmission rates and improvements in paediatric ARV 
treatment. 
 
Statistical analysis  
We calculated the percent reduction in incidence and death rates between the two periods 
(2005-2008 and 2013) using the following formula: 
 
 
Bootstrapping to create confidence intervals was used for all endpoints, to account for 
variability and uncertainty in detection rates, incidence rates and case-fatality rates from the 
surveillance data.  
 
Human subjects review 
% reduction = [Average incidence or death rate 2005 to 2008 – Incidence or death rate 2013]     
 Average incidence or death rate 2005 to 2008   
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Ethics approval was obtained for GERMS-SA surveillance (M081117) from the Human 
Research Ethics Committee (Medical), University of the Witwatersrand, Johannesburg, South 
Africa and other local hospital or provincial ethics committees, as required. Clearance for the 
surveillance programme was also obtained from the U.S. Centers for Disease Control (IRB 
00001223). 
 
Sensitivity analysis  
A one-way sensitivity analysis was performed by changing one variable at a time to see the 
effect on the total number of cases and deaths (parameters in Table 1b). A Tornado diagram 
was fitted around the base case estimates for cases (Supplementary figure 2a) and deaths 
(Supplementary figure 2b) to evaluate the sensitivity of the model to changes in the assumed 
values of key parameters (Details in Supplementary Material). 
 
Results 
 
Burden of invasive pneumococcal disease in the pre-vaccine era  
In the pre-vaccine era (2005-2008) an estimated national average of 196,100 (148,000-
251,000) annual cases of hospitalised pneumococcal disease, an incidence of 3799 (2870-
4853) per 100,000 person-years (py), occurred in children aged <5 years in South Africa 
(Tables 2 and 3). An average of 1100 (1000-1200) cases of pneumococcal meningitis (21 per 
100,000 py); 8600 (6700-11,200) bacteraemic pneumococcal pneumonia cases (167 per 
100,000 py), 181,500 (140,000-236,000) non-bacteraemic pneumococcal pneumonia cases 
(3515 per 100,000 py) and 4900 (3600-6100) non-pneumonia non-meningitis invasive 
pneumococcal disease cases (95 per 100,000 py) were estimated to occur annually in children 
0-59 months of age. Based on model inputs, the overall incidence for hospitalised 
pneumococcal disease was higher amongst infants <1 year of age (9024 per 100,000 py) than 
children 1-4 years of age (2472 per 100,000 py), a relative risk of 4; incidence was also 
higher among HIV-infected children (41,436 per 100,000 py) than among HIV-uninfected 
children aged 0-59 months (1741 per 100,000 py), a relative risk of 24. Similar trend were 
observed in all syndromes (Table 3).  
 
Pneumococcal related deaths and mortality rates in the pre-vaccine era   
In the pre-vaccine period an average of 8600 (4500-13,500) annual pneumococcal-related 
deaths, translating into a mortality rate of 166 per 100,000 py, was estimated to have occurred 
9 
 
in children 0-59 months of age (Table 4 and 5). An average of 370 (300-400) pneumococcal 
meningitis deaths (7 per 100,000 py), 1400 (900-2000) bacteraemic pneumococcal 
pneumonia deaths (27 per 100,000 py), 5800 (2200-10,000) non-bacteraemic pneumonia 
deaths (112 per 100,000 py) and 1000 (200-2000) non-pneumonia non-meningitis IPD deaths 
(20 per 100,000 py) were estimated per year. The overall pneumococcal mortality rate, based 
on CFRs, was higher amongst infants (550 per 100,000 py) than children 1-4 years of age (68 
per 100,000 py), a relative risk of 8, and also higher amongst HIV-infected children (1731 per 
100,000 py) than amongst HIV-uninfected children aged 0-59 months (80 per 100,000 py), a 
relative risk of 22 (Table 5).  
 
Impact of the pneumococcal conjugate vaccine and other interventions on the burden of 
disease   
Based on inputted model parameters we estimated that in 2013 there were 67,300 (49,000-
95,000) pneumococcal cases in children aged 0-59 months, 128,800 fewer cases than would 
have been expected based on the incidence of disease observed in 2005-2008 among this age 
group (Table 2). Since the IPD syndromic distribution observed in 2005-2008 and in 2013 
drives the case and death estimates for these two periods, any reductions by syndrome are 
inherently a result of the differences observed by syndrome in the IPD cases.  As a result of 
those differences, the model output had reductions in all syndromes between the pre- and the 
post-PCV periods. Similarly reductions were greatest in infants and HIV-infected children, 
the latter driven by the relative risk inputted into the model. 
The overall national annual incidence of pneumococcal disease in 2013 was estimated as 
1271 per 100,000 py in children 0-59 months of age, a total rate difference of 2528 per 
100,000 (67% reduction) compared with the pre-PCV period (Table 3). The annual incidence 
of pneumococcal meningitis in 2013 was 5 per 100,000 py in children 0-59 months of age 
(rate difference of 16 per 100,000, 77% reduction), 57 per 100,000 py for bacteraemic 
pneumococcal pneumonia (rate difference of 110 per 100,000, 66% reduction), 1187 per 
100,000 py for non-bacteraemic pneumococcal pneumonia (rate difference of 2328 per 
100,000, 66% reduction) and 22 per 100,000 py for non-pneumonia non-meningitis 
pneumococcal disease (rate difference of 73 per 100,000, 76% reduction). For all syndromes 
incidence was highest amongst infants and HIV-infected children as is expected based on the 
rates observed in the IPD GERMS data.   
 
Pneumococcal related deaths and mortality rates in 2013   
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In 2013 we estimated 3600 (1000-6800) annual pneumococcal deaths in children aged 0-59 
months, 5000 fewer than would have been expected based on modelled pneumococcal deaths 
in 2005-2008 (Table 4). The overall South African annual mortality rate for pneumococcal 
disease in 2013 was estimated at 67 per 100,000 py in children 0-59 months of age, a rate 
difference of 99 per 100,000 py (59% reduction) compared with the pre-PCV years (Table 5). 
The mortality rate was 10 times greater in infants (237 per 100,000 py) than in children 1-4 
years of age (24 per 100,000 py). The average pneumococcal meningitis mortality rate in 
2013 was 2 per 100,000 py in children 0-59 months of age, a rate difference of 5 per 100,000 
(76% reduction) compared with the 2005-2008 rate; 11 per 100,000 py for bacteraemic 
pneumococcal pneumonia (rate difference of 16 per 100,000, 58% reduction) and 49 per 
100,000 py for non-bacteraemic pneumococcal pneumonia (rate difference of 63 per 100,000, 
56% reduction).  
 
Sensitivity analysis  
The total numbers of pneumococcal cases and deaths estimated by the model changed 
depending on the values of key parameters used in the model (Table 1b); most variations 
resulted in lower estimates of cases and deaths (Supplementary Table 2a and 2b; Tornado 
diagrams, supplementary figures 2a and 2b).  The inclusion of death estimates in the 
community did not change the numbers of cases and deaths significantly from our base 
model, while variations in the CFR resulted in a 16-74% increase in the estimated number of 
pneumococcal deaths. In the sensitivity analysis when we changed other parameters, 
including the VAR NBP/BPP ratio of 11:1,  VAR NBP/BPP ratio of 7.6:1, the adjustment 
factor for systematic blood culturing and the HIV prevalence, the case numbers were reduced 
by 44%, 59%, 50% and 78% respectively. When the same parameters were altered in 
estimating pneumococcal deaths, numbers were reduced by between 33% and 49%.  
 
Discussion  
 
Our South African pneumococcal disease burden model has estimated that in the pre-vaccine 
era (2005-2008) an average of 196,100 (148,000-251,000) cases of severe pneumococcal 
disease were experienced per year in children 0-59 months of age. In 2013, 67,300 cases were 
estimated, a 2528 per 100,000 py rate difference. This 67% reduction in all serotype IPD 
compared with a non-PCV period was likely due to PCV introduction as well as 
improvements in HIV care and prevention. Other studies in the PCV13 era, which compared 
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reductions with the PCV7 period, showed a 64% (95% CI 59–68%) reduction in all IPD in 
the USA in children aged <5 years (23) and in the Gambia a 55% (95% CI 30-71%) reduction 
in children 2-23 months of age and 56% (95% CI 25-75%) reduction in children 2-4 years of 
age (24).  In the UK in 2014/2015 in all age groups the overall incidence of IPD, compared to 
the pre-PCV7 period, declined by 47%, but an increase was noted in non-PCV13 serotypes in 
this period (25).   
 
The model estimated 8600 (4500-13,500) annual pneumococcal deaths in children aged 0-59 
months in the pre-vaccine era; this translated into a mortality rate of 166 per 100,000 py. In 
children aged 0-59 months in South Africa there was an average of 61,749 annual all causes 
deaths and 14,927 annual pneumonia and influenza deaths over the 2005-2008 period based 
on Statistics South Africa data (26); the estimated pneumococcal deaths would have made up 
14% and 57% of these deaths respectively. A meta-analysis, including studies from the US, 
South Africa, Gambia and the Philippines, which assessed PCV efficacy on pneumonia 
concluded that approximately 21.2% of severe clinical pneumonia and 35.8% of CXR 
confirmed pneumonia was attributable to pneumococcal disease (5). In 2013 we estimated 
that 3600 (1000-6800) annual pneumococcal-related deaths occurred in children aged 0-59 
months, a mortality rate reduction of 99 per 100,000 py. In 2013 in children <5 years there 
were an estimated 35,094 overall deaths and 8596 pneumonia and influenza deaths in South 
Africa, based on Statistics South Africa data (26); the estimated pneumococcal deaths would 
have contributed to 10% and 41% of these deaths respectively. A review by Izadnegahdar, et. 
al. in 2013 (27) proposed that even in the post-PCV13 period, S. pneumoniae pneumonia may 
still make up 44% of pneumonia deaths due to non-PCV13 serotypes. This estimate is higher 
than that reported in a Child Health Epidemiology Reference Group (CHERG) systematic 
review which estimated that in 2011 S. pneumoniae made up 32.7% of pneumonia deaths in 
the African region and globally (28).  
 
An updated global burden model that includes a time series from 2000-2015 (1) with annual 
rates, calculated a total pneumococcal death rate of 203 (164-241) per 100,000 py, 19 (16-23) 
per 100,000 py for pneumococcal meningitis and 166 (133-198) per 100,000 py for 
pneumococcal pneumonia in children 1-59 months of age in 2008 for South Africa. When 
compared with our model which included children 0-59 months, the point estimates for the 
global model were slightly higher but the uncertainty ranges overlapped with our overall (166 
[87-261] per 100,000 py) and pneumonia (139 [59-243] per 100,000 py) rates. Our meningitis 
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rates were lower than those reported in the global model (7 [6-8] per 100,000 py). In 2013, 
our overall (67 [19-129] per 100,000 py) and pneumonia (60 [12-124] per 100,000 py) rates 
overlapped with the South African estimates from the global model (70 [57-83] and 56 [45-
66] per 100,000 py respectively). Our meningitis estimates were again slightly lower (2 [1-3] 
vs 8 [7-9] per 100,000 py) than the global model estimates. Even though the two models 
differed in their conceptual approach, their approach to neonatal deaths, and the inclusion of 
different input parameters, they provided similar death rate estimates. The global disease 
burden model is centred on a proportional mortality approach, taking as a given the all-
pathogen deaths for meningitis and for pneumonia provided by the Maternal and Child 
Epidemiology Estimation (MCEE) Group. These deaths are apportioned out to 
pneumococcus using country specific empirical data for meningitis and PCV clinical trial 
data (for pneumonia).  In contrast, the South Africa specific model used a bottom-up 
approach using IPD surveillance data as the anchor for the estimates, but it used the same 
PCV clinical trial data for pneumonia estimates. Lastly our model used the HIV prevalence 
rates for children identified with pneumococcal disease from our surveillance programme 
(67% in 2005-2008 and 30% in 2013) and not community prevalence rates (+/- 4% in 2008 
and 2% in 2013) used by other models.  
 
The greatest burden of pneumococcal disease in this study was contributed by pneumonia 
with a 96-fold higher rate than meningitis. This was similar to rates described in previous 
burden papers where pneumonia made up the bulk of pneumococcal disease (90-fold higher 
than meningitis) (5). 
 
The pre-PCV pneumococcal incidence rates calculated by this burden model were 
comparable to those from a clinical trial conducted in South Africa in the pre-antiretroviral 
treatment, pre-vaccine era from 1998-2001. This clinical trial reported an IPD incidence of 
331 per 100,000 py in young children in the placebo arm (21) which was slightly higher than 
this burden model rate of 283 per 100,000 py (2005-2008). The same trial demonstrated a 
bacteraemic pneumococcal pneumonia incidence for all children of 196 per 100,000 py (12) 
which was similar to our estimates of 167 per 100,000 py. The non-bacteraemic 
pneumococcal pneumonia rates (3515 per 100,000 py) were similar to the observed incidence 
of clinical lower respiratory tract infection (3565 per 100,000) rates among the placebo arm 
of the clinical trial (12). Our model utilised parameters from this clinical trial to calculate the 
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burden of non-bacteraemic from bacteraemic pneumonia, and this may have contributed to 
similar rates.  
 
Stratifying data by HIV status revealed a 49% reduction in the incidence of all serotype 
pneumococcal disease in HIV-uninfected children, and a 67% reduction in HIV-infected 
children aged <5 years based on data inputted into the model. The decrease in HIV-infected 
children is likely due to the combined effect of PCV, antiretroviral therapy and improvements 
in the prevention of mother-to-child transmission of HIV programme.  
 
Although we did not calculate costs of pneumococcal hospitalizations, there have been 
studies from Latin America which documented the substantial cost of pneumococcal disease 
and found that PCV introduction was cost-saving (29, 30). With approximately 26,000 
hospitalised cases averted annually in South Africa in 2013, it is expected that PCV will have 
significant cost reductions for the health system despite the expense of the vaccine. A health 
economic study in South Africa (Cohen, personal communication) calculated the median total 
cost for a severe acute respiratory infection (SARI) hospitalization as ZAR 8804.25; 
assuming a similar cost for pneumococcal disease, ZAR 228,910,500 (US$ 19,075,875) could 
be saved per annum in direct hospitalization costs compared with those that would occur 
without the PCV program. We did not account for the impact and costs of PMTCT and ART 
in these calculations.   
 
This study is subject to a number of limitations. First, the model is anchored on the GERMS-
SA IPD surveillance data which is primarily drawn from public sector laboratories, so may 
not be representative of all sectors in South Africa; however, 84% of the population access 
public health care in South Africa even though not all cases detected in private laboratories 
are captured. Second, a number of assumptions were made to adjust for the lack of sensitivity 
of detecting cases, and this contributes to higher incidence rates than would be inferred from 
the measured cases. It is possible that some of the difference in incidence rates were true 
differences. Although all the assumptions were based on published literature, it is possible 
that some of these assumptions were not accurate. For example, using a CFR for all 
hospitalised cases may have overestimated the CFR for non-bacteraemic pneumonia cases 
and the ratio of BPP to NBP may change by serotype distribution which we did not account 
for in our model. In addition some estimates (e.g. vaccine probe study data) were only 
available for the pre-vaccine period and were assumed to be relevant to the post-PCV period. 
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Third, we only calculated the burden of severe pneumococcal disease and did not include 
pneumococcal disease that was cared for only in the outpatient setting.  We were unable to 
include otitis media burden calculations in this model due to a lack of reliable African data.  
A US study showed that in children <5 years of age, acute otitis media made up 74% of 
pneumococcal cases (31), so this burden model is an underestimate of true pneumococcal 
burden. Fourth, as we used adjustment factors from a PCV-probe study in children (12) 
which based the diagnosis of pneumonia on clinical and CXR findings only, both of which 
have limitations in detection, we may have underestimated the burden of non-bacteraemic 
pneumonia in our calculations. We tried to account for this underestimate by including an 
adjustment for the increase in the known vaccine efficacy, based on more recent data, against 
non-bacteraemic pneumonia since these trials were conducted. Supporting evidence for this 
additional adjustment was seen in a recent PCV vaccine efficacy study in the elderly (13) 
which used a serotype-specific urinary antigen detection assay to detect vaccine-type S. 
pneumoniae. It is possible that this adjustment may have overinflated our numbers as it is not 
clear if the magnitude of the difference in VE for non-bacteraemic and bacteraemic 
pneumonia is the same for children as observed in the adult study. Fifth, we assumed similar 
PCV impact across all age strata among children less than 5 years and did not account for 
direct or indirect vaccine effects separately; we assumed that by using actual reported cases 
this would account for different impact rates. Lastly, there was a reduction in all-cause 
pneumonia deaths in South Africa over the 2005 to 2008 period (26); for the pre-PCV death 
rate calculations we assumed that rates were similar over this period and we may have 
therefore overestimated the change in pneumococcal death rates when compared with 2013.  
 
In summary, pneumococcal disease represents a major public health burden in children <5 
years of age in South Africa. Pneumococcal conjugate vaccination, in conjunction with other 
interventions, has resulted in a significant reduction in severe pneumococcal disease with 
approximately 130,000 cases and 5,000 deaths averted over a 5-year period. Although other 
interventions likely contribute to reductions in pneumococcal disease it is possible that PCV 
use may have a 'multiplier' effect of preventing other illnesses as children are generally 
healthier for not having had pneumonia or IPD.  
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Table 1a: Parameters used in base case model to estimate total number of cases, 
incidence and mortality rates for severe pneumococcal disease among children aged <5 
years in South Africa 
Parameter Value used in base case model Source of data 
Number of cases of invasive 
pneumococcal disease for 3 
clinical syndromes (meningitis, 
BPP, NPNM) 
IPD cases detected from enhanced and 
non-enhanced surveillance sites  
GERMS-SA 
surveillance programme  
Adjustment factor for 
systematic blood culturing from 
South African clinical trial: for 
Gauteng Province only  
Ratio of BPP incidence from Soweto 
clinical trial (1998-1999) to BPP 
incidence from GERMS-SA 
surveillance in same age group in 2005 
(<2 years of age) = 23 overall, 13 in 
HIV-uninfected and 23 in HIV-
infected children.  
Madhi 2005: VE clinical 
trial conducted in 
Soweto located in the 
Gauteng Province  
Adjustment for specimen-taking 
practices in provinces other than 
Gauteng Province  
 
(Provincial incidences rates 
calculated using provincial 
specific cases and provincial 
denominators) 
 
Provincial incidence rates were 
adjusted by the relative rate of blood 
cultures or CSF specimens collected in 
each province relative to Gauteng 
Province (baseline=1). Rate ratios 
differed by province and specimen 
type    
2005-
2008 
CSF Blood  
GA 1.00 1.00 
WC 1.27 1.26 
KZN 2.00 6.00 
NC 1.86 4.32 
EC 2.81 4.58 
NWP 2.48 10.51 
MP 2.53 18.06 
FS 2.04 2.43 
LP 5.60 80.13 
 
2013 CSF Blood  
GA 1.00 1.00 
WC 0.23 0.35 
KZN 2.30 35.35 
NC 1.84 11.82 
NHLS Corporate Data 
Warehouse (CDW): 
Collates data on CSF 
and blood specimens 
taken nationally & 
submitted to NHLS 
laboratories 
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EC 0.85 1.61 
NWP 1.66 15.08 
MP 2.71 40.06 
FS 0.39 10.71 
LP 5.70 82.37 
 
Number of cases of non-
bacteraemic pneumococcal 
pneumonia  
PCV9 clinical pneumonia VAR = 410 
cases/100,000 and all BPP VAR = 37 
cases/100,000 = ratio 11:1 
Additional adjustment for vaccine 
probe underestimate – VE against VT 
non-bacteraemic pneumonia is closer 
to 45% than 85% = 1.89   
Madhi 2005  
 
 
Bonten 2014  
HIV prevalence among IPD 
cases; used to calculate 
proportion of HIV-infected and 
–uninfected cases. 
Number of HIV-infected and –
uninfected cases calculated by 
syndrome and year  
GERMS-SA 
surveillance programme 
– HIV data available for 
enhanced sites  
Case fatality ratio  CFR for pneumococcal bacteraemic 
syndromes = unadjusted pneumococcal 
deaths from enhanced sites/unadjusted 
pneumococcal cases from enhanced 
sites; CFR determined by age, HIV 
status and syndrome. 
CFR for non-bacteraemic 
pneumococcal pneumonia based on 
published data on difference in CFR 
(28.2%) between all-cause bacteraemic 
cases and medical non-bacteraemic 
cases (5.7%) in Kenya.  
GERMS-SA 
surveillance data  
 
 
 
 
Ayieko 2013 
 
 
 
 
 
Adjusted number of deaths  Adjusted number of pneumococcal 
deaths = CFR*Adjusted pneumococcal 
case numbers  
GERMS-SA 
surveillance data  
Incidence and death rates using 
mid-year population 
denominators  
Incidence rates = Adjusted case 
numbers/population denominator  
Death rates = Adjusted death 
numbers/population denominator  
Statistics South Africa 
data  
HIV-specific denominators for 
incidence and death rates  
 
Incidence and death rates by HIV 
status  
AIDS and Demographic 
model developed by 
ASSA – was used to 
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adjust Statistics South 
Africa denominators for 
HIV influence 
 
Table 1b: Additional parameters for sensitivity analysis for severe pneumococcal 
disease among children aged <5 years in South Africa 
Parameter Value used in sensitivity model Source of data 
Number of cases of invasive 
pneumococcal disease for 3 
clinical syndromes (meningitis, 
BPP, NPNM) 
As for base calculations  GERMS-SA 
surveillance 
programme  
Adjustment factor for 
systematic blood culturing from 
South African clinical trial: for 
Gauteng Province only  
Ratio of IPD incidence from Soweto 
clinical trial (1998-1999) to IPD incidence 
from GERMS-SA surveillance in same 
age group in 2005 (<2 years of age) = 8.  
Klugman 2003: VE 
clinical trial 
conducted in Soweto 
located in the 
Gauteng Province  
Adjustment for specimen-taking 
practices in provinces other than 
Gauteng Province  
As for base calculations  NHLS CDW 
Number of cases of non-
bacteraemic pneumococcal 
pneumonia  
PCV9 Clinical pneumonia VAR = 410 
cases/100,000 and all BPP VAR = 37 
cases/100,000 = ratio 11:1 without 
additional adjustment  
Madhi 2005  
 
 
Number of cases of non-
bacteraemic pneumococcal 
pneumonia 
PCV9 WHO CXR confirmed VAR = 155 
cases/100,000 and all BPP VAR = 37 
cases/100,000 = ratio 4:1  
Madhi 2005  
 
HIV prevalence among general 
community used to calculate 
proportion of HIV-infected and 
–uninfected cases. 
Number of HIV-infected and –uninfected 
cases calculated by age group and year  
Age 
group 
 
Year HIV 
prevalence 
<2 years 2005 4.5 
 2006 4.3 
 2007 4.0 
 2008 3.5 
 2005_2008 4.1 
 2013 1.3 
2-4 2005 5.1 
Thembisa model (Lee 
Johnson)  
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years 
 2006 5.1 
 2007 4.9 
 2008 4.8 
 2005_2008 5.0 
 2013 2.5 
 
Case fatality ratio for all 
syndromes  
Specific CFR by age groups and all-cause 
bacteraemic/all-cause non-bacteraemic 
syndromes 
Age 
group 
Bacteraemic Non-
bacteraemic 
<1 year 34% 8% 
≥1 year 23% 4.3% 
All ages  28.2% 5.7% 
 
Berkley 2005  
Ayieko 2014 
Case fatality ratio of 
bacteraemic to non-bacteraemic 
pneumococcal pneumonia 
Ratio of end-point pneumonia CFR 
(3.0%) to the CFR for ‘other infiltrates/ 
abnormalities’ pneumonia (0.8%) = 4:1 
CFR of 6.6% in cases with bacteraemic 
pneumonia compared with a non-
pneumonia control group 
Enwere 2007 
 
 
Forgie 1991 
Adjusted number of deaths  Adjusted number of pneumococcal deaths 
= CFR*Adjusted pneumococcal case 
numbers – used different CFR 
GERMS-SA 
surveillance 
programme 
Deaths in the community  (Deaths by syndrome outside 
hospital/Deaths by syndrome in-
hospital)*(Deaths from GERMS-SA 
enhanced sites) by age, syndrome and 
year 
Vital statistics data 
from Statistics South 
Africa  
Mid-year population 
denominators for incidence and 
death rates  
As for base case model   Statistics South 
Africa data  
HIV-specific denominators for 
incidence and death rates  
 
As for base case model   ASSA model  
BPP = Bacteraemic pneumococcal pneumonia; NPNM = Non-pneumonia non-meningitis; IPD = invasive 
pneumococcal disease; PCV9 = 9-valent pneumococcal conjugate vaccine; VAR = Vaccine-attributable 
reduction; VE = vaccine efficacy; CSF = cerebrospinal fluid; NHLS = National Health Laboratory Service; 
ASSA = Actuarial Society of South Africa; PCV13 = 13-valent PCV; CFR = case fatality ratio; NBP = Non-
bacteraemic pneumococcal pneumonia 
Provinces: GA = Gauteng, WC = Western Cape, KZN = KwaZulu-Natal, NC = Northern Cape, EC = Eastern 
Cape, NW = North West Province, MP = Mpumalanga, FS = Free State, LP = Limpopo Province 
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Table 2: Number of pneumococcal cases, by syndrome, in South Africa, by age and HIV status, 2005-2008 and 2013 
 Total HIV-infected  HIV-uninfected 
Syndrome
/age group 
Mean case numbers 
2005-2008 (95% CI) 
Case numbers  
2013 (95% CI) 
Reduction 
in cases* 
Mean case numbers 
2005-2008 (95% CI) 
Case numbers  
2013 (95% CI) 
Reduction 
in cases* 
Mean case numbers 
2005-2008 (95% CI) 
Case numbers  
2013 (95% CI) 
Reduction 
in cases* 
Meningitis           
<1 year 700 (680-740) 200 (180-240) 500 350 (320-390) 40 (20-60) 310 350 (320-380) 170 (130-200) 180 
1-4 years 350 (300-390) 50 (30-60) 300 230 (200-250) 20 (10-30) 210 140 (120-160) 20 (10-30) 120 
<5 years  1100 (1000-1200) 300 (200-320) 800 600 (540-630) 60 (50-80) 540 590 (540-630) 200 (160-220) 390 
BPP           
<1 year 4100 (3000-5000) 1600 (1100-2200) 2500 2100 (1600-2700) 300 (150-550) 1800 2100 (1600-2700) 1300 (900-1800) 800 
1-4 years 4500 (3500-5900) 1400 (1100-2100) 3400 2800 (2200-3700) 700 (500-1000) 2100 1700 (1300-2300) 800 (600-1200) 900 
<5 years 8600 (6700-11200) 3000 (2000-4000) 5600 4900 (3800-6500) 1000 (700-
1500) 
3900 3800 (2800-4800) 2000 (1500-3000) 1800 
NBP          
<1 year 86800 (66000-
112000) 
33200 (23400-
45600) 
53600 43600 (33000-56100) 6600 (3100-
11500) 
37000 43200 (32400-56500) 26600 (18300-
37200) 
16600 
1-4 years 94700 (74000-97000) 29700 (23800-
44900) 
65000 59100 (45400-77300) 13900 (10100-
22700) 
45200 35600 (26800-48000) 15800 (12000-
25000) 
19800 
<5 years 181500 (140000-
236000) 
62800 (47000-
89000) 
118700 102700 (79389-
134106) 
20400 (13800-
30500) 
82300 78800 (59600-101500) 42400 (32000-
62000) 
36400 
NPNM            
<1 year 2800 (2100-3600) 600 (400-800) 2200 1400 (1100-1800) 100 (50-200) 1300 1400 (1100-1800) 500 (300-700) 900 
1-4 years 2200 (1500-2600) 600 (400-800) 1600 1400 (900-1700) 300 (200-400) 1100 800 (600-1000) 300 (200-400) 500 
<5 years 4900 (3600-6100) 1200 (800-1500) 3700 2700 (2000-3500) 400 (200-500) 2300 2100 (1600-2700) 800 (500-1000) 1300 
Total           
<1 year 94400 (71000-
120000) 
35500 (24600-
48300) 
58900 47400 (34400-60400) 7000 (3500-
12000) 
40400 46900 (34700-61300) 28500 (19000-
39000) 
18400 
1-4 years 101800 (77000-
130000) 
31800 (24100-
47400) 
70000 63500 (48100-81800) 14800 (11000-
23400) 
48700 38300 (28100-50700) 16900 (12400-
26800) 
21400 
<5 years 196100 (148000-
251000) 
67300 (49000-
95000) 
128800 111000 (84000-
145000) 
21900 (14800-
32400) 
89100 85200 (63500-108000) 45400 (33000-
66000) 
39800 
CI = confidence interval; BPP = Bacteraemic pneumococcal pneumonia; NBP = Non-bacteraemic pneumococcal pneumonia; NPNM = Non-pneumonia non-meningitis  
*Reduction in cases = difference in case numbers between 2005-2008 and 2013  
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Table 3: Pneumococcal incidence rates in South Africa, by syndrome, age and HIV status, 2005-2008 and 2013 
 Total HIV-infected (HI) HIV-uninfected (HU) IRR^ 
Syndrome 
and age 
group 
Incidence rate* 
2005-2008 
(95% CI) 
Incidence rate*  
2013 (95% CI) 
% 
reducti
on  
Incidence rate* 
2005-2008 
(95% CI) 
Incidence rate*  
2013 (95% CI) 
% 
reduction 
Incidence rate* 
2005-2008 
(95% CI) 
Incidence rate*  
2013 (95% CI) 
% 
reducti
on 
IRR^ 
HI/HU   
2005-8 
(95%CI) 
IRR^ 
HI/HU  
2013 
(95%CI) 
Meningitis            
<1 year 68 (66-71) 19 (17-22) 72 868 (786-947) 285 (152-446) 67 35 (33-39) 16 (13-19) 56 25 18 
1-4 years 9 (8-10) 1 (0.8-1.4) 88 102 (94-112) 15 (10-20) 85 3.5 (3-4) 0.6 (0.4-0.8) 84 26 15 
<5 years  21 (20-22) 5 (4-6) 77 221 (203-233) 40 (30-50) 82 10 (9-11) 4 (3-5) 63 22 10 
BPP              
<1 year 395 (300-509) 146 (102-200) 63 5043 (3785-
6491) 
2165 (1046-
3827) 
57 205 (154-266) 118 (82-165) 42 25 18 
1-4 years 110 (86-142) 34 (27-51) 69 1242 (960-
1620) 
469 (345-745) 62 44 (33-58) 19 (14-30) 58 28 25 
<5 years 167 (129-218) 57 (42-80) 66 1837 (1410-
2412) 
625 (439-940) 66 77 (58-97) 39 (29-57) 49 24 16 
NBP            
<1 year 8298 (6316-
10699) 
3056 (2153-
4200) 
63 105906 (80010-
136268) 
45471 (21554-
79645) 
57 4296 (3234-
5629) 
2485 (1707-
3470) 
42 25 18 
1-4 years 2301 (1803-
2993) 
705 (566-1066) 69 26085 (20062-
34146) 
9855 (7198-
16106) 
62 916 (689-1234) 389 (294-615) 58 28 25 
<5 years 3515 (2710-
4573) 
1187 (887-
1681) 
66 38367 (29655-
50094) 
13161 (8910-
19687) 
66 1609 (1218-
2074) 
826 (623-1208) 49 24 16 
NPNM            
<1 year 263 (204-342) 53 (34-77) 80 3354 (2549-
4391) 
784 (368-1418) 77 136 (105-177) 43 (26-63) 69 25 18 
1-4 years 53 (36-64) 15 (9-20) 72 598 (405-733) 205 (117-288) 66 21 (14-27) 8 (5-11) 62 28 26 
<5 years 95 (70-119) 22 (15-29) 76 1028 (756-
1291) 
258 (160-353) 75 45 (32-56) 15 (10-21) 66 23 17 
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Total            
<1 year 9024 (6743-
11483) 
3273 (2264-
4453) 
64 115171(83626-
146513) 
48705 (24398-
80060) 
58 4671 (3450-
6101) 
2662 (1767-
3680) 
43 25 18 
1-4 years 2472 (1873-
3185) 
755 (572-1128) 69 28027 (21214-
36095) 
10544 (7785-
16641) 
62 984 (721-1302) 416 (304-659) 58 28 25 
<5 years 3799 (2870-
4853) 
1271 (926-
1795) 
67 41436 (31406-
54037) 
14086 (9565-
20904) 
66 1741 (1297-
2200) 
884 (645-1285) 49 24 16 
*Per 100,000 population; ^IRR = incidence rate ratio; IPD = invasive pneumococcal disease; BPP = Bacteraemic pneumococcal pneumonia; NBP = Non-bacteraemic 
pneumococcal pneumonia; NPNM = Non-pneumonia non-meningitis 
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Table 4: Number of pneumococcal deaths in South Africa, by syndrome, age and HIV status, 2005-2008 and 2013 
 Total HIV-infected HIV-uninfected 
Syndrome 
and age 
group 
Mean number of 
deaths 2005-2008 
(95% CI) 
Number of 
deaths 2013 
(95% CI) 
Reduction 
in deaths 
(2005/8-
2013) 
Mean number of 
deaths 2005-2008 
(95% CI) 
Number of 
deaths 2013 
(95% CI) 
Reduction 
in deaths 
(2005/8-
2013) 
Mean number of 
deaths 2005-2008 
(95% CI) 
Number of 
deaths 2013 
(95% CI) 
Reduction 
in deaths 
(2005/8-
2013) 
Meningitis           
<1 year 300 (200-400) 60 (20-110) 240 140 (90-180)  10 (3-30) 130 150 (90-200) 50 (20-90) 100 
1-4 years 90 (50-130) 20 (10-40) 70 60 (10-110) 10 (4-20) 50 40 (10-60) 10 (5-20) 30 
<5 years  370 (300-400) 90 (50-140) 280 200 (100-300) 20 (10-40) 180 160 (100-200) 70 (40-100) 90 
BPP           
<1 year 900 (300-1600) 400 (100-900) 500 500 (100-800) 90 (20-220) 410 500 (200-800) 300 (100-700) 200 
1-4 years 500 (150-900) 200 (0-700) 300 300 (0-800) 80 (0-300) 220 200 (0-500) 100 (0-400) 100 
<5 years 1400 (900-2000) 600 (100-1300) 800 800 (300-1400) 200 (40-400) 600 600 (200-1000) 400 (90-900) 200 
NBP          
<1 year 3900 (1200-6800) 1800 (400-3700) 2100 2000 (600-3500) 400 (80-840) 1600 1900 (600-3400) 1500 (300-3000) 400 
1-4 years 2000 (0-5000) 700 (0-2900) 1300 1000 (0-3200)  400 (0-1400) 600 700 (0-2000) 400 (0-1600) 300 
<5 years 5800 (2200-10000) 2600 (500-5300) 3200 3000 (1300-6000) 700 (200-1700) 2300 2700 (1000-4500) 1900 (400-3600) 800 
NPNM           
<1 year 700 (100-1500) 200 (50-500) 500 300 (70-700) 40 (10-100) 260 300 (60-700) 200 (50-400) 100 
1-4 years 300 (0-900) 50 (0-400) 250 200 (0-600) 20 (0-200) 180 100 (0-400) 30 (0-200) 70 
<5 years 1000 (200-2000) 300 (0-600) 700 600 (100-1000) 70 (0-200) 530 500 (100-800) 200 (0-400) 300 
Total          
<1 year 5800 (2500-9100) 2600 (800-4900) 3200 2900 (1200-4600) 500 (100-1000) 2400 2900 (1200-4700) 2100 (700-3900) 800 
1-4 years 2800 (500-6200) 1000 (10-4000) 1800 1700 (70-4300) 500 (10-1800) 1200 1100 (40-2600) 500 (10-2200) 600 
<5 years 8600 (4500-13500) 3600 (1000-6800) 5000 4600 (2200-8200) 1000 (300-
2300) 
3600 3900 (1700-6300) 2600 (700-4700) 1300 
CI = confidence interval; BPP = Bacteraemic pneumococcal pneumonia; NBP = Non-bacteraemic pneumococcal pneumonia; NPNM = Non-pneumonia non-meningitis  
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Table 5: Pneumococcal mortality rate in South Africa, by syndrome, age and HIV status, 2005-2008 and 2013 
 Total HIV-infected (HI) HIV-uninfected (HU) Incidence rate ratio 
Syndrome
age group 
MR* 2005-
2008 
(95% CI) 
MR* 2013 
(95% CI) 
% 
reductio
n  
MR* 2005-2008 
(95% CI) 
MR* 2013 
(95% CI) 
% 
reduc
tion  
MR* 2005-
2008 
(95% CI) 
MR* 2013 
(95% CI) 
% 
reducti
on  
IRR HI/HU   
2005-2008 
(95% CI) 
IRR 
HI/HU  
2013 
(95% CI) 
Meningiti
s  
           
<1 year 26 (21-31)  6 (2-10) 78 334 (213-446) 87 (22-181) 74 14 (9-19) 5 (2-8) 65 24 17 
1-4 years 2 (1-3) 0.6(0.2-1) 75 26 (6-47) 8 (3-14) 69 1 (0.2-2) 0.3 (0.1-0.5) 65 26 8 
<5 years  7 (6-8) 2 (1-3) 76 73 (50-101) 15 (7-25) 79 3 (2-4) 1 (0.7-2) 63 18 15 
BPP             
<1 year 88 (28-155) 40 (9-80) 54 1128 (351-1992) 601 (126-1495) 47 46 (15-83) 33 (7-66) 28 25 18 
1-4 years 11 (4-21) 4 (0-16) 62 125 (0-333) 59 (0-233) 53 4 (0-12) 2 (0-9) 47 31 30 
<5 years 27 (17-40) 11 (2-24) 58 279 (114-538) 109 (27-266) 61 13 (5-22) 8 (2-17) 35 21 14 
NBP            
<1 year 371 (118-653) 170 (38-337) 54 4736 (1497-8444) 2526 (1707-3470) 47 192 (62-342) 138 (30-286) 28 25 18 
1-4 years 46 (0-125) 18 (0-68) 62 524 (0-1421) 246 (0-985) 53 18 (0-51) 10 (0-38) 47 29 25 
<5 years 112 (42-203) 49 (10-100) 56 1172 (469-2238) 458 (115-1099) 61 54 (19-92) 36 (7-71) 33 22 13 
NPNM            
<1 year 65 (13-139) 21 (5-42) 68 828 (165-1748) 89 (19-225) 89 34 (6-74) 17 (4-34) 50 24 18 
1-4 years 8 (0-23) 1 (0-8) 85 94 (0-255) 17 (0-120) 82 3 (0-9) 1 (0-5) 80 31 17 
<5 years 20 (4-37) 5 (0-12) 74 207 (46-399) 44 (0-139) 79 10 (2-17) 4 (0-8) 58 21 11 
Total             
<1 year 550 (235-871) 237 (77-454) 57 7025 (2976-11066) 1545(479-3125) 50 285 (124-464) 192 (63-363) 32 25 18 
1-4 years 68 (13-150) 24 (0.3-94) 65 769 (30-1899) 330 (4-1306) 57 27 (1-67) 13 (0.2-53) 52   28 25 
<5 years 166 (87-261) 67 (19-129) 59 1731 (813-3074) 626 (200-1466) 64 80 (34-128) 50 (13-91) 37 22 13 
*Mortality rate (MR) per 100,000; IRR = incidence rate ratio; IPD = invasive pneumococcal disease; BPP = Bacteraemic pneumococcal pneumonia; NBP = Non-bacteraemic 
pneumococcal pneumonia; NPNM = Non-pneumonia non-meningitis  
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Figure 1: Flow diagram of the steps used to estimate the burden of invasive and non-
invasive pneumococcal cases in children <5 years of age in South Africa in 2005-2008 
and 2013 
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= 11:1*1.89^ 
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non-meningitis (NPNM) 
cases in children <5 years of 
age (2005-2008 or 2013) 
GERMS-SA IPD cases in children 
<5 years of age (2005-2008 or 2013)  
Number of bacteraemic 
pneumococcal pneumonia (BPP) 
cases in children <5 years of age 
(2005-2008 or 2013) 
#For all syndromes total case numbers as well as numbers stratified by HIV status were determined 
^Additional adjustment (1.89) for difference in VE estimated with use of urinary antigen  
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included in supplement  
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Methods (see Figure 1a and 1b)  
 
Model overview 
Estimated pneumococcal cases, deaths and incidence rates by clinical syndrome in the pre-
pneumococcal conjugate vaccine (PCV) period (2005-2008) and post-PCV period (2013)  
A number of steps were followed to estimate pneumococcal case numbers, numbers of deaths 
and incidence rates in both the pre- and post-PCV periods: 
STEP 1 (Figure 1a) 
1) All GERMS-SA hospitalised IPD cases from both enhanced and non-enhanced sites from 
2005 to 2008 and for 2013, were included in the baseline numbers on which the model 
was based because specimen type was available for all cases. An average of the case 
numbers for the pre-vaccine period (2005-2008) was calculated. Based on specimen type 
(i.e. CSF or non-CSF), IPD cases were defined as meningitis cases or non-meningitis 
cases. Cases numbers were determined by province and age group (<1 and 1-4 years) for 
each of the time periods (2005-2008 and 2013). 
2) Pneumococcal meningitis cases were defined as all IPD cases with S. pneumoniae isolated 
from CSF (enhanced and non-enhanced sites) or IPD cases where the organism was 
isolated from blood and the clinical diagnosis was meningitis (enhanced sites). The 
proportion of meningitis cases diagnosed clinically, with only a positive blood culture, 
was determined from enhanced site cases and extrapolated to non-enhanced site cases (as 
for other syndromes). This extrapolation was done by province and age for each of the 
time periods (2005-2008 and 2013). The calculated non-enhanced site cases were 
combined with the diagnosed meningitis cases by province and age group (<1 year and 1-4 
years). 
3) Non-meningitis pneumococcal cases were defined as all the remaining IPD cases that were 
not meningitis cases. Among the remaining IPD cases we applied the proportions of 
bacteraemic pneumococcal pneumonia and non-pneumonia non-meningitis IPD cases 
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observed at enhanced sites in each year and by province and age group (<1 and 1-4 years) 
to the non-meningitis IPD cases at non-enhanced sites to calculate case numbers by 
syndrome. Case counts, by syndrome, from non-enhanced sites were combined with those 
from enhanced sites for each of the categories. 
 
STEP 2: Figure 1b 
4) Pneumococcal meningitis cases were adjusted for specimen-taking practices by province 
(see 5b) as certain provinces had better access to care and more cerebrospinal fluid 
specimens were taken in certain provinces compared with others, assuming that IPD 
incidence was similar across all provinces. We totalled meningitis cases and stratified by 
HIV (see 9) to calculate numbers of HIV-infected and –uninfected meningitis 
pneumococcal cases.  
5) For bacteraemic pneumococcal pneumonia we adjusted for incomplete blood culturing in 
the Gauteng Province (see 5a) and for specimen-taking practices by province (see 5b) as 
certain provinces had better access to care and some provinces took more blood culture 
specimens for patients presenting with pneumonia. We totalled bacteraemic pneumococcal 
pneumonia cases and stratified by HIV (see 9) to calculate numbers of HIV-infected and –
uninfected bacteraemic pneumococcal pneumonia cases.  
a. We assumed that Gauteng Province had the highest rate of specimen-taking for 
pneumonia but knew that not all children with pneumonia would have had a blood 
culture taken as part of routine practice. In contrast in a clinical trial setting all 
children presenting with pneumonia had a blood culture taken. To account for 
incomplete blood culture collection among children hospitalised with pneumonia, we 
adjusted the measured rate of bacteraemic pneumococcal pneumonia in 2005-2008 by 
a ratio (23:1) comparing the bacteraemic pneumococcal pneumonia hospitalisation 
incidence from a PCV clinical trial (control arm) in Soweto [1,2] to the measured 
bacteraemic pneumococcal pneumonia incidence in the same province (2005-2008). 
The same ratio was used to adjust 2013 measured case numbers.  
b. Specimen-taking practices varied across facilities and provinces. To account for 
differences in specimen-taking practices and the underdiagnosis of IPD, we adjusted 
GERMS case numbers for meningitis, bacteraemic pneumonia and non-pneumonia 
non-meningitis using a specimen ratio where the Gauteng province incidence was 
estimated to be the baseline (= 1,0) and have the most complete specimen taking after 
been adjusted (as in 5a), compared with the incidence rates in other provinces by year. 
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Data on total numbers of blood and cerebrospinal fluid specimens taken on an annual 
basis and submitted to public-sector laboratories was obtained from the National 
Health Laboratory Service Corporate Data Warehouse. These data were broken down 
by province, age group and year. We assumed that this adjustment would account for 
children who did not reach a hospital for care as this also differed between provinces.  
6) To calculate the number of hospitalised non-bacteraemic pneumococcal pneumonia cases 
we used published data on the PCV9 attributable reduction (VAR) ratio (11:1) of clinical 
pneumonia to all bacteraemic pneumococcal pneumonia [2]. We used the clinical 
pneumonia outcome because it was found to be the most sensitive measure of 
pneumococcal pneumonia burden in the clinical trial (i.e. had the highest VAR). Based on 
a clinical trial in adults [3] which incorporated urine antigen testing for non-bacteraemic 
pneumonia, a higher vaccine efficacy was demonstrated against pneumonia. The ratio 
(1.89) of the original and inflated vaccine efficacy was used to adjust our non-bacteraemic 
pneumococcal pneumonia cases. The total non-bacteraemic pneumococcal pneumonia 
cases were stratified by HIV (see 9) to calculate numbers of HIV-infected and –uninfected 
non-bacteraemic pneumococcal pneumonia cases.  
7) For non-pneumonia non-meningitis IPD case numbers we adjusted the observed cases 
from GERMS for specimen-taking practices by province (see 5b) as certain provinces had 
better access to care and some provinces took proportionally more blood culture 
specimens. We totalled the adjusted non-pneumonia non-meningitis IPD cases and 
stratified by HIV (see 9) to calculate numbers of HIV-infected and –uninfected non-
pneumonia non-meningitis IPD cases.  
8) To calculate the relative risk (RR) of IPD in HIV-infected versus HIV-uninfected cases we 
used the following formula: 
 
 
9) We stratified by HIV for all pneumococcal syndromes by estimating the number of HIV-
infected cases in each group using the following formula: 
 
 
 
The number of HIV-uninfected cases was assumed to be the difference between the total 
number of cases and the HIV-infected cases (IPD HIV-uninfected cases = IPD Total cases 
– IPD HIV-infected cases).  
IPD HIV-infected cases =                   _________1___                               
                                (PopHIV-    +1) * 1/IPDTotal  
                        (RR* PopHIV+)  
 
RR = ((Number of enhanced site (ES) cases*HIV prevalence)/HIV-infected population denominator)  
         ((Number of ES cases – (Number of ES cases*HIV prevalence))/HIV-uninfected population denominator) 
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10) We calculated the adjusted number of pneumococcal deaths for each syndrome by age 
group by multiplying adjusted case number estimates (as calculated above) by case fatality 
ratios (CFRs) observed at the GERMS-SA enhanced sites for bacteraemic cases 
(meningitis, bacteraemic pneumonia and non-pneumonia non-meningitis). For non-
bacteraemic pneumococcal pneumonia we used CFRs from a study in Kenya [4] that 
observed case fatality rates among children under 5 years of age admitted to hospital for 
any reason with and without bacteraemia (all children had blood cultures obtained 
regardless of their admission diagnosis). The observed CFR for non-bacteraemic 
admissions was (5.7%) which was 5-fold lower than that observed for bacteraemic 
admissions (28.2%).  
11) For all syndromes we calculated incidence and mortality rates using the adjusted case 
and death estimates from the model in combination with  the and mid-year population 
estimates obtained from Statistics South Africa as denominators for different age groups 
(http://www.statssa.gov.za/). The Thembisa model which accounted for PMTCT and HIV 
treatment impact, was used for HIV specific denominators [5]. We calculated incidence 
rate ratios for all syndromes comparing incidence or mortality rates in HIV-infected to 
HIV-uninfected children (Supplementary table 1).  
 
Supplementary table 1: Population denominators from Thembisa model for children <5 years of 
age in South Africa [5] 
2005 2006 2007 2008 2005_2008 2013 
<1 year  
Pop Total 993446 1071503 1085777 1133330 1071014 1129271 
Pop HIV+ 44033 44702 41169 38857 42190 14982 
Pop HIV- 949413 1026801 1044608 1094473 1028824 1114289 
1-4 years 
Pop Total 3674623 3683421 3805687 3981501 3786308 4494190 
Pop HIV+ 212561 209114 207500 204103 208320 150315 
Pop HIV- 3462062 3474307 3598187 3777398 3577989 4343875 
<5 year  
Pop Total 4668070 4754925 4891464 5114831 4857322 5623461 
Pop HIV+ 256595 253817 248669 242960 250510 165297 
Pop HIV- 4411475 4501108 4642795 4871871 4606812 5458164 
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Sensitivity analysis  
A one-way sensitivity analysis was performed by changing one variable at a time to see the 
effect on the total number of cases and deaths (Tornado diagrams, supplementary figure 2a 
and figure 2b).  
Parameters that we varied in the sensitivity analysis of cases and deaths included HIV 
prevalence, proportion of under 5 year old deaths that occur in the community, adjustment for 
the likelihood of obtaining a blood culture among hospitalised children with suspected 
pneumococcal disease and the ratio of bacteraemic to non-bacteraemic pneumococcal 
pneumonia. For estimates of pneumococcal deaths we also assessed the effect of changes in 
CFRs (see Table 1b for parameters).  
1) For HIV prevalence we used values from the Thembisa model which reflects HIV 
prevalence in the community instead of the prevalence in hospitalised IPD cases used in 
our main analysis. 
2) For the proportion of all deaths that occur in the community (which we did not include in 
our main analysis) we used vital statistics data from Statistics South Africa which 
enumerates deaths in the community and in hospitals by syndrome. The limitation is that 
cases that die in and out of hospital may not be directly comparable with each other in 
terms of severity and causation. 
3) For incomplete blood culturing practices among children hospitalised with IPD, we 
adjusted the measured rate of bacteraemic pneumococcal pneumonia by a ratio of 8:1 
which compared the IPD hospitalisation incidence from the PCV clinical trial (control 
arm) in Soweto [2] to the measured IPD incidence in the same province.  
4) For the ratio of bacteraemic to non-bacteraemic pneumococcal pneumonia we used the 
same published data on the vaccine attributable reduction (VAR) ratio (11:1) of clinical 
pneumonia to bacteraemic pneumococcal pneumonia as in our main analysis [2] but 
without the additional factor (1.89) accounting for the change in vaccine efficacy [3] 
which was included in our main analysis. 
5) A second VAR calculation using the ratio of CXR-confirmed pneumonia to bacteraemic 
pneumococcal pneumonia (4:1) [2] and including the additional factor (1.89) accounting 
for the change in vaccine efficacy [3] which was included in our main analysis (7.6:1) was 
conducted. 
6) For the alternative calculation of non-bacteraemic pneumococcal pneumonia we calculated 
the number of HIV-infected and –uninfected cases separately and summed the numbers to 
calculate the total. The sensitivity of blood culture for diagnosing pneumococcal 
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pneumonia was assumed to be 3-5% in HIV-uninfected children and 18% in HIV-infected 
children. 
7) For the CFR we used published rates for bacteraemic and non-bacteraemic disease [4] 
instead of the rates calculated from our surveillance programme (which were assumed to 
be underestimates). We used the published bacteraemic CFRs for meningitis, for 
bacteraemic pneumococcal pneumonia and non-pneumonia non-meningitis invasive 
disease, and the non-bacteraemic CFRs for non-bacteraemic pneumococcal pneumonia. 
The limitations with using these published rates were that they were from Kenya, the 
bacteraemic group included all causes of bacteraemia and all syndromes, the non-
bacteraemic group included children with all medical conditions who did not have a 
positive blood culture and the age groups reported in this paper were different those used 
in our model.  
8) Lastly for the CFR ratio of bacteraemic to non-bacteraemic pneumococcal pneumonia we 
used the death risk ratio reported by a trial from The Gambia [6]. This ratio (4:1) was 
considered an underestimate as it compared the CFR for end-point pneumonia (3.0%) 
which included the highest proportion of bacteraemic pneumonia to the CFR for ‘other 
infiltrates /abnormalities’ pneumonia (0.8%) which had the lowest proportion of positive 
blood cultures. The CFR for bacteraemic pneumonia was also lower than that reported in 
another study from The Gambia (6.6%), but the control group did not have pneumonia and 
no control children died [7].  
 
Results  
 
Sensitivity analysis  
Supplementary table 2a: Sensitivity analysis for case numbers showing key variables 
altered in analysis, 2005-2008 and 2013  
Key variables altered in analysis  Number of cases  
2005-2008 2013 
0) Base numbers  196,100 67,300 
1) Community HIV prevalence 43,100 3200 
2) Community deaths 196,900 68,900 
3) Altered blood culturing estimates 98,100 34,400 
4) NBP/BPP VAR ratio of 11:1  109,700 37,300 
5) NBP/BPP VAR ratio of 7.6:1 80,300 27,200 
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6) Altered NBP calculations with separate HIV 
estimates  
214,300 77,800 
NBP = non-bacteraemic pneumococcal pneumonia; BPP = bacteraemic pneumococcal 
pneumonia 
 
Supplementary table 2b: Sensitivity analysis for numbers of deaths showing key 
variables altered in analysis, 2005-2008 and 2013  
Key variables altered in analysis  Number of deaths  
2005-2008 2013 
0) Base numbers  8600 3600 
1) Community HIV prevalence 5300 700 
2) Community deaths 8600 3700 
3) Altered blood culturing estimates 4400 1800 
4) NBP/BPP VAR ratio of 11:1  5800 2300 
5) NBP/BPP VAR ratio of 7.6:1 4900 1900 
6) Altered NBP calculations with separate HIV 
estimates  
8700 3900 
7) Separate case fatality ratios for bacteraemic and 
non-bacteraemic syndromes 
15,000 5000 
8) Adjusted case fatality ratio for BPP to NBP (4:1 
ratio)  
10,000 4200 
NBP = non-bacteraemic pneumococcal pneumonia; BPP = bacteraemic pneumococcal pneumonia 
 
The highest mortality rate (when new CFRs were included) in children <5 years estimated a 
death rate of 1492 per 100,000 py in 2005-2008 and 468 per 100,000 py in 2013. 
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Figure 1a: Initial step in estimating the burden of invasive and non-invasive pneumococcal cases in children aged <5 years in South Africa, 2005-
2008 and 2013  
 
STEP 1 
  
GERMS-SA IPD cases 
in children <5 years old: 
2005-2008 (n=1483) & 
2013 (n=498) 
Meningitis* cases in children <5 
year old from enhanced sites 
(ES) & non-enhanced sites 
(NES): 2005-2008 (n=521) & 
2013 (n=164) (Box 1) 
 
All other IPD cases in 
children <5 year old: 
2005-2008 (n=962) & 
2013 (n=334) 
 
ES: 2005-2008 
(n=492) & 2013 
(n=170) 
Proportion of ES bacteraemic cases with 
clinical meningitis diagnosis: 2005-2008 
(7%, n=35) & 2013 (10%, n=17) (Box 2) 
NES: 2005-
2008 (n=470) & 
2013 (n=164) 
Pneumonia: 2005-2008 
(59%, n=290) & 2013 
(64%, n=109) (Box 3) 
Non-pneumonia non-
meningitis (NPNM): 2005-
2008 (34%, n=167) & 2013 
(26%, n=44) (Box 4) 
Inferred NES NPNM: 2005-2008 
(n=160) & 2013 (n=43) (Box 7) 
Inferred NES meningitis: 2005-2008 
(n=33) & 2013 (n=16) (Box 5) 
Inferred NES pneumonia: 2005-2008 
(n=277) & 2013 (n=105) (Box 6) 
ES and NES meningitis: 2005-2008 
(n=554) & 2013 (n=180) (Box 1+5) 
 
ES and NES pneumonia: 2005-2008 
(n=567) & 2013 (n=214) (Box 3+6) 
ES and NES NPNM: 2005-2008 
(n=327) & 2013 (n=87) (Box 4+7) 
Total IPD cases by syndromes 
 
Distribution of bacteraemic cases 
by syndrome from Box 2, 3, 4  
2005-08=7%; 2013=10% 
2005-08=59%; 2013=64% 
2005-08=34%; 2013=26% 
*Includes cases positive for pneumococcus from CSF at ES and NES, and among ES sites, 
cases with pneumococcus from blood culture along with a clinical meningitis diagnosis  
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Figure 1b: Second step in estimating the burden of invasive and non-invasive pneumococcal cases in children <5 years in South Africa, , 2005-2008 
and 2013  
STEP 2 
 
 
    
  
Bacteraemic pneumonia: 
2005-2008 (n=567) & 
2013 (n=214) 
NPNM cases: 2005-2008 
(n=327) & 2013 (n=87) 
Meningitis cases in 
children <5 year old: 
2005-2008 (n=554) & 
2013 (n=180) 
 
Adjusted meningitis 
cases in children <5 
year old: 2005-2008 
(n=1100) & 2013 
(n=300) 
 
Adjustment for 
specimen-taking 
practice by province 
Adjusted meningitis cases in 
children <5 year old: 2005-
2008 (HIV-pos n=600, HIV-
neg n=590) & 2013 (HIV-
pos n=60, HIV-neg n=200) 
 
Stratify by 
HIV 
Adjusted bacteraemic 
pneumonia (BPP) cases in 
children <5 year old: 2005-
2008 (n=8600) and 2013 
(n=3000) 
 
Adjustment for PCV 
clinical trial incidence 
for Gauteng Province  
Adjustment for 
specimen-taking practice 
in other provinces 
(Gauteng baseline) 
Adjusted BPP cases in 
children <5 year old: 2005-
2008 (HIV-pos n=4900, 
HIV-neg n=3800) & 2013 
(HIV-pos n=1000, HIV-neg 
n=2000) 
Stratify 
by HIV 
Stratify 
by HIV 
Adjusted NPNM cases in children <5 
year old: 2005-2008 (HIV-pos n=2700, 
HIV-neg n=2100) & 2013 (HIV-pos 
n=400, HIV-neg n=800) 
Adjusted NPNM cases in 
children <5 year old: 2005-
2008 (n=4900) and 2013 
(n=1200) 
Adjustment for specimen-taking 
practice by province 
Adjusted non-bacteraemic 
pneumonia (NBP) cases in 
children <5 year old: 2005-
2008 (n=181500) and 2013 
(n=62800) 
 
Adjusted NBP cases in 
children <5 year old: 2005-
2008 (HIV-pos n=102700, 
HIV-neg n=78800) & 2013 
(HIV-pos n=20400, HIV-
neg n=42400) 
 
Ratio Clinical pneumonia: 
BPP = 11:1 * 1.89 
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Figure 2a: Tornado sensitivity diagram representing change in pneumococcal case estimates in children <5 years of age in the pre-vaccine era, when 
values of key variables are modified. 
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Figure 2b: Tornado sensitivity diagram representing change in pneumococcal death estimates in children <5 years of age in the pre-vaccine era, 
when values of key variables are modified. 
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 PAPER II 
In South Africa, 7-valent pneumococcal conjugate vac-
cine (PCV) was introduced in April 2009 and replaced with 
13-valent PCV in April 2011. We describe the epidemiology 
of serotype 1 Streptococcus pneumoniae disease during 
the pre- and post-PCV eras (2003–2013). Using laboratory-
based invasive pneumococcal disease (IPD) surveillance, 
we calculated annual incidences, identified IPD clusters, 
and determined serotype 1–associated factors. Of 46,483 
IPD cases, 4,544 (10%) were caused by serotype 1. Two 
clusters of serotype 1 infection were detected during 2003–
2004 and 2008–2012, but incidence decreased after 2011. 
Among children <5 years of age, those who had non–sero-
type 1 IPD had shorter hospital stays, fewer cases of pen-
icillin-nonsusceptible disease, and lower HIV prevalence 
and in-hospital death rates than did those with serotype 1 
IPD; similar factors were noted for older patients. Serotype 
1 IPD had distinctive clinical features in South Africa, and 
annual incidences fluctuated, with decreases noted after 
the introduction of PCV13.
Streptococcus pneumoniae serotype 1 is highly invasive and rarely carried asymptomatically (1). The incidence 
of serotype 1 invasive pneumococcal disease (IPD) fluctu-
ates year to year; disease is associated with outbreaks in 
closed communities and hospitals and, in Africa, with com-
munitywide meningitis outbreaks (2). Compared with other 
S. pneumoniae serotypes, serotype 1 tends to cause fewer 
cases of fatal disease, and antibiotic-resistant cases are un-
usual (1).
IPD is common in children with underlying diseases, 
especially HIV. A study conducted among children <18 
years of age in Israel before introduction of 7-valent pneu-
mococcal conjugate vaccine (PCV7) showed that, com-
pared with other common serotypes, serotype 1 caused 
more bacteremic pneumonia and peritonitis, occurred 
in older children and certain ethnic groups, and affected 
otherwise healthy children (3). After PCV7 introduction, 
infections caused by serotypes included in the vaccine de-
clined, but other pneumococcal serotypes (e.g., serotype 1, 
which was later included in 13-valent vaccine [PCV13]) 
became relatively more common (4–6); serotype 1 ranked 
among the top 4 serotypes infecting children <5 years of 
age (7). Although PCV7 use may have contributed to the 
relative increase in serotype 1 infections, some studies 
showed no correlation between the vaccine and serotype 
1 disease incidence (8). Lack of correlation is likely due 
to the epidemic-prone nature of serotype 1 disease and 
annual fluctuations in disease incidence (9). In addition, 
replacement disease is mainly due to common colonizing 
serotypes. An indirect cohort analysis using data from the 
United Kingdom Health Protection Agency (now Public 
Health England) surveillance program could not dem-
onstrate significant protection against serotype 1 IPD by 
PCV13, although the point estimate suggested protection 
(vaccine effectiveness 62% [95% CI −112% to 92%]) (10). 
Two trials of a 9-valent vaccine showed waning protection 
against serotype 1 in the absence of a booster vaccine dose 
in the second year of life; vaccine failures clustered in chil-
dren >18 months of age (11,12).
In South Africa, PCV7 was introduced into the na-
tional immunization schedule in April 2009 as a 3-dose 
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regimen for infants 6 weeks, 14 weeks, and 9 months of 
age; in April 2011, the vaccine was replaced with PCV13. 
Among children <1 year of age, reported coverage for the 
third dose of PCV improved from 10% in 2009 to 81% 
in 2012 but declined to 62% in 2013 (13). In 2012, after 
PCV13 introduction, serotype 1 IPD incidence showed a 
temporally associated decline in children <2 years of age 
(–57%, 95% CI –79% to –16%) and adults 25–44 years of 
age (–33%, 95% CI –46% to –17%) compared with inci-
dence in 2005–2008 (14).
Information regarding S. pneumoniae serotype 1 epi-
demiology in Africa is limited. We compared serotype 1 
disease epidemiology in South Africa with that of other 
serotypes over an 11-year period, before and after intro-
duction of PCV7 and PCV13. We also explored whether 
temporal or spatial clusters of serotype 1 disease occurred 
during the study period.
Methods
Study Design and Setting
Persons of any age were included in the study if they were 
hospitalized in South Africa during 2003–2013 for labo-
ratory-confirmed IPD and had an available S. pneumoniae 
serotype result for an isolate from a normally sterile site. 
Patients were identified through an active national, lab-
oratory-based surveillance program for S. pneumoniae. 
Data were contributed by >200 hospital-based diagnostic 
laboratories that submitted pneumococcal isolates to the 
National Institute for Communicable Diseases, Johannes-
burg, South Africa. Most laboratories were nonenhanced 
sites where only isolates and accompanying laboratory 
report forms with patient age, sex, date and source of the 
specimen were submitted. However, 24 sites (primarily 
tertiary hospitals) implemented enhanced surveillance, in 
which dedicated surveillance officers collected additional 
clinical information on identified patients; at least 1 site 
was located in each South Africa province, giving na-
tional representation (14). Enhanced sites were chosen on 
the basis of convenience, interest from site investigators, 
and number of isolates submitted each year; thus, some 
differences existed between enhanced and nonenhanced 
sites (online Technical Appendix, http://wwwnc.cdc.gov/
EID/article/22/2/15-0967-Techapp1.pdf). Annual audits 
conducted by using a laboratory-based information sys-
tem were used to identify unreported cases, which were 
included and used in incidence calculations.
Participants identified from enhanced and nonen-
hanced sites were included for determining incidence rates 
and cluster mapping. For the analyses of factors associated 
with serotype 1 pneumococcal disease and fatality, only 
participants from enhanced sites with detailed clinical in-
formation and known in-hospital outcomes were included.
Approval was obtained from the Human Research Eth-
ics Committee (Medical), University of the Witwatersrand, 
Johannesburg (M081117), and other hospital or provincial 
ethics committees, as required. Informed consent was ob-
tained for all patients.
Definitions
IPD cases were defined as disease in persons with S. pneu-
moniae detected in cultures of specimens from normally 
sterile sites or persons with culture-negative samples that 
were positive by latex agglutination and/or Gram stain mi-
croscopy or lytA PCR (15). Pneumococci were serotyped 
by the Quellung method (Statens Serum Institut, Copenha-
gen, Denmark).
Serotype 1 clusters were defined as an increase in se-
rotype 1 IPD numbers relative to other serotype numbers in 
a specific geographic area and time. Cluster location was 
based on hospital district where cases were diagnosed; ac-
tual geographic location was considered to be the centroid 
of the district polygon. Other definitions are provided in the 
online Technical Appendix.
Incidence Estimations
We calculated annual incidence of serotype 1 disease per 
100,000 population during 2003–2013 by using data for 
participants in defined age groups. We divided the num-
ber of age-specific, culture-positive serotype 1 IPD cases 
reported each year by age-specific midyear population 
estimates. Incidences for non–serotype 1 disease were 
similarly calculated. Serotype data for cases without se-
rotype results from culture (including cases with only 
PCR serotype results) were imputed by age and year 
to obtain final incidence rates. Missing data were as-
sumed to be random among different serotypes. Midyear 
population denominators were obtained from Statistics 
South Africa (http://www.statssa.gov.za/). To show dif-
ferences in serotype incidences between prevaccine and 
postvaccine years, we compared an average incidence 
from prevaccine years (2003–2008) to 1 postvaccine 
year (2013). As a baseline for comparison, we included 
the average for years without clusters (2005–2007). CIs 
were calculated by using Poisson distribution for inci-
dence rates.
Factors Associated with Serotype 1 IPD and  
Case-Fatality Rates
For the analyses of factors associated with serotype 1 IPD, 
we included only participants with culture- and PCR-pos-
itive results from enhanced sites during 2003–2013. Pa-
tients were stratified into 2 age groups (<5 and >5 years), 
and disease-associated factors in those with serotype 1 IPD 
were compared with those in patients with non–serotype 1 
IPD by using a multivariable logistic regression model. A 
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second model to assess in-hospital fatalities restricted the 
analysis to serotype 1 IPD cases.
For both models, we assessed all variables considered 
significant (p<0.2) on univariate analysis and removed non-
significant factors (p>0.05) by manual backward elimina-
tion. Patients with missing data for included variables were 
excluded. Statistical analysis was implemented by using Sta-
ta version 13.1 (StataCorp LP, College Station, TX, USA).
Spatiotemporal Analysis for Detection of  
Serotype 1 IPD Clusters
We conducted a space–time scan analysis to detect sero-
type 1 clusters by aggregating IPD cases with available 
serotype results from January 2003–December 2013 by 
month and district. To minimize potential biases intro-
duced by temporal and geographic differences in spec-
imen-collecting practices, healthcare-seeking behavior, 
or surveillance system improvements over time, we com-
pared cases (serotype 1 IPD cases) with controls (non–
serotype 1 IPD cases) from the same geographic area 
and time period; a Bernoulli model (16,17) was used for 
the comparison.
To account for control number reductions after PCV7 
introduction, we adjusted (increased) observed control 
numbers by the percent reduction from the prevaccine peri-
od (14). To obtain estimated monthly numbers of controls, 
assuming no PCV introduction, we linearly interpolated es-
timated annual proportional reductions from June to June 
of consecutive years from 2009 through 2013. Because the 
percentage of reduction in the control numbers may have 
differed by geographic area due to locality differences in 
PCV7 uptake over time, we obtained monthly adjustment 
factors for each province. This adjustment would decrease 
the likelihood of detecting a cluster if, in fact, a cluster did 
not occur (null hypothesis).
To identify spatial clusters, we used an elliptical area 
of search that was allowed to vary in size, shape, and di-
rection. Significance was assessed at p<0.05 over 999 
replications. Space-time analysis was conducted by using 
SaTScan version 9.3.1 (http://www.satscan.org/); maps 
were generated by using ArcGIS version 9.2 (http://www.
esri.com/). To calculate relative risks for districts, we di-
vided observed number of cases by expected number of 
cases in each district.
Results
During 2003–2013, a total of 46,483 persons with IPD 
were enrolled in the study; 32,841 (71%) had viable iso-
lates and known S. pneumoniae serotype, and 1,204 (3%) 
had serotype determination by PCR. Of the 46,483 persons, 
20,564 (44%) were enrolled from enhanced sites; of these 
6,211 (30%) were <5 years of age, 14,004 (68%) were >5 
years of age, and 349 (2%) had unknown age (Figure 1). Of 
the 4,985 patients who died, 68% (3,365) did so within 3 
days of admission. Of the 12,013 patients who recovered, 
14% (1,673) were hospitalized for <3 days, 62% (7,427) 
for 4–14 days, and 24% (2,913) for >2 weeks. In the pre-
PCV7 period (2003–2008), serotype 1 was the sixth most 
common S. pneumoniae serotype among children <5 years 
of age, but by 2013, it was eleventh. In contrast, among 
persons >5 years of age, serotype 1 was the most common 
serotype across all years, although case numbers decreased 
after PCV13 introduction.
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Figure 1. Selection flowchart for study of invasive 
Streptococcus pneumoniae disease (IPD) cases in South 
Africa, 2003–2013. Cases were reported by Group for Enteric 
Respiratory and Meningeal Disease Surveillance sites 
(GERMS-SA). Years indicate prevaccine (2003–2008), baseline 
(2005–2007), and postvaccine (2013) periods. Nonenhanced 
sites only submitted isolates and accompanying laboratory 
report forms, which included patient age and sex and the 
date and source of the specimen; enhanced sites (primarily 
tertiary hospitals) implemented enhanced surveillance, in which 
dedicated surveillance officers collected additional clinical 
information on identified patients.
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Comparison of Enhanced and Nonenhanced Sites
Characteristics of enhanced and nonenhanced sites differed 
(online Technical Appendix Table 1). Compared with 
nonenhanced sites, enhanced sites had a higher proportion 
of cases among younger children, more cases from certain 
provinces, fewer cases in 2012–2013, more penicillin-
nonsusceptible cases, more blood culture results, and fewer 
serotype 1 IPD cases.
Incidence of Serotype-Specific IPD in  
Different Age Groups
During the prevaccine era (2003–2008), serotype 1 inci-
dence per 100,000 population was highest among persons 
<1 (1.8 cases), 5–9 (1.6 cases), and 25–44 (1.8 cases) years 
of age (Figure 2, panel A). Serotype 1 incidence did not dif-
fer significantly for 2003–2008 compared with 2005–2007, 
when there were no clusters. In 2013, serotype 1 incidence 
was highest among persons 5–9 (0.7 cases) and 25–44 (0.6 
cases) years of age; reductions were significant (p<0.001) in 
all age groups except the >64-year-old age group (p = 0.07).
For all other serotypes during 2003–2008, the highest 
incidence rates per 100,000 population were among per-
sons <1 (71.8 cases), 1–4 (13.9 cases), and 25–44 (10.1 
cases) years of age (Figure 2, panel B). In 2013, the high-
est incidence rates were among persons <1 (27.3 cases) 
and >25 (>5.0 cases) years of age. Reductions in incidence 
among persons <5 and 25–44 years of age were significant 
(p<0.001).
The incidence of serotype 1 IPD fluctuated over the 
11-year period (online Technical Appendix Figure 1). For 
the <5-year-old age group, incidence rates were significant-
ly reduced in 2006 (p = 0.01), 2007 (p = 0.03), 2010 (p = 
0.006), and 2012–2013 (p<0.001) compared with rates in 
2005. In the >5-year-old age group, incidence rates were 
significantly higher in 2003 (p = 0.001) and 2004 (p = 
0.002) compared with 2005 but lower during 2006–2008 
and 2010–2013 (p<0.001).
Factors Associated with Serotype 1 IPD
After adjustment for geographic location (province), year 
(based on prominent serotype 1 fluctuations), and clinical 
syndrome, we saw a difference among patients at enhanced 
sites who had IPD caused by serotype 1 versus other sero-
types. Multivariable analysis showed a difference in dis-
ease distribution by province, year, and age among children 
<5 years of age; these difference were more apparent in 
children >3 than <1 years of age. Compared with children 
with non–serotype 1 IPD, those with serotype 1 disease 
had significantly shorter hospitalizations (<3 days vs. 4–14 
days [odds ratio (OR) 0.58, 95% CI 0.33–1.02] or >15 days 
[OR 0.44, 95% CI 0.23–0.85]) and were less likely to have 
HIV disease (OR 0.19, 95% CI 0.12–0.31), to die while 
hospitalized (OR 0.38, 95% CI 0.19–0.76), or to have pen-
icillin-nonsusceptible disease (OR 0.02, 95 CI 0.01–0.05) 
(Table 1).
Among persons >5 years of age, serotype 1 IPD (com-
pared with non–serotype 1 IPD) was significantly associated 
with province, year, and patient age: compared with persons 
>64 years of age, ORs (95% CIs) were 13.48 (5.53–32.82) 
for children 5–9 years of age; 8.02 (3.15–20.43) for children 
10–14 years of age; 5.65 (2.31–13.82) for persons 15–24 
years of age; 3.67 (1.53–8.76) for persons 25–44 years of 
age; and 2.57 (1.06–6.23) for persons 45–64 years of age 
(online Technical Appendix Table 2). Compared with per-
sons with non–serotype 1 IPD, those with serotype 1 disease 
had significantly shorter hospitalization (<3 days vs. 4–14 
days [OR 0.86, 95% CI 0.68–1.09] and vs. >15 days [OR 
0.64, 95% CI 0.48–0.86]) and lower rates of previous admis-
sions (OR 0.45, 95% CI 0.35–0.57) and tuberculosis treat-
ment (OR 0.73, 95% CI 0.57–0.95).
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Figure 2. Incidence of serotype 1 and non–serotype 1 invasive 
pneumococcal disease (IPD) by age group, South Africa, 
2003–2013. Years indicate prevaccine (2003–2008), baseline 
without clusters (2005–2007), and postvaccine (2013) periods. 
A) Serotype 1 IPD incidence by age group during prevaccine (no. 
cases = 622), baseline (no. cases = 549), and postvaccine (no. 
cases = 246) years. B) Non–serotype 1 IPD incidence by age 
group during prevaccine (no. cases = 3,982), baseline (no. cases 
= 4,239), and postvaccine years (no. cases = 2,618). Error bars 
indicate 95% CIs.
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Table 1. Characteristics of 5,272 patients <5 years of age with invasive pneumococcal disease caused by serotype 1 or non–serotype 
1 Streptococcus pneumoniae, South Africa, 2003–2013* 
Variable 
No. cases/no. total (%) 
 
Univariate analysis† 
 
Multivariable analysis† 
Serotype 1 Non–serotype 1 OR (95% CI) p value aOR (95% CI) p value 
Age, y         
 <1 63/211 (30) 2,754/5,061 (54)  Reference <0.001  Reference <0.001 
 1 35/211 (17) 1,155/5,061 (23)  1.32 (0.87–2.01)   2.36 (1.31–4.26)  
 2 43/211 (20) 519/5,061 (10)  3.62 (2.43–5.40)   6.91 (3.78–12.64)  
 3 37/211 (18) 355/5,061 (7)  4.56 (2.99–6.94)   12.03 (6.12–23.64)  
 4 33/211 (16) 278/5,061 (5)  5.19 (3.35–8.05)   7.13 (3.60–14.13)  
Province         
 Gauteng 95/211 (45) 2,067/5,061 (41)  Reference <0.001  Reference <0.001 
 Western Cape 11/211 (5) 1,158/5,061 (23)  0.21 (0.11–0.39)   0.11 (0.04–0.26)  
 KwaZulu-Natal 46/211 (22) 957/5,061 (19)  1.05 (0.73–1.50)   1.04 (0.59–1.84)  
 Eastern Cape 15/211 (7) 152/5,061 (3)  2.15 (1.22–3.79)   1.98 (0.74–5.28)  
 Free State 25/211 (12) 383/5,061 (8)  1.42 (0.90–2.24)   1.06 (0.56–2.00)  
 Mpumalanga 4/211 (2) 104/5,061 (2)  0.84 (0.30–2.32)   0.58 (0.07–4.86)  
 North-West 5/211 (2) 46/5,061 (1)  2.36 (0.92–6.09)   5.65 (1.33–24.05)  
 Limpopo 4/211 (2) 48/5,061 (1)  1.81 (0.64–5.13)   1.79 (0.41–7.90)  
 Northern Cape 6/211 (3) 146/5,061 (3)  0.89 (0.39–2.08)   0.50 (0.15–1.64)  
Year of specimen collection         
 2003 31/211 (15) 544/5,061 (11)  1.20 (0.72–1.99) 0.004  1.10 (0.49–2.49) 0.05 
 2004 26/211 (12) 699/5,061 (14)  0.78 (0.46–1.32)   0.58 (0.25–1.34)  
 2005 32/211 (15) 672/5,061 (13)  Reference   Reference  
 2006 21/211 (10) 551/5,061 (11)  0.80 (0.46–1.40)   0.77 (0.34–1.72)  
 2007 15/211 (7) 547/5,061 (11)  0.58 (0.31–1.07)   0.67 (0.26–1.75)  
 2008 10/211 (5) 542/5,061 (11)  0.39 (0.19–0.80)   0.40 (0.15–1.03)  
 2009 23/211 (11) 494/5,061 (10)  0.98 (0.57–1.69)   1.43 (0.63–3.24)  
 2010 19/211 (9) 361/5,061 (7)  1.11 (0.62–1.98)   0.82 (0.33–2.08)  
 2011 19/211 (9) 240/5,061 (5)  1.66 (0.92–2.99)   1.04 (0.44–2.44)  
 2012 12/211 (6) 190/5,061 (4)  1.33 (0.67–2.63)   0.49 (0.18–1.33)  
 2013 3/211 (1) 221/5,061 (4)  0.29 (0.09–0.94)   0.12 (0.02–0.59)  
Medical conditions/treatment         
 Length of hospital stay, d         
  <3 57/186 (31) 1,238/4,489 (28)  Reference 0.09  Reference 0.04 
  4–14 96/186 (52) 2,138/4,489 (48)  0.98 (0.70–1.36)   0.58 (0.33–1.02)  
  >15 33/186 (18) 1,113/4,489 (25)  0.64 (0.42–1.00)   0.44 (0.23–0.85)  
 Previously hospitalized 39/164 (24) 1,676/4,110 (41)  0.45 (0.31–0.65) <0.001    
 Underlying medical condition‡ 27/114 (24) 1,321/3,371 (39)  0.48 (0.31–0.75) 0.001    
 Antimicrobial drug use in 
previous 2 mo§ 
10/147 (7) 742/3,549 (21)  0.28 (0.14–0.53) <0.001    
 HIV infected 43/132 (33) 2,125/3,539 (60)  0.32 (0.22–0.47) <0.001  0.19 (0.12–0.31) <0.001 
 TB treatment in previous 3 mo 11/161 (7) 570/3,928 (15)  0.43 (0.23–0.80) 0.008    
 Malnourished¶ 24/95 (25) 1,109/2,619 (42)  0.46 (0.29–0.74) 0.001    
 Died during hospitalization 24/191 (13) 1,105/4,513 (24)  0.44 (0.29–0.68) <0.001  0.38 (0.19–0.76) 0.006 
Pneumococcal isolate 
characteristics 
        
 Penicillin nonsusceptible# 4/203 (2) 2,580/4,950 (52)  0.02 (0.01–0.05) <0.001  0.02 (0.01–0.05) <0.001 
 Previous invasive 
pneumococcal disease** 
2/211 (1) 356/5,061 (7)  0.13 (0.03–0.51) 0.004    
Clinical syndrome††         
 Meningitis 59/198 (30) 1,668/4,736 (35)  Reference 0.001    
 Pneumonia 124/198 (63) 2,358/4,736 (50)  1.49 (1.08–2.04)     
 Bacteremia 15/198 (8) 710/4,736 (15)  0.60 (0.34–1.06)     
*All patients were reported from the enhanced Group for Enteric, Respiratory, and Meningeal Disease Surveillance in South Africa (GERMS-SA) 
surveillance sites. aOR, adjusted odds ratio; OR, odds ratio; TB, tuberculosis. 
†Only variables significant on univariate and multivariable analysis are shown. Variables not included are sex, race, Pitt bacteremia score, prematurity, 
antimicrobial drug use in previous 24 h, viable culture, and specimen type. 
‡Includes asplenia or sickle cell anemia; chronic illness (i.e., chronic lung, renal, liver, cardiac disease, and diabetes); other immunocompromising 
conditions (i.e. including organ transplant, primary immunodeficiency, immunotherapy, and malignancy, but excluding HIV); and other risk factors (i.e., 
head injury with possible cerebral spinal fluid leak, neurologic disorders, burns, and chromosomal abnormalities). Excludes malnutrition. 
§Use of any antimicrobial drug in 2 mo prior to admission. 
¶Malnutrition was classified as a weight-for-age z-score of less than 2 (World Health Organization child growth standards 2009) (18), nutritional edema, 
or both. 
#Considered penicillin nonsusceptible at MIC >0.12 g/mL; intermediately resistant and resistant groups were combined into a nonsusceptible group. 
**Invasive pneumococcal disease diagnosis >21 d before this episode. 
††Clinical diagnoses were made on the basis of documented discharge diagnoses in patient medical records; clinical syndrome were separated into 3 
groups: meningitis, bacteremic pneumonia, and bacteremia without focus or other diagnosis (e.g., septic arthritis, endopthalmitis, peritonitis, pericarditis). 
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Persons >5 years of age with serotype 1 disease were 
also significantly less likely to have HIV (OR 0.39, 95% 
CI 0.31–0.49) or penicillin-nonsusceptible disease (OR 
0.02, 95% CI 0.01–0.04), and they were more likely than 
those with non–serotype 1 IPD to receive a diagnosis of 
pneumonia (OR 1.28, 95% CI 1.03–1.58) or bacteremia 
(OR 1.76, 95% CI 1.22–2.55) rather than meningitis. In-
hospital death compared with recovery was not significant 
in the >5 year age group.
Factors Associated with In-Hospital Deaths  
among Patients with Serotype 1 IPD
We conducted multivariable analysis to explore factors as-
sociated with death in children <5 years of age with sero-
type 1 IPD (Table 2). Compared with 4-year-old children, 
those <1 year of age were more likely to die (OR 12.06, 
95% CI 1.45–100.26), as were children with underlying 
medical conditions than those without. Odds of death were 
also increased among children with HIV (OR 2.82, 95% CI 
1.36–5.84) or meningitis versus those with pneumonia or 
bacteremia. Duration of hospitalization was shorter among 
persons who died compared with those who recovered (<3 
days vs. 4–14 days [OR 0.06, 95% CI 0.03–0.15] or >15 
days [OR 0.02, 95% CI 0.01–0.07]).
Similar factors were associated with increased odds 
of death in persons >5 years of age with serotype 1 IPD 
(online Technical Appendix Table 3). In addition, death 
was more likely among persons who had received tu-
berculosis treatment in the previous 3 months (OR 1.75, 
95% CI 1.25–2.45) and among severely ill persons (OR 
5.26, 95% CI 3.53–7.84 for patients with a Pitt bacteremia 
score >4). No difference was seen in the odds of death 
by HIV status. Compared with children 5–9 years of age, 
persons >25 years of age had incrementally increased 
odds of death by age group: 25–44 years of age, OR 5.07 
(95% CI 2.74–9.38); 45–64 years of age, OR 9.00 (95% 
CI 4.66–17.35); and >64 years of age, OR 10.13 (95% CI 
4.46–23.00).
Detection of Serotype 1 IPD Clusters
Of the 46,483 IPD cases, 34,032 (73%) had available data 
(i.e., date of specimen collection, geographic location of 
patient, and serotype results) and were included in the 
space–time scan analysis. Of these 34,032 cases, 4,544 
(13%) were caused by serotype 1 IPD. Two clusters of 
serotype 1 were detected. The first (713 cases) occurred 
during May 2003–December 2004 and affected Gauteng 
Province and adjacent districts of Mpumalanga, Limpopo, 
and North-West Provinces (Figure 3, panel A; online Tech-
nical Appendix Table 4). The second cluster (718 cases) 
occurred during September 2008–April 2012 and affected 
KwaZulu-Natal and Free State Provinces and adjacent dis-
tricts of Gauteng, North-West, Mpumalanga, and Eastern 
Cape Provinces (Figure 3, panel B; online Technical Ap-
pendix Table 4). We also assessed clustering of disease 
caused by 2 other epidemic-prone serotypes (serotypes 5 
and 8); neither showed significant increases in case num-
bers compared with numbers in 2005.
Discussion
In South Africa, serotype 1 pneumococcal disease had a 
number of distinct features. Children <5 years of age with 
serotype 1 IPD were less likely to die than were children 
with disease caused by other serotypes; this association be-
tween serotype 1 and death was not seen in older children 
and adults. Patients with serotype 1 IPD had fewer cases 
of penicillin-nonsusceptible disease, a lower prevalence of 
HIV, and less severe disease than patients with non–sero-
type 1 IPD. However, pneumonia and bacteremia occurred 
more commonly in patients with serotype 1 IPD than in 
patients with IPD caused by other serotypes.
Serotype 1 IPD incidence differed by geographic area 
and year, reflecting its epidemic potential (1). In older chil-
dren and adults, serotype 1 was the most common serotype 
over the entire study period, even though numbers were 
lower after PCV13 introduction. Before PCV7 introduc-
tion, serotype 1 was the sixth most common serotype in 
children <5 years of age; by 2013, it no longer ranked in the 
top 10 serotypes in this age group.
IPD is common in children with underlying diseases, 
including HIV. Compared with infections caused by other 
common pneumococcal serotypes, serotype 1 IPD was as-
sociated with more bacteremic pneumonia and peritonitis, 
occurred in older children and specific ethnic groups, and 
affected otherwise healthy children (3).
Serotype 1 IPD has marked temporal variability (19) 
and is associated with outbreaks (20,21). In our study, we 
noted fluctuations in incidence rates for serotype 1 IPD, es-
pecially among young children before PCV introduction. 
Incidence of serotype 1 IPD decreased in all age groups af-
ter 2011, likely due to the effect of PCV13, and serotype 1 
disease nearly disappeared among the youngest children by 
2013, two years after PCV13 introduction (10). We cannot 
exclude that other factors (e.g., improvements in access to 
antiretroviral treatment and programs for the prevention of 
mother-to-child HIV transmission) may have contributed 
to this decrease (14,22). We identified 2 large clusters that 
were not recognized prospectively because of the difficulty 
in identifying communitywide clusters in real time, espe-
cially using laboratory-based surveillance.
Our findings showed differences in the geograph-
ic distribution of serotype 1 and non–serotype 1 dis-
ease. Serotype 1 has been described to occur more 
frequently in underprivileged populations in develop-
ing countries (19); in our study, differences in speci-
men collection practices between provinces may have 
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contributed to differences seen in disease distribution, 
as shown in other studies (23). Similar to findings by 
others (24,25), we found a difference in serotype dis-
tribution by age: serotype 1 IPD incidence was propor-
tionally similar among older children and adults com-
pared with that among children <1 year of age, whereas 
other serotypes predominated in the youngest age group 
and showed only a small peak in young adults. A number of 
factors may contribute to these age-associated differences 
(25). Compared with other serotypes, serotypes 1 and 5 are 
rarely carried by healthy persons; a short duration of carriage 
results in less opportunity for recombination events and 
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Table 2. Factors associated with death in patients <5 years of age with serotype 1 invasive pneumococcal disease, South 
Africa, 2003–2013* 
Variable 
Univariate analysis  Multivariable analysis 
No. deaths/no. cases (%) OR (95% CI) p value aOR (95% CI) p value 
Age group, y       
 <1 102/355 (29) 11.49 (2.75–47.95) <0.001  12.06 (1.45–100.26) 0.02 
 1 22/154 (14) 4.75 (1.08–20.88)   3.83 (0.41–35.35)  
 2 11/94 (12) 3.78 (0.81–17.69)   1.30 (0.12–14.34)  
 3 6/73 (8) 2.55 (0.49–13.14)   1.40 (0.12–15.82)  
 4 2/59 (3) Reference   Reference  
Province       
 Gauteng 53/327 (16) Reference 0.001    
 Western Cape 15/111 (14) 0.81 (0.44–1.50)     
 KwaZulu-Natal 26/111 (23) 1.58 (0.93–2.68)     
 Eastern Cape 12/44 (27) 1.94 (0.94–4.01)     
 Free State 11/62 (18) 1.11 (0.55–2.28)     
 Mpumalanga 7/19 (37) 3.02 (1.13–8.01)     
 North-West 11/23 (48) 4.74 (1.99–11.30)     
 Limpopo 7/21 (33) 2.58 (1.00–6.71)     
 Northern Cape 1/17 (6) 0.32 (0.04–2.49)     
Medical condition/treatment       
 Length of hospital stay, d       
  <3 94/209 (45) Reference <0.001  Reference <0.001 
  4–14 36/354 (10) 0.14 (0.09–0.21)   0.06 (0.03–0.15)  
  >15 10/160 (6) 0.08 (0.04–0.16)   0.02 (0.01–0.07)  
 Pitt bacteremia score†       
  0–3 102/608 (17) Reference <0.001    
  >4 16/28 (58) 6.61 (3.04–14.40)     
 Underlying medical condition‡       
  No 55/343 (16) Reference 0.19  Reference 0.003 
  Yes 33/158 (21) 1.38 (0.86–2.23)   3.21 (1.49–6.91)  
 Antimicrobial drug use in 24 h before admission 
  No 82/504 (16) Reference 0.05    
  Yes 15/56 (26) 1.88 (1.00–3.56)     
 HIV status       
  HIV-uninfected 37/252 (15) Reference 0.13  Reference 0.005 
  HIV-infected 52/263 (20) 1.43 (0.90–2.27)   2.82 (1.36–5.84)  
 Malnourished§       
  No 44/277 (16) Reference 0.03    
  Yes 43/176 (24) 1.71 (1.07–2.74)     
Clinical syndrome/specimen type       
 Specimen type       
  CSF 59/166 (36) Reference <0.001    
  Blood 83/530 (16) 0.34 (0.23–0.50)     
  Other 1/39 (3) 0.05 (0.01–0.36)     
 Clinical syndrome¶       
  Meningitis 74/209 (35) Reference <0.001  Reference 0.0003 
  Pneumonia 50/410 (12) 0.25 (0.17–0.38)   0.25 (0.11–0.54)  
  Bacteremia 18/111 (16) 0.35 (0.20–0.63)   0.11 (0.03–0.42)  
*All patients were reported from the enhanced Group for Enteric, Respiratory, and Meningeal Disease Surveillance in South Africa (GERMS-SA) 
surveillance sites. Only variables significant on univariate and multivariable analysis are shown. Variables not included in table are sex, year, previous 
hospital admission, prematurity, antimicrobial drug in previous 2 mo, and penicillin nonsusceptible invasive pneumococcal disease. aOR, adjusted odds 
ratio; OR, odds ratio. 
†Pitt bacteremia score calculated using temperature, hypotension, mechanical ventilation, cardiac arrest and mental status. Severe disease defined as 
score of >4 points. 
‡Includes asplenia or sickle cell anemia; chronic illness (i.e., chronic lung, renal, liver, cardiac disease, and diabetes); other immunocompromising 
conditions (i.e., organ transplant, primary immunodeficiency, immunotherapy, and malignancy, but excluding HIV); and other risk factors (i.e., head injury 
with possible cerebral spinal fluid leak, neurologic disorders, burns, and chromosomal abnormalities). Excludes malnutrition. 
§Children with weight-for-age z-score of less than 2 (World Health Organization child growth standards 2009) (18), nutritional edema, or both. 
¶Clinical diagnoses were made on the basis of documented discharge diagnoses in patient medical records, with clinical syndrome separated into 3 
groups: meningitis, bacteremic pneumonia, and bacteremia without focus or other diagnosis (e.g., septic arthritis, endopthalmitis, peritonitis, pericarditis) 
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less antibiotic selection pressure, resulting in reduced an-
tibiotic nonsusceptibility in serotype 1 isolates (26).
Similar to findings in other studies (3), we found that, 
compared with other pneumococcal serotypes, serotype 1 
caused more bacteremic pneumonia than meningitis. In addi-
tion, among HIV-uninfected children, serotype 1 IPD made 
up a larger proportion of disease than in HIV-infected chil-
dren (27,28), suggesting that serotype 1 is more invasive and 
virulent, thus affecting otherwise healthy persons (29,30). 
Among children <5 years of age, those with serotype 1 dis-
ease were less likely to die than those with disease caused 
by other serotypes (31), and those most at risk of death were 
the very young (<1 year of age) and those HIV infected. In 
older persons, no association was found between serotype 1 
disease and death when compared with other serotypes. An-
other analysis from the prevaccine era showed an increased 
risk of death among adults with serotype 1 disease compared 
with those with serotype 4 disease (32); this increased risk 
has been shown in few other studies (33).
Our study had several limitations. First, we included 
only patients who sought care at healthcare facilities with 
laboratories that submitted pneumococcal isolates to the 
National Institute for Communicable Diseases and who 
had specimens collected; patients with mild clinical pneu-
mococcal disease treated in the community were not in-
cluded. Second, we were able to map serotype 1 IPD inci-
dence only at district level, so minor changes in incidence 
and clusters at the individual healthcare facility level may 
have been missed. Third, because of the small number of 
patients in the <5-year-old age group, we did not show 
clusters by age. We expect that reported clusters would 
have been similar for all ages. Fourth, we did not collect 
details regarding duration of symptoms before admission 
and thus could not assess whether intensity of symptoms 
when healthcare was sought affected case-fatality rates. 
Fifth, PCR serotype results from samples with a lytA cy-
cle threshold (C
t
) of >35 may not be accurate. We did not 
use PCR results in the trend analysis, and the proportion 
of lytA samples with high C
t
 values was low in the surveil-
lance program (34), so the C
t
 accuracy is unlikely to have 
affected our results. Sixth, we used non–serotype 1 cases 
as our comparison group in the descriptive factor analy-
sis; although this group changed over the study period, 
PCV13 serotypes (excluding serotype 1) made up >50% 
of this group until 2012 and 40% in 2013. Last, our study 
covered only a short period of observation after PCV13 
introduction, making it difficult to determine whether re-
ductions in serotype 1 IPD were due to introduction of 
this vaccine.
In conclusion, compared with IPD caused by other 
serotypes, IPD caused by serotype 1 in South Africa was 
characterized by shorter hospital stays, fewer cases of resis-
tant disease, fewer in-hospital fatalities in children <5 years 
of age, and lower prevalence among HIV-infected persons. 
Serotype 1 caused disease in all age groups, although prev-
alence peaked in older children and young adults. Tempo-
ral reductions in serotype 1 IPD have been observed within 
2 years of PCV13 introduction in South Africa; this obser-
vation must be corroborated by ongoing surveillance over 
an extended period of time.
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Figure 3. Serotype 1 invasive pneumococcal disease clusters by district, South Africa. A) May 2003–December 2004. B) September 
2008–April 2012. Gray borders indicate district boundaries; black borders indicate provincial boundaries. Provinces: EC, Eastern 
Cape; FS, Free State; GP, Gauteng; KZN, KwaZulu-Natal; LP, Limpopo; MP, Mpumalanga; NC, Northern Cape; NWP, North-West; 
WC, Western Cape. District relative risk was calculated by dividing the observed number of cases per district by the number of cases 
expected by district (as determined on the basis of numbers in control groups). 
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Technical Appendix 
Methods 
Invasive Pneumococcal Disease Surveillance in South Africa 
Invasive pneumococcal disease (IPD) surveillance began in South Africa in 1999 (1) and 
was limited to the collection of laboratory data and isolates from pneumococcal cases. The 
surveillance program was expanded in 2003 through GERMS-SA (Group for Enteric, 
Respiratory and Meningeal Disease Surveillance in South Africa), a national, active, laboratory-
based surveillance system. The number of hospitals and laboratories covered by the surveillance 
increased over time, however more than 70% of hospitals remained consistent in the program 
over most of the reported period (2). 
All laboratories record basic demographic information (age, sex, date of specimen 
collection, and source of isolate) for all pneumococcal isolates. Enhanced surveillance with 
trained surveillance officers at 24 sentinel hospitals located in all nine provinces of South Africa, 
includes the collection of additional clinical data, for example, admission and discharge date, 
HIV serologic status, vaccination information and discharge diagnosis and outcome. Enhanced 
surveillance sites account for 50% of all reported pneumococcal cases nationally. 
Enhanced surveillance sites were chosen based on convenience, interest from site 
investigators and number of isolates submitted. Larger sites with higher isolate submissions were 
favored, resulting in enhanced sites being mainly tertiary and some secondary (regional) 
hospitals. Non-enhanced sites include district, regional and tertiary public hospitals, private 
hospitals and clinics. The regional and tertiary hospitals however made up over 70% of isolates 
sent from non-enhanced sites. 
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To identify missed unreported cases, annual laboratory audits were conducted throughout 
the study period using a centralized National Health Laboratory Service Corporate Data 
Warehouse which consolidates cases for all public-sector laboratories. Audit cases were included 
in the surveillance database for incidence rate calculations. Cases were likely missed as isolates 
were submitted by staff working in busy routine clinical microbiological laboratories. Isolates 
were often delayed at the sites and submitted in batches with other surveillance organisms sent to 
the NICD. As S. pneumoniae is fastidious it was often non-viable by the time it reached the 
NICD. 
Definitions 
At enhanced sites where additional clinical information was available, underlying 
conditions were defined as asplenia, including sickle cell anemia; chronic illness (chronic lung, 
renal, liver, cardiac disease and diabetes); other immunocompromising conditions (excluding 
HIV), including organ transplant and malignancy; and other risk factors, including head injury 
with possible CSF leak, neurologic disorders, burns, chromosomal abnormalities, alcohol use 
and smoking. Clinical diagnoses were based on documented discharge diagnoses in patient 
medical records, with clinical syndrome separated into three groups: meningitis, bacteremic 
pneumonia, and bacteremia without focus/other. Pitt bacteremia score was calculated using 5 
parameters: (1) oral temperature, (2) hypotension, (3) receipt of mechanical ventilation, (4) 
cardiac arrest, and (5) mental status. Severe disease was defined as a score of ≥4 points (3). 
Serotypes were defined as serotype 1 or non-serotype 1 IPD. Penicillin non-susceptibility 
was categorized using 2013 Clinical and Laboratory Standards Institute breakpoints for oral 
penicillin V (susceptible, ≤0.06 g/L; intermediately resistant, 0.12–1 g/L and resistant, ≥2 
g/L) (4). Intermediately resistant and resistant groups were combined into a non-susceptible 
group for analysis. Pneumococcal disease was considered recurrent if diagnosed >21 days after a 
previous case in the same patient. 
Other Interventions Affecting Invasive Pneumococcal Disease Trends in South Africa 
Comprehensive HIV/AIDS treatment programs were implemented in South Africa in 
2003 and access to treatment improved steadily with 80% coverage reported by 2012 (5). 
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Prevention of mother-to-child transmission programs also improved steadily with an associated 
decrease in mother-to-child HIV transmission rates from 12% in 2007 to 2.7% in 2011 (6) and 
2.5% during 2012/2013 (7). This was despite a relatively constant prevalence of HIV in pregnant 
women of around 30% over the same period. 
A manuscript describing the reduction in IPD in South Africa following the introduction 
of PCV (2) showed a 49% reduction in all serotype IPD and 85% reduction in PCV7 serotypes in 
HIV-uninfected children <2 years of age by 2012. In HIV-infected children PCV7 serotypes 
decreased by 86% and non-vaccine serotypes by 31% which showed the benefit of 
improvements in prevention of mother-to-child transmission of HIV, antiretroviral treatment in 
children and PCV7. Reductions in PCV13-serotype disease in 2009 and 2010, before the 
introduction of PCV13, were also most likely a result of ART. In HIV-infected children it was 
thought to be difficult to tease out the exact amount of reduction in pneumococcal disease due to 
PCV and that due to other interventions. 
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Technical Appendix Table 1. Comparison of cases from GERMS-SA enhanced and non-enhanced sites for all age groups, 2003–
2013 
Variable Enhanced sites n/N (%) 
Non-enhanced sites n/N 
(%) OR (95% CI) p value 
Age    <0.001 
 <1 y 3431/20,826 (16) 3470/23,397 (15) 1.21 (1.08–1.36)  
 1–4 y 2899/20,826 (14) 2828/23,397 (12) 1.26 (1.12–1.41)  
 5–9 y 1286/20,826 (6) 1587/23,397 (7) 0.99 (0.88–1.13)  
 10–14 y 510/20,826 (2) 700/23,397 (3) 0.89 (0.77–1.04)  
 15–24 y 1269/20,826 (6) 1551/23,397 (7) 1.00 (0.89–1.14)  
 25–44 y 7909/20,826 (38) 9058/23,397 (39) 1.07 (0.96–1.19)  
 45–64 y 2844/20,826 (14) 3371/23,397 (14) 1.04 (0.92–1.16)  
 >64 y 678/20,826 (3) 832/23,397 (4) Reference  
Sex    0.83 
 Female 10,686/20,984 (51) 12,510/24,516 (51) Reference  
 Male 10,298/20,984 (49) 12,006/24,516 (49) 1.00 (0.97–1.04)  
Province    <0.001 
 Gauteng 11,287/21,188 (53) 10,950/25,297 (43) Reference  
 Western Cape 3038/21,188 (14) 2864/25,297 (11) 1.03 (0.97–1.09)  
 KwaZulu-Natal 3045/21,188 (14) 2321/25,297 (9) 1.27 (1.20–1.35)  
 Eastern Cape 570/21,188 (3) 3101/25,297 (12) 0.18 (0.16–0.20)  
 Free State 1365/21,188 (6) 1687/25,297 (7) 0.78 (0.73–0.85)  
 Mpumalanga 726/21,188 (3) 1873/25,297 (7) 0.38 (0.34–0.41)  
 North West 338/21,188 (2) 1510/25,297 (6) 0.22 (0.19–0.25)  
 Limpopo 363/21,188 (2) 719/25,297 (3) 0.49 (0.43–0.56)  
 Northern Cape 456/21,188 (2) 272/25,297 (1) 1.63 (1.40–1.89)  
Year    <0.001 
 2003 1927/21,188 (9) 1962/25,297 (8) Reference  
 2004 2297/21,188 (11) 2245/25,297 (9) 1.04 (0.96–1.13)  
 2005 2488/21,188 (12) 2398/25,297 (9) 1.06 (0.97–1.15)  
 2006 2202/21,188 (10) 2534/25,297 (10) 0.88 (0.81–0.96)  
 2007 2148/21,188 (10) 2595/25,297 (10) 0.84 (0.77–0.92)  
 2008 2051/21,188 (10) 2784/25,297 (11) 0.75 (0.69–0.82)  
 2009 2039/21,188 (10) 2725/25,297 (11) 0.76 (0.70–0.83)  
 2010 1918/21,188 (9) 2280/25,297 (9) 0.86 (0.78–0.93)  
 2011 1615/21,188 (8) 2189/25,297 (9) 0.75 (0.69–0.82)  
 2012 1305/21,188 (6) 1917/25,297 (8) 0.69 (0.63–0.76)  
 2013 1198/21,188 (6) 1668/25,297 (7) 0.73 (0.66–0.81)  
Penicillin non-susceptibility    <0.001 
 Susceptible 10,536/16,338 (64) 10,986/16,510 (67) Reference  
 Non-susceptible 5802/16,338 (36) 5524/16,510 (33) 1.10 (1.05–1.15)  
Specimen type    <0.001 
 CSF 5697/21,188 (27) 11,446/25,297 (45) Reference 
 Blood culture 13,897/21,188 (66) 11,104/25,297 (44) 2.51 (2.41–2.62) 
 Other specimens 1594/21,188 (8) 2747/25,297 (11) 1.17 (1.09–1.25) 
Serotype    <0.001 
 Non-serotype 1 19,246/21,186 (91) 22,690/25,294 (90) Reference  
 Serotype 1 1940/21,186 (9) 2604/25,294 (10) 0.88 (0.83–0.93)  
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Technical Appendix Table 2. Characteristics of 10,899 patients >5 years of age with invasive pneumococcal disease caused by 
serotype 1 and non–serotype 1 Streptococcus pneumoniae, South Africa, 2003–2013* 
Variable 
No. cases/no. total (%) 
 
Univariate analysis† 
 
Multivariable analysis† 
Serotype 1 Non–serotype 1 OR (95% CI) p value aOR (95% CI) p value 
Age group, y         
 5–9 254/1,642 (15) 809/9,257 (9)  3.19 (2.29–4.45) <0.001  13.48 (5.53–32.82) <0.001 
 10–14 115/1,642 (7) 298/9,257 (3)  3.92 (2.71–5.66)   8.02 (3.15–20.43)  
 15–24 201/1,642 (12) 755/9,257 (8)  2.71 (1.93–3.79)   5.65 (2.31–13.82)  
 25–44 768/1,642 (47) 5,078/9,257 (55)  1.54 (1.13–2.10)   3.67 (1.53–8.76)  
 45–64 257/1,642 (16) 1,839/9,257 (20)  1.42 (1.03–1.97)   2.57 (1.06–6.23)  
 >64 47/1,642 (3) 478/9,257 (5)  Reference   Reference  
Black race 1452/1,576 
(92) 
7,854/8,889 (88)  1.54 (1.27–1.87) <0.001    
Province         
 Gauteng 951/1,642 (58) 4,804/9,257 (52)  Reference <0.001  Reference <0.001 
 Western Cape 99/1,642 (6) 1,443/9,257 (16)  0.35 (0.28–0.43)   0.24 (0.17–0.34)  
 KwaZulu-Natal 228/1,642 (14) 1,469/9,257 (16)  0.78 (0.67–0.92)   0.80 (0.60–1.07)  
 Eastern Cape 47/1,642 (3) 166/9,257 (2)  1.43 (1.03–1.99)   0.80 (0.39–1.63)  
 Free State 130/1,642 (8) 516/9,257 (6)  1.27 (1.04–1.56)   0.89 (0.64–1.22)  
 Mpumalanga 64/1,642 (4) 358/9,257 (4)  0.90 (0.69–1.19)   0.80 (0.43–1.49)  
 North-West 34/1,642 (2) 148/9,257 (2)  1.16 (0.79–1.70)   2.25 (1.13–4.48)  
 Limpopo 42/1,642 (3) 143/9,257 (2)  1.48 (1.04–2.11)   0.97 (0.47–2.01)  
 Northern Cape 47/1,642 (3) 210/9,257 (2)  1.13 (0.82–1.56)   1.39 (0.85–2.26)  
Year of specimen collection         
 2003 209/1,642 (13) 733/9,257 (8)  1.45 (1.16–1.80) <0.001  1.17 (0.76–1.82) 0.01 
 2004 225/1,642 (14) 891/9,257 (10)  1.28 (1.03–1.58)   1.32 (0.87–2.00)  
 2005 196/1,642 (12) 994/9,257 (11)  Reference   Reference  
 2006 142/1,642 (9) 962/9,257 (10)  0.75 (0.59–0.95)   0.67 (0.42–1.09)  
 2007 112/1,642 (7) 892/9,257 (10)  0.64 (0.50–0.82)   0.71 (0.44–1.14)  
 2008 116/1,642 (7) 842/9,257 (9)  0.70 (0.55–0.89)   0.86 (0.56–1.32)  
 2009 156/1,642 (10) 866/9,257 (9)  0.91 (0.73–1.15)   1.21 (0.80–1.84)  
 2010 164/1,642 (10) 995/9,257 (11)  0.84 (0.67–1.05)   1.02 (0.66–1.57)  
 2011 134/1,642 (8) 819/9,257 (9)  0.83 (0.65–1.05)   0.98 (0.63–1.51)  
 2012 112/1,642 (7) 676/9,257 (7)  0.84 (0.65–1.08)   0.96 (0.62–1.48)  
 2013 76/1,642 (5) 587/9,257 (6)  0.66 (0.49–0.87)   0.64 (0.40–1.04)  
Medical conditions/treatment         
 Length of hospital stay, d         
  <3 481/1,443 (33) 2518/8,311 (30)  Reference 0.001  Reference 0.01 
  4–14 758/1,443 (53) 4289/8,311 (52)  0.93 (0.82–1.05)   0.86 (0.68–1.09)  
  >15 204/1,443 (14) 1504/8,311 (18)  0.71 (0.60–0.85)   0.64 (0.48–0.86)  
 Previous hospital admission 166/1,153 (14) 2000/6,816 (29)  0.40 (0.34–0.48) <0.001  0.45 (0.35–0.57) <0.001 
 Underlying medical 
condition‡ 
310/953 (33) 2571/6,083 (42)  0.66 (0.57–0.76) <0.001    
 Antimicrobial drug use in 
previous 2 mo§ 
32/962 (3) 412/5,550 (7)  0.43 (0.30–0.62) <0.001    
 HIV infected 717/1,007 (71) 5373/6,338 (85)  0.44 (0.38–0.52) <0.001  0.39 (0.31–0.49) <0.001 
 Treated for TB in previous 3 
mo 
146/1,126 (13) 1373/6,659 (21)  0.57 (0.48–0.69) <0.001  0.73 (0.57–0.95) 0.02 
 Died during hospitalization 461/1,422 (32) 2650/8,228 (32)  1.01 (0.90–1.14) 0.88    
Pneumococcal isolate 
characteristics 
        
 Penicillin nonsusceptible¶ 15/1,555 (1) 2916/8,829 (33)  0.02 (0.01–0.03) <0.001  0.02 (0.01–0.04) <0.001 
 Previous invasive 
pneumococcal disease** 
26/1,642 (2) 396/9,257 (4)  0.36 (0.24–0.54) <0.001  0.32 (0.16–0.63) 0.001 
Clinical syndrome/specimen 
type 
        
 Specimen type         
  Cerebral spinal fluid 512/1,642 (31) 2626/9,257 (28)  Reference 0.05    
  Blood 1025/1,642 
(62) 
5967/9,257 (64)  0.88 (0.78–0.99)     
  Other 105/1,642 (6) 664/9,257 (7)  0.81 (0.65–1.02)     
 Clinical syndrome††         
  Meningitis 587/1,541 (38) 3043/8,793 (35)  Reference 0.02  Reference 0.006 
  Pneumonia 832/1,541 (54) 5076/8,793 (58)  0.85 (0.76–0.95)   1.28 (1.03–1.58)  
  Bacteremia 122/1,541 (8) 674/8,793 (8)  0.94 (0.76–1.16)   1.76 (1.22–2.55)  
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*All patients were reported from the enhanced Group for Enteric, Respiratory, and Meningeal Disease Surveillance in South Africa (GERMS-SA) 
surveillance sites. aOR, adjusted odds ratio; OR, odds ratio; TB, tuberculosis 
†Only variables significant on univariate and multivariable analysis are shown (exception is death during hospital admission). Variables not included 
in table are sex, Pitt bacteremia score, antimicrobial drug in previous 24 h, and viable culture. Prematurity and malnutrition were not included in the 
analysis because they were not considered relevant or actively collected for patients >5 years of age. 
‡Includes asplenia or sickle cell anemia; chronic illness (i.e., chronic lung, renal, liver, cardiac disease, and diabetes); other immunocompromising 
conditions (i.e., organ transplant, primary immunodeficiency, immunotherapy, and malignancy, but excluding HIV); and other risk factors (i.e., head 
injury with possible cerebral spinal fluid leak, neurologic disorders, burns, chromosomal abnormalities, smoking, and alcohol use). 
§Use of any antimicrobial drug in 2 mo before admission. 
¶Considered penicillin nonsusceptible at MIC >0.12 g/mL; intermediately resistant and resistant groups were combined into a nonsusceptible group. 
**Invasive pneumococcal disease diagnosis >21 days before this episode. 
††Clinical diagnoses were made on the basis of documented discharge diagnoses in patient medical records; clinical syndrome separated into 3 
groups: meningitis, bacteremic pneumonia, and bacteremia without focus or other diagnosis (e.g., septic arthritis, endopthalmitis, peritonitis, 
pericarditis). 
 
 
 
 
Technical Appendix Table 3. Factors associated with death in patients >5 years of age with serotype 1 invasive pneumococcal 
disease, South Africa, 2003–2013* 
Variable 
Univariate analysis 
 
Multivariable analysis 
No. deaths/no. cases (%)  OR (95% CI) p value aOR (95% CI) p value 
Demographic/socioeconomic 
characteristic 
      
 Age group, y       
  5–9 37/350 (11) Reference <0.001  Reference <0.001 
  10–14 23/143 (16) 1.62 (0.92–2.84)   1.24 (0.65–4.57)  
  15–24 90/362 (25) 2.80 (1.85–4.24)   3.05 (1.47–6.32)  
  25–44 611/1,950 (31) 3.86 (2.71–5.50)   5.07 (2.74–9.38)  
  45–64 285/686 (42) 6.01 (4.14–8.73)   9.00 (4.66–17.35)  
  >64 58/133 (44) 6.54 (4.03–10.61)   10.13 (4.46–23.00)  
 Race       
  Nonblack 61/250 (24) Reference 0.03    
  Black 1,023/3,313 (31) 1.38 (1.02–1.86)     
 Province       
  Gauteng 706/2,444 (29) Reference <0.001    
  Western Cape 54/217 (25) 0.82 (0.59–1.12)     
  KwaZulu-Natal 98/329 (30) 1.04 (0.81–1.34)     
  Eastern Cape 29/68 (43) 1.83 (1.12–2.98)     
  Free State 59/189 (31) 1.12 (0.81–1.54)     
  Mpumalanga 63/154 (41) 1.70 (1.22–2.38)     
  North-West 34/70 (49) 2.32 (1.44–3.75)     
  Limpopo 42/94 (45) 1.99 (1.31–3.01)     
  Northern Cape 19/59 (32) 1.17 (0.67–2.03)     
Medical condition/treatment       
 Length of hospital stay, d       
  >3 750/1,130 (66) Reference <0.001  Reference <0.001 
  4–14 254/1,891 (13) 0.08 (0.07–0.09)   0.07 (0.05–0.10)  
  >15 93/577 (16) 0.10 (0.08–0.13)   0.06 (0.04–0.09)  
 Pitt bacteremia score†       
  0–3 744/2,920 (26) Reference <0.001  Reference <0.001 
  >4 258/361 (71) 7.33 (5.74–9.34)   5.26 (3.53–7.84)  
 Underlying medical condition‡       
  No 357/1,582 (23) Reference <0.001  Reference 0.004 
  Yes 257/827 (31) 1.55 (1.28–1.87)   1.53 (1.14–2.04)  
 Antimicrobial drug use in 24 h before 
admission 
      
  No 644/2,537 (25) Reference 0.05    
  Yes 32/93 (34) 1.54 (1.00–2.39)     
 HIV status       
  HIV uninfected 108/514 (21) Reference 0.001    
  HIV infected 610/2,165 (28) 1.47 (1.17–1.86)     
 Treated for tuberculosis in previous 
3 mo 
      
  No 508/2,156 (24) Reference 0.001  Reference 0.001 
  Yes 154/496 (31) 1.46 (1.18–1.81)   1.75 (1.25–2.45)  
 Previous invasive 
pneumococcal disease§ 
      
  No 1097/3,536 (31) Reference <0.001    
  Yes 7/88 (8) 0.19 (0.09–0.42)     
Clinical syndrome/specimen type       
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 Specimen type       
  Cerebral spinal fluid 461/802 (57) Reference <0.001    
  Blood 565/2,440 (23) 0.22 (0.19–0.26)     
  Other 78/382 (20) 0.19 (0.14–0.25)     
 Clinical syndrome¶       
  Meningitis 531/982 (54) Reference <0.001  Reference <0.001 
  Pneumonia 490/2,311 (21) 0.23 (0.19–0.27)   0.18 (0.13–0.25)  
  Bacteremia 75/307 (24) 0.27 (0.21–0.37)   0.29 0.18–0.48)  
*All patients were reported from the enhanced Group for Enteric, Respiratory, and Meningeal Disease Surveillance in South Africa (GERMS-SA) 
surveillance sites. Only variables significant on univariate and multivariable analysis are shown. Variables not included in table are sex, year, 
previous hospital admission, any antimicrobial drug used in 2 mo before admission, and penicillin-nonsusceptible invasive pneumococcal disease. 
Prematurity and malnutrition were not included in the analysis because they were not considered relevant or actively collected for patients >5 years 
of age. aOR, adjusted odds ratio; OR, odds ratio. 
†Pitt bacteremia score calculated by using temperature, hypotension, mechanical ventilation, cardiac arrest, and mental status. Severe disease 
defined as score of >4 points. 
‡Includes asplenia or sickle cell anemia; chronic illness (i.e., chronic lung, renal, liver, cardiac disease and diabetes); other immunocompromising 
conditions (i.e., organ transplant, primary immunodeficiency, immunotherapy, and malignancy, but excluding HIV); and other risk factors (i.e. head 
injury with possible cerebral spinal fluid leak, neurologic disorders, burns, and chromosomal abnormalities). 
§Invasive pneumococcal disease diagnosis >21 days before this episode. 
¶Clinical diagnoses were made on the basis of documented discharge diagnoses in patient medical records, with clinical syndrome separated into 3 
groups: meningitis, bacteremic pneumonia, and bacteremia without focus or other diagnosis (e.g. septic arthritis, endopthalmitis, peritonitis, 
pericarditis). 
 
 
 
Technical Appendix Table 4. Serotype 1 clusters, by district, in South Africa, 2003–2013 
Cluster Period 
Location 
Relative risk p value District Province 
1 May 2003–Dec 2004 City of Johannesburg Gauteng 1.7 <0.001 
  City of Tshwane Gauteng   
  Ekurhuleni Gauteng   
  Metweding Gauteng   
  Sedibeng Gauteng   
  West Rand Gauteng   
  Sekhukhune Cross Limpopo   
  Govan Mbeki Mpumalanga   
  Nkangala Mpumalanga   
  Bojanala North-West   
  Southern North-West   
2 Sep 2008–Apr 2012 Alfred Nzo Eastern Cape 1.4 <0.001 
  Amatole Eastern Cape   
  Chris Hani Eastern Cape   
  Ukhahlamba Eastern Cape   
  Lejweleputswa Free State   
  Motheo Free State   
  Northern Free State   
  Thabo Mofutsanyane Free State   
  Xhariep Free State   
  Ekurhuleni Gauteng   
  Sedibeng Gauteng   
  Amabuja KwaZulu-Natal   
  Ethekwini KwaZulu-Natal   
  iLembe KwaZulu-Natal   
  Sisonke KwaZulu-Natal   
  Ugu KwaZulu-Natal   
  UMgungundlovu KwaZulu-Natal   
  Umkhanyakude KwaZulu-Natal   
  Umzinyathi KwaZulu-Natal   
  Uthukela KwaZulu-Natal   
  Uthungulu KwaZulu-Natal   
  Zululand KwaZulu-Natal   
  Govan Mbeki Mpumalanga   
  Southern North-West   
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Technical Appendix Figure. Incidence rates for serotype 1 in children <5 years (n = 714) and individuals 
>5 years (n = 5167) of age, South Africa, 2003–2013. Error bars indicate CIs for incidence rates. N, 
imputed serotype 1 cases. 
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Background. High antenatal human immunodeficiency virus (HIV) seroprevalence rates (∼30%) with low peri-
natal HIV transmission rates (2.5%), due to HIV prevention of mother-to-child transmission program improve-
ments in South Africa, has resulted in increasing numbers of HIV-exposed but uninfected (HEU) children. We
aimed to describe the epidemiology of invasive pneumococcal disease (IPD) in HEU infants.
Methods. We conducted a cross-sectional study of infants aged <1 year with IPD enrolled in a national, labo-
ratory-based surveillance program for incidence estimations. Incidence was reported for 2 time points, 2009 and
2013. At enhanced sites we collected additional data including HIV status and in-hospital outcome.
Results. We identified 2099 IPD cases in infants from 2009 to 2013 from all sites. In infants from enhanced sites
(n = 1015), 92% had known HIV exposure status and 86% had known outcomes. IPD incidence was highest in HIV-
infected infants, ranging from 272 to 654 per 100 000 population between time points (2013 and 2009), followed by
HEU (33–88 per 100 000) and HIV-unexposed and uninfected (HUU) infants (18–28 per 100 000). The case-fatality
rate in HEU infants (29% [74/253]) was intermediate between HUU (25% [94/377]) and HIV-infected infants (34%
[81/242]). When restricted to infants <6 months of age, HEU infants (37% [59/175]) were at significantly higher risk
of dying than HUU infants (32% [51/228]; adjusted relative risk ratio, 1.76 [95% confidence interval, 1.09–2.85]).
Discussion. HEU infants are at increased risk of IPD and mortality from IPD compared with HUU children,
especially as young infants. HEU infants, whose numbers will likely continue to increase, should be prioritized for
interventions such as pneumococcal vaccination along with HIV-infected infants and children.
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Programs for prevention of mother-to-child transmission
(PMTCT) of human immunodeficiency virus (HIV) have ex-
panded over the last decade in many countries. South Africa re-
ported a decrease in mother-to-child HIV transmission rates
from 12% in 2007 to 2.7% in 2011 [1] and 2.5% during 2012–
2013 [2], despite a relatively constant prevalence of HIV in
pregnant women of approximately 30%. This has resulted in
an increasing number of HIV-exposed but uninfected (HEU)
infants, especially in countries with elevated HIV prevalence
such as South Africa.
All-cause hospitalization rates and complicated hospital ad-
missions are more frequent in HEU than in HIV-unexposed
and uninfected (HUU) infants [3, 4]. Some infectious diseases,
including respiratory tract infections [5], are more common and
often more severe among HEU than HUU children. Compared
with HIV-infected children, 1 study reported similar rates of
pneumonia and bacterial meningitis in HEU children, but high-
er rates of gastroenteritis and sepsis [6].
Some studies report higher mortality rates in HEU than
HUU infants [7, 8] whereas others show no difference [9, 10].
In contrast, studies consistently report higher mortality rates
in HIV-infected vs HEU or HUU infants [7]. Risk factors for
mortality in HEU children include advanced maternal HIV
disease [11, 12], malnutrition [8], severe pneumonia, and bacte-
rial meningitis [6]. Mortality among HEU children peaks in
younger infants (3–6 months), with death being predominan-
tly associated with lower respiratory tract infections [8].Within
the general population, pneumococcus is estimated to cause
30%–40% of childhood community-acquired pneumonia
cases [13]
There are no published data evaluating or quantifying the
risk of hospitalization or mortality associated with invasive
pneumococcal disease (IPD) among HEU children. We aimed
to describe the epidemiology of IPD from 2009 to 2013 in South
African HEU infants <1 year of age, compared to the epidemi-
ology of IPD in similarly aged HUU and HIV-infected infants.
METHODS
Study Design and Setting
Detailed methods are available in the Supplementary Appendix.
Children hospitalized from 2009 through 2013 with laboratory-
confirmed IPD were prospectively identified by a national, lab-
oratory-based, active surveillance program for Streptococcus
pneumoniae. More than 200 routine hospital-based diagnostic
laboratories (enhanced and nonenhanced hospital sites) sys-
tematically report IPD cases of all ages to the surveillance pro-
gram. For the subset of cases occurring at 25 enhanced sentinel
hospital sites, located in all 9 provinces, dedicated study surveil-
lance officers collect additional clinical and demographic
information.
Study Population
We included all infants <1 year of age with IPD from 2009
through 2013. For incidence calculations, infants from en-
hanced and nonenhanced sites were included. For analyses of
factors associated with HIV exposure/infection status and mor-
tality, only infants from enhanced sites with known HIV expo-
sure status and in-hospital outcome were included.
Case Definitions
IPD cases were defined as S. pneumoniae identified from nor-
mally sterile site (eg, cerebrospinal fluid [CSF], blood, joint
fluid, pleural fluid) specimens at participating sites. HUU in-
fants were defined as infants with documented negative mater-
nal HIV status at birth or time of illness, with or without a
negative HIV enzyme-linked immunosorbent assay (ELISA)
or polymerase chain reaction (PCR) result for the infant.
HEU infants were defined as infants who had a negative HIV
PCR result with known positive maternal HIV status (verbal
or documented positive result) or infants with a positive HIV
ELISA result and negative HIV PCR result. HEU infants who
had symptoms suggestive of HIV at the current admission
were retested. HIV-infected infants were defined as infants
with a positive HIV PCR result before or at time of illness.
Incidence
We calculated annual incidence of pneumococcal disease from
2009 through 2013 for infants <1 year of age, by HIV infection/
exposure status, by dividing the number of laboratory-
confirmed IPD cases reported each year in each category
(HEU, HUU, and HIV) by the midyear population estimates
for each group. Population denominators were obtained from
the THEMBISA model [14]. Due to significant decreasing
trends in IPD incidence rates (IRs) from 2009 through 2013, re-
sulting from progressive pneumococcal conjugate vaccine
(PCV) introduction and HIV-related interventions [15], we
only presented data from 2 time points, prevaccine (2009)
and postvaccine (2013) introduction.
As HIV infection/exposure status information was only avail-
able for cases identified at enhanced sites, we assumed a similar
prevalence of HIV infection and exposure among cases with
unknown (from nonenhanced sites) status as that found at en-
hanced sites. We calculated relative risk of IPD hospitalization
comparing HEU children with HUU and HIV-infected chil-
dren. Confidence intervals were calculated using Poisson distri-
bution for incidence rates IRs and incidence rate ratios (IRRs).
Factors Associated With HIV Exposure Status and Death
We included infants <1 years of age with IPD from enhanced
sites only, from 2009 through 2013, and developed 2 multivar-
iable models to identify factors associated with outcome vari-
ables: (1) HIV infection/exposure status and (2) mortality.
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Multinomial regression was used for comparison of factors as-
sociated with HIV infection/exposure. Multinomial regression
allows modeling of outcome variables with >2 categories and
relates the probability of being in category j to the probability
of being in a baseline category. A complete set of coefficients
are estimated for each of the j levels being compared with the
baseline, and the effect of each predictor in the model is mea-
sured as relative risk ratio (RRR). HEU cases were used as the
referent group and compared with HUU and HIV-infected in-
fants so that all described differences would be related to
Figure 1. Patients with invasive pneumococcal disease (IPD) reported from the Group for Enteric, Respiratory and Meningeal Disease Surveillance in
South Africa sites, 2009–2013. Abbreviation: HIV, human immunodeficiency virus.
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exposed children. The model to assess factors associated with
mortality used logistic regression and was presented stratified
by age (<6 months and 6 to <12 months) as there was significant
interaction between age and HIV infection/exposure status.
Statistical analysis was implemented using Stata software, ver-
sion 12 (StataCorp, College Station, Texas).
Ethics
Ethics approval was obtained for Group for Enteric, Respiratory
and Meningeal Disease Surveillance in South Africa (GERMS-
SA) surveillance (M081117) from the Human Research Ethics
Committee (Medical), University of the Witwatersrand, Johan-
nesburg, South Africa, and other local hospital or provincial
ethics committees, as required.
RESULTS
We identified 2099 IPD cases in infants <1 year of age from
2009 through 2013 from all sites (Figure 1). Enhanced sites, pre-
dominantly regional and tertiary hospitals, contributed about
50% (n = 1015) of all isolates received. Nonenhanced sites in-
cluded district, regional, and tertiary public hospitals, as well
as private hospitals and clinics. Regional and tertiary hospitals
contributed 73% (787/1084) of isolates sent from nonenhanced
sites. In cases from enhanced sites, 92% (937/1015) had known
HIV exposure/infection status and 86% (872/1015) had known
in-hospital outcomes. Compared with nonenhanced sites, pa-
tients at enhanced sites were more likely to be diagnosed on
positive blood (odds ratio [OR], 1.24; 95% confidence interval
[CI], 1.04–1.48) or other specimen culture (OR, 2.36; 95% CI,
1.39–4.03), compared with CSF, as these specimens were more
likely to be done at enhanced sites. Age distribution (<6 months
and 6 to <12 months) did not differ (OR, 1.10; 95% CI, .92–
1.31) between enhanced and nonenhanced sites (data not
shown).
Breastfeeding information was only available for children en-
rolled in a nested case-control study. In the first 4 months of life,
33% (30/90) of HEU children, 81% (119/147) of HUU children,
and 56% (43/77) of HIV-infected children were breastfed. Sev-
enty-six percent (n = 207) of all HEU children from enhanced
sites had known HIV testing dates; only 61 (29%) were tested
more than a month prior to admission, and 34 (of the 61)
had a known feeding status, with only 7 being breastfed.
Serotype distribution differed by known HIV status for en-
hanced-site patients. Across all years, isolates fromHIV-infected
cases were more likely to be vaccine serotypes (71% [160/225])
than isolates from HEU cases (57% [139/244]; P < .001), where-
as prevalence was similar between isolates from HEU and HUU
cases (56% [198/356]; P = .88). A similar proportion of cases
was isolated from CSF and blood cultures in HIV-infected
(33% [84/257] and 65% [167/257], respectively) and HEU
cases (38% [103/273] and 61% [166/273], respectively), whereas
proportions differed among HUU cases (CSF, 43% [175/407];
blood culture, 51% [207/407]; P < .001). The proportion of vac-
cine-type IPD decreased in all 3 groups between 2009 and 2013:
79% (48/61) and 30% (12/40) for HEU infants (P < .001); 72%
(72/100) and 23% (15/64) for HUU infants (P < .001); and 85%
(75/88) and 35% (7/20) (P < .001), for HIV-infected infants,
respectively.
Incidence Rates
In 2009 (Table 1), IPD incidence in the <1-year age group was
higher in HIV-infected compared with HUU (20-fold) and
HEU infants (7-fold). HEU infants also had a 3-fold higher in-
cidence of IPD than HUU infants. When stratified into 2 age
groups, incidence was similarly highest in HIV-infected infants,
intermediate in HEU infants, and lowest in HUU infants
(Table 1). By 2013, although IRs had decreased due to PCV
and HIV interventions, in all groups compared with 2009, rel-
ative trends in incidence by HIV exposure/infection status were
Table 1. Invasive Pneumococcal Disease Incidence Rates and Incident Rate Ratios Between Infants Aged <12 Months, <6 Months, and 6
to <12 Months, South Africa, 2009 and 2013
Age Group
Incidence Rates per 100 000 Population (95% CI) Incidence Rate Ratio (95% CI)
HI HEU HUU HI/HEU HI/HUU HEU/HUU
2009 (prevaccine)
<6 mo 1156 (972–1364) 112 (94–132) 31 (26–37) 10.3 (8.1–13.1) 37.0 (29.0–47.2) 3.6 (2.8–4.6)
6 to <12 mo 467 (394–551) 59 (46–75) 26 (21–31) 7.9 (5.9–10.8) 18.0 (14.0–23.3) 2.3 (1.7–3.1)
<12 mo 654 (579–736) 88 (76–100) 28 (25–32) 7.5 (6.2–9.0) 23.1 (19.4–27.6) 3.1 (2.6–3.7)
2013 (postvaccine)
<6 mo 581 (389–835) 57 (46–71) 21 (17–26) 10.1 (6.4–15.7) 27.2 (17.2–41.7) 2.7 (2.0–3.7)
6 to <12 mo 149 (92–227) 11 (6–18) 14 (11–18) 13.9 (6.7–29.5) 10.4 (6.0–17.4) 0.8 (.4–1.4)
<12 mo 272 (203–357) 33 (26–40) 18 (15–21) 8.4 (5.9–12.0) 15.0 (10.7–20.6) 1.8 (1.4–2.3)
Abbreviations: CI, confidence interval; HEU, HIV exposed but uninfected; HI, HIV infected; HIV, human immunodeficiency virus; HUU, HIV unexposed and
uninfected.
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similar. In 2013, among infants aged 6 to <12 months, inci-
dence was similar between HEU and HUU cases, but case num-
bers were small in this age group, limiting the ability to detect
relative differences in rates. Incidence rate and IRR were higher
in the <6-month age group than in the 6- to <12-month age
group regardless of HIV status (Table 1).
Factors Associated With HIV Exposure and Infection Status
For cases <1 year of age, with known outcomes and HIV status,
the overall case-fatality ratio was high (29% [249/872]), with
mortality in HEU infants (29% [74/253]) intermediate between
HUU (25% [94/377]) and HIV-infected infants (34% [81/242])
(P = .07; Supplementary Table 1). When comparing HEU
(n = 273) with HUU (n = 407) infants on multivariable analysis,
HUU infants were twice as likely to be >6 months of age or to
have meningitis vs pneumonia, but less likely to be of black race.
On multivariable analysis, HIV-infected infants (n = 257)
(Supplementary Table 1) were more likely to be >6 months of
age, to be infected with penicillin-nonsusceptible S. pneumo-
niae, to have used cotrimoxazole prophylaxis in the last
month, and to have died compared with HEU children. In ad-
dition, HIV-infected infants were less likely to have underlying
conditions other than HIV and malnutrition.
When we restricted the analysis to cases <6 months of age
(Table 2), on multivariable analysis, HUU cases were at signifi-
cantly lower risk of dying during the IPD episode, had a de-
creased risk of IPD caused by a penicillin-nonsusceptible
strain, and had an increased risk of meningitis compared with
pneumonia compared with HEU children with IPD. HIV-
infected infants with IPD were more likely to have disease
caused by a penicillin-nonsusceptible strain and be malnour-
ished than HEU infants with IPD.
For cases aged 6 to <12 months (Table 3), on multivariable
analysis, HUU infants were less likely to be of black race and
at significantly increased risk of dying from their IPD episode
compared with HEU children. HIV-infected infants were
more likely to be malnourished and die than HEU infants, de-
spite having less-severe disease at time of presentation (as as-
sessed with Pitt bacteremia score), and fewer underlying
conditions other than HIV. Among HUU cases, underlying
conditions were significantly more common in infants aged 6
to <12 months (41/141 [29.1%]) than in younger infants (22/
209 [10.5%] (P < .001).
Factors Associated With Case Fatality
On multivariable analysis to explore factors associated with
death, in infants aged <6 months (Table 4), being of black
race, malnourished, or HEU or HIV-infected and having men-
ingitis (compared with pneumonia) were associated with an in-
creased odds of death. In infants aged 6 to <12 months (Table 5)
with malnutrition (compared with no malnutrition), those with
meningitis (compared with pneumonia) and HUU cases (com-
pared with HEU cases) had increased odds of death.
DISCUSSION
In South Africa, HIV-infected pediatric numbers continue to de-
cline due to PMTCT improvements [1]; however, numbers of
HEU children remain high and are growing. We have shown that
these HEU children are twice as likely to have an IPD-associated
hospitalization; and that HEU children aged <6 months are less
likely to survive an IPD episode than HUU children. It is impor-
tant to prioritize and continue targeting these HEU children for
public health interventions such as PCV vaccination.
Following PCV introduction into the national immunization
program in South Africa, a significant reduction in vaccine-
type disease in both HIV-infected and HIV-uninfected children
was observed [15]. In our study, we similarly observed a reduc-
tion in the estimated incidence of IPD inHEU children from2009
to 2013. Although other interventions such as improvements in
maternal immune status [12] may have contributed to this, it is
likely that the bulk of this reduction resulted from the introduc-
tion of PCV [15].A case-control study from South Africa showed
that PCV, when given in the routine program, was highly effective
in HEU children [16]. Despite generally lower prevaccination
antibody levels, HEU children respond quantitatively as well as
HUU infants to routine immunization program vaccinations
such as tetanus, pertussis, Haemophilus influenzae type b, and
hepatitis B [17]. In contrast, PCV functional assays have shown
that HEU children require higher antibody concentrations for ef-
fectiveness against certain pneumococcal serotypes [18].
In South Africa, antiretroviral therapy (ART) coverage in
HIV-infected children increased from 2004, but by 2011, pedi-
atric ART initiation rates still lagged behind that of adults. Na-
tionally, the 2011–2012 coverage for children aged <18 months
was reported as 54.4% with large variations between districts
[14, 19]. In our study, HIV-infected children still had an elevat-
ed risk of IPD-associated hospitalization (15-fold) and IPD-
related death (2-fold), compared with unexposed children.
Other studies have shown that following ART introduction,
although overall incidence of IPD decreased in HIV-infected
children [20], the absolute risk of IPD remained approximately
20-fold greater in HIV-infected than HIV-uninfected children
<2 years of age [21]. A case-control study from South Africa
found that HIV exposure was associated with nearly 2 times
greater odds of all serotype IPD, although the control group
in this study was children hospitalized with a nonpneumonia
diagnosis, a group also at increased likelihood of HIV exposure,
and therefore this study likely underestimated the increased
odds of IPD associated with HIV exposure [16].
In our study, a number of differences were noted between
HEU, HUU, and HIV-infected infants with IPD. Malnutrition
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Table 2. Univariate and Multivariate Multinomial Logistic Regression Model of Patients Aged <6 Months With Invasive Pneumococcal Disease, in Enhanced Sites, Group for Enteric,
Respiratory and Meningeal Disease Surveillance in South Africa, 2009–2013 (n = 572)
Characteristic
HEU Cases (Reference) HUU Cases HIV-Infected Cases
no./No. (%) no./No. (%) RRR (95% CI) ARRR (95% CI) no./No. (%) RRR (95% CI) ARRR (95% CI)
Demographics and socioeconomic characteristics
Black race 172/176 (97.7) 203/239 (84.9) 0.13 (.05–.38) 0.15 (.05–.45) 129/130 (99.2) 3.00 (.33–27.16) 3.48 (.37–32.69)
Length of hospital stay
<4 d 48/174 (27.6) 47/227 (20.7) Reference 37/127 (29.1) Reference
4–14 d 90/174 (51.7) 102/227 (44.9) 1.16 (.71–1.89) 60/127 (47.2) 0.86 (.50–1.48)
≥15 d 36/174 (20.7) 78/227 (34.4) 2.21 (1.26–3.89) 30/127 (23.6) 1.08 (.57–2.06)
Medical conditions and treatment
Underlying conditionsa 21/151 (13.9) 22/209 (10.5) 0.73 (.38–1.38) 4/113 (3.5) 0.23 (.08–.68)
Malnutritionb 58/168 (34.5) 81/221 (36.7) 1.10 (.72–1.67) 1.20 (.72–2.02) 80/122 (65.6) 3.61 (2.21–5.90) 3.19 (1.80–5.64)
Previous hospital admission in last 12 mo 32/172 (18.6) 42/224 (18.8) 1.01 (.61–1.68) 41/119 (34.5) 2.30 (1.34–3.94)
In-hospital mortality 59/175 (33.7) 51/228 (22.4) 0.57 (.36–.88) 0.46 (.26–.81) 50/126 (39.7) 1.29 (.80–2.08) 1.55 (.87–2.76)
Previous IPD infectionc 2/189 (1.1) 4/249 (1.6) 1.53 (.28–8.42) 7/134 (5.2) 5.15 (1.05–25.21)
Cotrimoxazole prophylaxis 26/170 (15.3) 0/249 (0.0) Not calculated 37/110 (33.6) 2.81 (1.58–4.99)
Treated for tuberculosis 5/174 (2.9) 6/229 (2.6) 0.91 (.27–3.03) 12/116 (10.3) 3.90 (1.34–11.39)
Pneumococcal isolate characteristics
Penicillin nonsusceptibled 69/157 (43.9) 69/201 (34.3) 0.67 (.43–1.02) 0.61 (.38–.99) 64/105 (61.0) 1.99 (1.20–3.29) 1.79 (1.03–3.09)
Vaccine serotypese 94/171 (55.0) 110/217 (50.7) 0.84 (.56–1.26) 77/111 (69.4) 1.86 (1.12–3.07)
Clinical syndrome
Pneumonia 74/183 (40.4) 77/239 (32.2) Reference Reference 69/131 (52.7) Reference Reference
Meningitis 92/183 (50.3) 129/239 (54.0) 1.35 (.88–2.04) 1.89 (1.12–3.20) 47/131 (35.8) 0.55 (.34–.89) 0.86 (.46–1.57)
Bacteremia 17/183 (9.3) 33/239 (13.8) 1.87 (.96–3.63) 1.96 (.86–4.44) 15/131 (11.5) 0.95 (.44–2.04) 1.81 (.75–4.36)
Specimen typef
Blood culture 105/189 (55.6) 117/249 (47.0) Reference 89/134 (66.4) Reference
Cerebrospinal fluid 81/189 (42.9) 123/249 (49.4) 1.36 (.93–2.00) 42/134 (31.3) 0.61 (.38–.98)
Other 3/189 (1.6) 9/249 (3.6) 2.69 (.71–10.21) 3/134 (2.2) 1.18 (.23–5.99)
Only variables significant on univariate and multivariable analysis are shown. Variables not included in table: sex, Pitt bacteremia score, antibiotics in last 24 hours, antibiotics in last 2 months, and vaccination status.
Abbreviations: ARRR, adjusted relative risk ratio; CI, confidence interval; HEU, HIV exposed but uninfected; HIV, human immunodeficiency virus; HUU, HIV unexposed and uninfected; IPD, invasive pneumococcal
disease; RRR, relative risk ratio.
a Asplenia, including asplenia or sickle cell anemia; chronic illness, including chronic lung, renal, liver, or cardiac disease, and diabetes; other immunocompromising conditions (excluding HIV), including organ transplant,
primary immunodeficiency, immunotherapy, and malignancy; and other risk factors, including head injury with possible cerebrospinal fluid leak, neurological disorders, burns, and chromosomal abnormalities. Excludes
malnutrition.
b Malnutrition was classified as weight-for-age z score <−2 (World Health Organization child growth standards 2009) and/or nutritional edema.
c Previously diagnosed with IPD >21 days prior to this episode.
d Penicillin-nonsusceptible minimum inhibitory concentration ≥0.12 μg/mL.
e Vaccine serotypes were considered as serotypes in the 13-valent pneumococcal conjugate vaccine.
f Elected to use clinical diagnosis rather than specimen type in multivariable model.
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Table 3. Univariate and Multivariate Multinomial Logistic Regression Model in Patients Aged 6 to <12 Months With Invasive Pneumococcal Disease at Enhanced Sites, Group for
Enteric, Respiratory and Meningeal Disease Surveillance in South Africa, 2009–2013 (n = 365)
Characteristic
HEU Cases Reference HUU Cases HIV-Infected Cases
no./No. (%) no./No. (%) RRR (95% CI) ARRR (95% CI) no./No. (%) RRR (95% CI) ARRR (95% CI)
Demographics and socioeconomic characteristics
Black race 78/81 (96.3) 132/154 (85.7) 0.23 (.07–.80) 0.15 (.03–.70) 114/117 (97.4) 1.46 (.29–7.43) 0.82 (.09–7.23)
Medical conditions and treatment
Underlying conditionsa 15/77 (19.5) 41/141 (29.1) 1.69 (.87–3.31) 1.99 (.90–4.37) 11/103 (10.7) 0.49 (.21–1.15) 0.29 (.09–.87)
Malnutritionb 31/78 (39.7) 54/147 (36.7) 0.88 (.50–1.55) 0.68 (.35–1.34) 73/109 (67.0) 3.07 (1.68–5.63) 2.36 (1.13–4.96)
Previous hospital admission in last 12 mo 19/74 (25.7) 57/148 (38.5) 1.81 (.98–3.36) 51/111 (45.9) 2.46 (1.29–4.67)
In-hospital mortality 15/78 (19.2) 43/149 (28.9) 1.70 (.88–3.31) 3.38 (1.34–8.53) 31/116 (26.7) 1.53 (.76–3.08) 2.82 (1.02–7.78)
Pitt bacteremia score (≥4)c 9/76 (11.8) 21/151 (13.9) 1.20 (.52–2.77) 0.62 (.21–1.84) 5/113 (4.4) 0.34 (.11–1.07) 0.13 (.02–0.72)
Antibiotics in last 2 mod 7/73 (9.6) 37/145 (25.5) 3.23 (1.36–7.66) 23/104 (22.1) 2.68 (1.08–6.63)
Cotrimoxazole prophylaxis 8/73 (11.0) 0/158 (0.0) Not calculated Not calculated 50/111 (45.1) 6.66 (2.92–15.17) 11.18 (4.04–30.91)
Treated for tuberculosis 4/75 (5.3) 4/148 (2.7) 0.49 (.11–2.02) 18/112 (16.1) 3.40 (1.10–10.48)
Pneumococcal isolate characteristics
Penicillin nonsusceptiblee 30/62 (48.4) 68/130 (52.3) 1.17 (.64–2.14) 74/111 (66.7) 2.13 (1.13–4.03)
Specimen type
Blood culture 61/84 (72.6) 90/158 (57.0) Reference 78/123 (63.4) Reference
Cerebrospinal fluid 22/84 (26.2) 52/158 (32.9) 1.60 (.88–2.90) 42/123 (34.1) 1.49 (.81–2.76)
Other 1/84 (1.2) 16/158 (10.1) 10.84 (1.40–83.92) 3/123 (2.4) 2.35 (.24–23.12)
Only variables significant on univariate and multivariable analysis are shown. Variables not included in table: sex, length of hospital stay, antibiotics in last 24 hours, previous IPD infection, vaccine serotypes, vaccination
status, and clinical syndrome.
Abbreviations: ARRR, adjusted relative risk ratio; CI, confidence interval; HEU, HIV exposed but uninfected; HIV, human immunodeficiency virus; HUU, HIV unexposed and uninfected; IPD, invasive pneumococcal
disease; RRR, relative risk ratio.
a Asplenia, including asplenia or sickle cell anemia; chronic illness, including chronic lung, renal, liver, or cardiac disease, and diabetes; other immunocompromising conditions (excluding HIV), including organ transplant,
primary immunodeficiency, immunotherapy, and malignancy; and other risk factors, including head injury with possible cerebrospinal fluid leak, neurological disorders, burns, and chromosomal abnormalities. Excludes
malnutrition.
b Malnutrition was classified as weight-for-age z score <−2 (World Health Organization child growth standards 2009) and/or nutritional edema.
c Pitt bacteremia score calculated using temperature, hypotension, mechanical ventilation, cardiac arrest, and mental status. Severe disease defined as score of ≥4 points.
d Any antibiotics used in 2 months prior to admission.
e Penicillin nonsusceptible minimum inhibitory concentration ≥0.12 μg/mL.
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was significantly more common in HIV-infected infants, but
not in HEU compared with HUU infants. This concurs with a
review of studies that showed an association between HIV infec-
tion and being stunted or underweight [22]; no differences were
observed in the early growth of HEU children and healthy con-
trols [22]. Combined ART used for PMTCT has been shown
to cause lower birth weight and length in some HEU infants,
but this rapidly corrects over the first few months of life [23].
Other differences between the 3 IPD case groups included
clinical presentation, with HUU IPD cases more likely to pre-
sent with meningitis than pneumonia. HIV-infected children
are less likely to be diagnosed with meningitis than other
types of IPD [24], and children with meningitis have a higher
mortality than children with pneumonia or bacteremia, espe-
cially if they are HIV infected [24]. Specimen-collection practic-
es differed between different case groups, reflecting different
clinical syndromes; HUU infants were less likely to have
blood cultures taken than HEU and HIV-infected infants.
Racial differences, with HUU children being more likely to be
of nonblack race, has been shown in other local studies [25].
Children of black race had a higher likelihood of dying with
IPD, possibly reflecting poorer socioeconomic status and higher
HIV infection rates. IPD in HIV-infected individuals is more
often caused by antibiotic-resistant strains than IPD in HIV-
Table 4. Univariate and Multivariable Analysis Showing Factors Associated With Mortality in Infants Aged <6 Months With Invasive
Pneumococcal Disease, South Africa, 2009–2013 (n = 530)
Characteristic
Univariate Analysisa Multivariable Analysisa
CFR, no./No. (%) OR (95% CI) P Value AOR (95% CI) P Value
Demographics and socioeconomic characteristics
Race
Nonblack 5/44 (11.4) Reference .03 Reference .02
Black 164/501 (32.7) 3.31 (1.14–9.64) 4.14 (1.22–14.04)
Length of hospital stay
<4 d 121/140 (86.4) Reference <.001
4–14 d 35/254 (13.8) 0.02 (.01–.04)
≥15 d 9/144 (6.3) 0.01 (.004–.02)
Medical conditions and treatment
Malnutritionb
No 77/292 (26.4) Reference .27 Reference .03
Yes 75/218 (34.4) 1.26 (.84–1.90) 1.63 (1.05–2.53)
Pitt bacteremia scorec
0–3 109/440 (24.8) Reference <.001
≥4 46/73 (63.0) 5.03 (2.92–8.65)
Any antibiotics used in last 24 hd
No 114/439 (26.0) Reference .02
Yes 23/58 (39.7) 2.05 (1.15–3.66)
HIV status
HUU 51/228 (31.9) Reference .002 Reference .007
HEU 59/175 (36.9) 1.77 (1.13–2.75) 1.76 (1.09–2.85)
HIV-infected 50/126 (31.3) 2.28 (1.42–3.67) 2.25 (1.32–3.82)
Clinical syndrome
Pneumonia 64/223 (28.7) Reference .10 Reference .009
Meningitis 90/260 (34.6) 1.47 (.98–2.22) 1.92 (1.22–3.03)
Bacteremia 17/66 (25.8) 0.89 (.46–1.74) 0.92 (.45–1.88)
Abbreviations: AOR, adjusted odds ratio; CFR, case-fatality rate; CI, confidence interval; HEU, HIV exposed but uninfected; HIV, human immunodeficiency virus;
HUU, HIV unexposed and uninfected; OR, odds ratio.
a Only variables significant on univariate andmultivariable analysis are shown. Variables not included in table: age group, sex, wood fire in the home, referral, previous
admission, low birth weight, underlying conditions, antibiotics in last 2 months, penicillin nonsusceptibility, previous invasive pneumococcal disease infection,
cotrimoxazole prophylaxis, tuberculosis treatment, and vaccination status.
b Malnutrition was classified as weight-for-age z score <−2 (World Health Organization child growth standards 2009) and/or nutritional edema.
c Pitt bacteremia score calculated using temperature, hypotension, mechanical ventilation, cardiac arrest, and mental status. Severe disease defined as score of ≥4
points.
d Any antibiotics used in 24 hours prior to admission.
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uninfected individuals [26, 27]. Antimicrobial resistance is an
important adverse consequence of cotrimoxazole prophylaxis
[28]; this correlated with what we found in our study.
Cohort studies suggest that mortality among children born to
HIV-infected mothers is higher than that among children born
to HIV-uninfected mothers [29, 30]. A pooled mortality analysis,
using African data, showed a 9 times higher mortality rate in
HIV-infected than HIV-uninfected children. Children with a
early positive PCR result (<4 weeks of age) were more likely to
die, as were those with mothers who died or who had low
CD4+ cell counts at delivery [31]. In our study, we observed a
higher IPD-associated case fatality rate in HEU infants compared
with HUU infants in the <6-month age group. The increased fa-
tality rate among HEU children may be due to immunological
differences that resolve as these children age; thus, younger
HEU children may be more vulnerable to adverse clinical out-
comes [32]. Other studies have also shown a higher mortality
in younger HEU children [8]. In the older infants (6 to <12
months), this relationship was reversed, with HUU infants less
likely to survive IPD, but there were small numbers of infants
in the comparison group of HEU infants aged 6 to <12 months
(n = 78). By 6 months of age, the immunologic deficit associated
with HIV exposure is reduced [8], and effects of HIV exposure on
adverse outcomes in this group are less marked. Last, increased
case-fatality rates in older HUU infants with IPDmay be due to a
higher proportion of these infants having an underlying condi-
tion or, possibly, other factors leading to high mortality in
HUU infants with IPD that we were not able to document. Chil-
dren with underlying conditions have been extensively described
to have a higher risk of IPD than healthy children [33]. HIV in-
fection is an independent risk factor for IPD [34, 35]. This would
account for the higher rate of underlying conditions in HEU and
HUU infants with IPD, compared to HIV-infected infants with
IPD. The difference in underlying condition rates between HEU
and HUU cases was not statistically significant and no solid con-
clusions could be made regarding this comparison.
Table 5. Multivariable Analysis Showing Factors Associated With Mortality in Infants Aged 6 to <12 Months With Invasive
Pneumococcal Disease, South Africa, 2009–2013 (n = 342)
Characteristic
Univariate Analysisa Multivariable Analysisa
CFR, no./No. (%) OR (95% CI) P Value AOR (95% CI) P Value
Demographics and socioeconomic characteristics
Length of hospital stay
<4 d 67/91 (73.6) Reference <.001
4–14 d 15/164 (9.2) 0.03 (.02–.07)
≥15 d 15/99 (15.2) 0.07 (.03–.15)
Medical conditions
Malnutritionb
No 32/177 (18.1) Reference .003 Reference .001
Yes 48/158 (30.4) 2.30 (1.32–4.01) 2.58 (1.45–4.60)
Pitt bacteremia scorec
0–3 66/309 (21.4) Reference <.001
≥4 28/41 (68.3) 8.66 (3.94–19.05)
HIV status
HUU 43/149 (28.9) Reference .29 Reference .06
HEU 15/78 (19.2) 0.59 (.30–1.14) 0.46 (.22–.98)
HIV-infected 31/116 (26.7) 0.90 (.52–1.55) 0.55 (.29–1.04)
Clinical syndrome
Pneumonia 37/164 (22.6) Reference .04 Reference .03
Meningitis 48/130 (36.9) 1.82 (1.06–3.10) 2.16 (1.19–3.92)
Bacteremia 16/67 (23.9) 0.88 (.42–1.84) 1.03 (.48–2.24)
Abbreviations: AOR, adjusted odds ratio; CFR, case-fatality rate; CI, confidence interval; HEU, HIV exposed but uninfected; HIV, human immunodeficiency virus;
HUU, HIV unexposed and uninfected; OR, odds ratio.
a Only variables significant on univariate and multivariable analysis are shown. Variables not included in table: age group, sex, race, wood fire in the home, referral,
previous admission, low birth weight, underlying conditions, antibiotics in last 24 hours, antibiotics in last 2 months, penicillin nonsusceptibility, previous invasive
pneumococcal disease infection, cotrimoxazole prophylaxis, tuberculosis treatment, and vaccination status.
b Malnutrition was classified as weight-for-age z score <−2 (World Health Organization child growth standards 2009) and/or nutritional edema.
c Pitt bacteremia score calculated using temperature, hypotension, mechanical ventilation, cardiac arrest, and mental status. Severe disease defined as score of ≥4
points.
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A number of factors are thought to contribute to differences in
case-fatality rates between HEU and HUU children. Most impor-
tant are different immunological deficits documented in HEU
children [36–39]. Second, a clear trend has been shown between
the degree of maternal immunosuppression and infant survival
[40]. We did not collect details regarding maternal CD4 count
or use of ART by the mother during pregnancy and could there-
fore not explore this association further, which was a limitation.
Our study had other limitations. As with most surveillance
studies, only patients who had samples taken could be identified
as an IPD case and included in the study. For the multinomial
and mortality analyses, we only included IPD cases from en-
hanced sites with viable isolates. These enhanced-site cases
were more likely to be diagnosed with positive blood cultures,
which may limit the generalizability of our findings. Infection
status of HEU children was decided by 1 negative PCR result
in some infants, so it is possible there may have been some mis-
classification of HIV status. The majority of patients had PCR
testing done within a month of admission and nurses were
trained to request retesting in symptomatic children, which
would have minimized HIV-infected children being included
in the HEU group. Some data, such as cotrimoxazole prophy-
laxis, were ascertained on verbal report if not available in the
medical records; therefore, underreporting is possible.
In conclusion, we have described a higher incidence of
hospitalization for IPD in HEU children compared with HUU
children, as well as a lower chance of surviving IPD in HEU
children <6 months of age compared with those who are HUU.
Although we did not collect maternal data, we propose that op-
timizing maternal immunological status for HIV-infected
women during pregnancy may help to improve outcomes in
HEU children. Although widespread PCV introduction has
led to substantial reductions in IPD incidence in South Africa
[15], some differences were observed in vaccination rates be-
tween HIV exposure groups. It is important to ensure that all
HEU children receive PCV, to reduce the risk of IPD and its
negative health outcomes, including death.
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1.2 Methods 
Study design and setting  
For each non-enhanced case a laboratory report form (with information on age, gender, 
date of specimen collection and source of specimen) and the associated pneumococcal 
isolate is submitted to the National Institute for Communicable Diseases (NICD), 
Johannesburg, South Africa. Additional clinical and demographic information collected at 
enhanced sites includes admission date, HIV exposure and infection status, discharge 
diagnosis, vaccination status and outcome through patient interview and medical record 
review.  
 
Case definitions  
Laboratory testing for pneumococcus was performed as part of routine medical care. Only 
IPD cases diagnosed by positive culture or polymerase chain reaction (PCR), or by latex 
agglutination test with supporting evidence (Gram stain or PCR positive) were included.  
 
Malnutrition was defined according to the World Health Organization (WHO) child growth 
standards. Malnourished infants included those with weight-for-age Z-scores less than 
minus two standard deviations or nutritional edema. Underlying conditions included 
asplenia; chronic illness, including chronic lung, renal, liver and cardiac disease; other 
immunocompromising conditions (excluding HIV); and other risk factors, including head 
injury with possible CSF leak, neurological disorders, burns and chromosomal abnormalities, 
but excluded malnutrition. Clinical diagnoses were based on documented discharge 
diagnoses in the medical records with clinical syndrome, being defined as meningitis, 
bacteremic pneumonia, and bacteremia without focus/other. Pitt bacteremia score was 
5 
 
calculated using (1) oral temperature, (2) hypotension, (3) receipt of mechanical ventilation, 
(4) cardiac arrest and (5) mental status. Severe disease was defined as a score of ≥4 points 
[1]. A case was considered to be recurrent if pneumococcal disease was diagnosed in the 
same patient more than 21 days after the first confirmed laboratory diagnosis of S. 
pneumoniae disease.  
Cotrimoxazole prophylaxis is administered in HEU and HIV-infected children for differing 
time periods to prevent PCP and is not given to HUU children. We therefore included this 
variable a priori in our analysis as it could confound other associations.  
 
Penicillin non-susceptibility was categorized using the 2010 Clinical and Laboratory 
Standards Institute breakpoints for oral penicillin V (susceptible, ≤0.06mg/L; intermediately 
resistant, 0.12-1mg/L and resistant, ≥2mg/L) [2]. The intermediately resistant and resistant 
groups were combined into a non-susceptible group for analysis. Vaccine-serotype (VT) IPD 
was defined as serotypes present in the 13-valent pneumococcal conjugate vaccine (PCV-13) 
(1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F). All other serotypes were designated 
non-vaccine types (NVT). 
 
Incidence  
Denominators for HIV-infected infants <1 year of age were calculated by combining 
denominators for new HIV infection at/before birth and new HIV infection due to 
breastfeeding in infants <1 year. Denominators for HEU infants were calculated from the 
population denominator for HIV-infected pregnant women, adjusted for live births and less 
HIV-infected infants <1 year of age and infants who were infected postnatally.  
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Factors associated with HIV exposure status and death 
Multinomial regression allows modeling of outcome variables with more than 2 categories 
and relates the probability of being in category j to the probability of being in a baseline 
category. A complete set of coefficients are estimated for each of the j levels being 
compared with the baseline and the effect of each predictor in the model is measured as 
relative risk ratio (RRR).  
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1.3 Tables 
Supplementary Table 1: Univariate and multivariate multinomial logistic regression model showing comparison of demographic, socio-economic 
characteristics, and underlying conditions in HIV-exposed-uninfected (HEU), HIV-unexposed-uninfected (HUU) and HIV-infected (HI) IPD cases <1 year of 
age, at enhanced GERMS-SA sites in South Africa, 2009-2013 (n=937)  
 HEU cases 
Reference 
HUU cases 
 
HI cases  
 
 n/N (%) n/N (%) RRRa (95%CI) ARRRb (95%CI) n/N (%) RRRa (95%CI) ARRRb (95%CI) 
Demographics and socioeconomic characteristics 
Age ≥ 6 months 84/273 (31.0) 158/407 (38.8) 1.43 (1.03-1.98) 1.82 (1.17-2.84) 123/257 (47.9) 2.07 (1.45-2.95) 2.71 (1.67-4.38) 
Male Sex 147/273 (53.9) 229/407 (56.3) 1.10 (0.81-1.50)  138/256 (53.9) 1.00 (0.71-1.41)  
Black Race 250/257 (97.3) 335/393 (85.2) 0.16 (0.07-0.36) 0.13 (0.05-0.36) 243/247 (98.4) 1.70 (0.49-5.88) 1.39 (0.32-5.99) 
Length of hospital stay:        
<4 days  
4-14 days  
≥15 days  
65/251 (25.9) 
129/251 (51.4) 
57/251 (22.7) 
85/376 (22.6) 
170/376 (45.2) 
121/376 (32.2) 
Reference 
1.01 (0.68-1.50) 
1.62 (1.03-2.55) 
 
65/244 (26.6) 
113/244 (46.3) 
66/244 (27.1) 
Reference 
0.88 (0.57-1.34) 
1.16 (0.71-1.90) 
 
Medical conditions, treatment and vaccination status   
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Underlying conditionsc 36/228 (15.8) 63/350 (18.0) 1.17 (0.75-1.83) 1.31 (0.73-2.35) 15/216 (6.9) 0.40 (0.21-0.75) 0.30 (0.14-0.63) 
Malnutritiond 89/246 (36.2) 135/368 (36.7) 1.02 (0.73-1.43)  153/231 (66.2) 3.46 (2.37-5.04)  
Previous hospital admission 
in last 12 months 
51/246 (20.7) 99/372 (26.6) 1.39 (0.94-2.04)  92/230 (40.0) 2.55 (1.70-3.82)  
In-hospital mortality   74/253 (29.3) 94/377 (24.9) 0.80 (0.56-1.15) 1.06 (0.65-1.74) 81/242 (33.5) 1.22 (0.83-1.78) 2.03 (1.18-3.49) 
Pitt bacteremia score (≥4)e 35/245 (14.3) 49/367 (13.4) 0.92 (0.58-1.48)  20/237 (8.4) 0.55 (0.31-0.99)  
Antibiotics in last 24 hoursf 20/240 (8.3) 49/362 (13.5) 1.72 (1.00-2.98)  24/223 (10.8) 1.33 (0.71-2.48)  
Antibiotics in last 2 months g 24/235 (10.2) 69/365 (18.9) 2.05 (1.25-3.37)  45/212 (21.2) 2.39 (1.39-4.05)  
Previous IPD infection h 4/273 (1.5) 12/407 (3.0) 2.04 (0.65-6.40)  15/257 (5.8) 4.16 (1.36-12.73)  
Cotrimoxazole prophylaxis  34/243 (14.0) 0/407 (0.0) Not calculated Not calculated 87/221 (39.4) 3.99 (2.54-6.27) 4.56 (2.63-7.89) 
Treated for tuberculosis 9/249 (3.6) 10/377 (2.7) 0.73 (0.29-1.81)  30/228 (13.2) 4.04 (1.87-8.71)  
Vaccination status i        
- 0 doses 115/238 (48.3) 134/339 (39.5) Reference  62/173 (35.8) Reference  
- 1 dose 64/238 (26.9) 98/339 (28.9) 1.31 (0.88-1.96)  47/173 (27.1) 1.36 (0.84-2.22)  
- 2 doses 59/238 (24.8) 107/339 (31.6) 1.56 (1.03-2.33)  64/173 (37.0) 2.01 (1.26-3.22)  
Pneumococcal isolate characteristics  
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Penicillin non-susceptible j 99/219 (45.2) 137/331 (41.4) 0.86 (0.61-1.21) 0.74 (0.49-1.11) 138/216 (63.9) 2.14 (1.46-3.15) 1.66 (1.04-2.65) 
Vaccine serotypesk 139/244 (57.0) 198/356 (55.6)    0.95 (0.68-1.31)  160/225 (71.1) 1.86 (1.27-2.73)  
Clinical syndrome and specimen type  
Clinical syndrome  
- Pneumonia  
- Meningitis 
- Bacteremia  
115/266 (43.2) 
118/266 (44.4) 
33/266 (12.4) 
141/395 (35.7) 
188/395 (47.6) 
66/395 (16.7) 
Reference 
1.30 (0.93-1.82) 
1.63 (1.01-2.65) 
Reference 
1.61 (1.04-2.50) 
1.67 (0.88-3.18) 
124/249 (49.8) 
94/249 (37.8) 
31/249 (12.5) 
Reference 
0.74 (0.51-1.07) 
0.87 (0.50-1.51) 
Reference 
0.72 (0.44-1.19) 
1.05 (0.51-2.15) 
Specimen typel        
- Blood culture 166/273 (60.8) 207/407 (50.9) Reference   167/257 (65.0) Reference   
- Cerebrospinal fluid  103/273 (37.7) 175/407 (43.0) 1.36 (0.99-1.87)  84/257 (32.7) 0.81 (0.57-1.16)  
- Other  4/273 (1.5) 25/407 (6.1)   5.01 (1.71-14.69)  6/257 (2.3) 1.49 (0.41-5.38)  
a
Relative risk ratio; 
b
Adjusted relative risk ratio; 
c
Asplenia, including asplenia or sickle cell anemia; chronic illness, including chronic lung, renal, liver, cardiac disease and diabetes; other 
immunocompromising conditions (excluding HIV), including organ transplant, primary immunodeficiency, immunotherapy and malignancy; and other risk factors, including head injury with 
possible CSF leak, neurological disorders, burns and chromosomal abnormalities. Excludes malnutrition; 
d
Malnutrition was classified as children with weight-for-age Z-score < -2 (WHO child 
growth standards 2009) and/or children with nutritional edema; 
e
Pitt bacteremia score calculated using temperature, hypotension, mechanical ventilation, cardiac arrest and mental status. 
Severe disease defined as score of ≥4 points; 
f
Any antibiotics used in 24 hours prior to admission; 
g
Any antibiotics used in 2 months prior to admission; 
h
Previously diagnosed with IPD 
(invasive pneumococcal disease) more than 21 days prior to this episode; 
i
Vaccination status determined only for cases eligible to have received the pneumococcal conjugate vaccine;   
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j
Penicillin non-susceptible MIC ≥ 0.12 μg/mL; 
k
Vaccine serotypes were considered as serotypes in the 13-valent pneumococcal conjugate vaccine; 
l
Elected to use clinical diagnosis rather than 
specimen type in multivariable model  
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Original StudieS
Background: invasive pneumococcal disease (iPD) causes significant dis-
ease burden, especially in developing countries, even in the era of pneumo-
coccal conjugate vaccine and maternal-to-child HiV transmission preven-
tion programs. We evaluated factors that might increase iPD risk in young 
children in a high HiV prevalence setting.
Methods: We conducted a case–control study using iPD cases identified at 
24 group for Enteric, respiratory and Meningeal disease Surveillance—
South africa program sites (2010–2012). at least 4 controls were matched 
by age, HiV status and hospital to each case. Potential risk factors were 
evaluated using multivariable conditional logistic regression.
Results: in total, 486 age-eligible cases were enrolled. Factors associated 
with iPD in HiV-uninfected children (237 cases, 928 controls) included 
siblings <5 years [adjusted odds ratio (aOr) = 1.68, 95% confidence 
interval (Ci): 1.16–2.46], underlying medical conditions (aOr = 1.99, Ci 
1.22–3.22), preceding upper respiratory tract infection (aOr = 1.79, Ci 
1.19–2.69), day-care attendance (aOr = 1.58, Ci 1.01–2.47), perinatal HiV 
exposure (aOr = 1.62, Ci 1.10–2.37), household car ownership (aOr = 
0.45, Ci 0.25–0.83) and ≥2 7-valent pneumococcal conjugate vaccine doses 
(aOr = 0.67, Ci 0.46–0.99). among HiV-infected children (124 cases, 394 
controls), iPD-associated factors included malnutrition (aOr = 2.68, Ci 
1.40–5.14), upper respiratory tract infection (aOr = 3.49, Ci 1.73–7.03), 
tuberculosis in the last 3 months (aOr = 5.12, Ci 1.69–15.50) and current 
antiretroviral treatment (aOr = 0.13, Ci 0.05–0.38).
Conclusion: Previously identified factors related to poverty, poor health 
and intense exposure continue to be risk factors for iPD in children. Ensur-
ing delivery of pneumococcal conjugate vaccine and antiretroviral treat-
ment are important for improving disease prevention.
Key Words: pneumococcus, risk factors, HiV, HiV exposure, children, 
South africa, pneumococcal conjugate vaccine
(Pediatr Infect Dis J 2015;34:27–34)
Pneumococcal disease is an important contributor to mortality in young children in developing countries.1 in spite of this, few 
studies have evaluated specific factors that might lead to severe 
pneumococcal infections in such settings. HiV infection, common 
in South africa and several other developing countries, is one well-
described factor that increases the risk of invasive pneumococcal 
disease (iPD) in young children.2
South africa and other countries have begun aggressive 
programs to prevent HiV infection, and therefore pneumococcal 
disease and other HiV-related complications, in newborns. in South 
africa, prevention of mother to child transmission and early infant 
diagnosis programs have been rapidly scaled up from 2008, and 
by 2010, treatment was being offered at more than 95% of health 
facilities.3 in 2010, the percentage of HiV-exposed children who 
were infected was 3.5% (Ci 2.9–4.1%),3 and this dropped to 2.7% 
(Ci 2.1–3.2%) in 2011, despite an increase in the percentage of 
HiV-exposed infants (31.4% to 32.2%).4 While the numbers of 
HiV-exposed, uninfected (HEU) children are growing because of 
programs designed to prevent HiV infection in newborns, the risk 
of iPD in this group of children is unknown. Data from developing 
countries have shown an increased risk of lower respiratory tract 
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infections5 and infection-related hospitalizations in the first year of 
life in children born to HiV-infected mothers but who themselves 
are not HiV infected.6,7
in addition to HiV prevention programs, pneumococcal con-
jugate vaccines (PCVs) are now being introduced in many develop-
ing countries to prevent serious pneumococcal disease.8 in South 
africa, PCV was first introduced into the national immunization 
program in april 2009. Only a few studies have evaluated risk fac-
tors for ongoing disease in settings using PCV, and all are from high-
income settings.9 in addition, in studies conducted prior to PCV 
introduction, risk factors for iPD are well described for high-income 
settings10 while data from developing countries are more limited.11
The main objective of this analysis was to identify factors 
related to iPD among HiV-infected and HiV-uninfected children 
eligible to receive PCV through the South african Expanded Pro-
gram on immunization, including an examination of whether HiV 
exposure was a risk factor for disease in HiV-uninfected children. 
We separately evaluated risk factors for all-serotype, vaccine-type 
(VT) and nonvaccine type (nVT) iPD, as well as for PCV-vacci-
nated and unvaccinated children.
METHODS
Study Design and Population
The study was part of a larger protocol that evaluated effec-
tiveness of the 7-valent PCV; the methods have been previously 
described.12 in brief, we used a matched case–control study design 
to examine iPD risk factors in South african children admitted to 
selected hospitals from March 2010 to november 2012. Only chil-
dren aged ≥8 weeks of age who were part of the birth cohort eligi-
ble to receive PCV through the South african Expanded Program 
on immunization were included in the study. The study was nested 
within the group for Enteric, respiratory and Meningeal disease 
Surveillance—South africa national, laboratory-based, active 
surveillance program for iPD and was conducted at 24 sentinel-
enhanced surveillance hospitals, each with dedicated surveillance 
officers who collected clinical, demographic, vaccination and out-
come information for cases and controls. all data, including infor-
mation on potential disease risk factors, were collected on inter-
view and medical record review using a structured questionnaire.
iPD cases were defined as Streptococcus pneumoniae iden-
tified from a sterile specimen, for example, cerebrospinal fluid, 
blood, joint fluid and pleural fluid. VT iPD cases were defined as 
those caused by serotypes in the 7-valent vaccine (4, 6B, 9V, 14, 
18C, 19F, 23F). Serotype 6a was excluded from the VT and nVT 
groups as the effect of cross-protection was unclear in this popula-
tion. all other serotypes were considered to be nVT. For each case, 
we attempted to enroll at least 4 matched controls per case. Surveil-
lance officers enrolled controls from children admitted to the same 
hospital as the case or from patients seen in the hospital casualty or 
outpatient departments. Controls were excluded if they were diag-
nosed with iPD, pneumonia or diseases with established vaccine 
programs, like measles and pertussis. Patients admitted with gas-
troenteritis were eligible as controls, although South africa began 
using rotavirus vaccine in august 2009. Controls, who were at least 
8 weeks of age at case specimen date, were matched by date of birth 
(within ±1 calendar month from date of birth of case for children 
≤12 months and ±2 months for children >12 months of age), hospi-
tal and HiV status (HiV-infected or HiV-uninfected).
Malnutrition was classified as children with weight-for-
age Z scores <−2 using the 2009 World Health Organization child 
growth standards and/or those with nutritional edema.13 HiV sta-
tus was determined by HiV enzyme-linked immunosorbent assay 
testing for patients ≥18 months of age and by qualitative HiV 
Dna polymerase chain reaction testing for children <18 months 
of age. HEU children were defined as children who had a nega-
tive HiV polymerase chain reaction result with a known verbal or 
documented positive maternal HiV result. Data were collected for 
a reference period (1 month prior to the specimen collection date) 
for each case and their matched controls.
Pneumococci were serotyped by the Quellung reaction using 
specific antisera (Statens Serum institut, Copenhagen, Denmark). 
Specimens that were culture negative were confirmed as pneumo-
cocci using real-time lytA polymerase chain reaction.14 Minimum 
inhibitory concentrations were determined for all isolates using 
broth dilution. results were interpreted as penicillin susceptible or 
nonsusceptible based on the 2010 Clinical and laboratory Stand-
ards institute meningitis breakpoints (penicillin nonsusceptible if 
minimum inhibitory concentrations are ≥0.12 μg/l).15
Statistical Methods
Data were entered into an access database and analyzed 
using STaTa software (STaTa version 12; Stata Corp., College 
Station, TX). all models were run separately for HiV-uninfected and 
HiV-infected children. To determine risk factors associated with iPD 
we ran separate multivariable models for all-serotype, VT, nVT and 
penicillin nonsusceptible iPD. We conducted an open-ended anal-
ysis aiming to identify all factors associated with having iPD. all 
factors, including socioeconomic factors, with a P value ≤0.20 in 
the univariate analysis were included in conditional logistic regres-
sion models for multivariable analysis. all nonsignificant factors 
(assessed at P > 0.05) were dropped from the multivariable mod-
els employing stepwise regression starting with predictors with the 
highest P values. We checked for collinearity and 2-way interactions 
in all final models. We hypothesized that factors associated with VT 
iPD might differ among vaccinated (children who received ≥2 PCV 
doses) and unvaccinated (no PCV doses) children. To assess this we 
contrasted the effect of each predictor using vaccination status as 
an interaction term for each covariate included in the model. For all 
multivariable models, children with missing values for certain vari-
ables were excluded from models containing these variables.
Ethical Considerations
The study was approved by the Human research Ethics 
Committee, University of the Witwatersrand (M090915), the CDC 
Human research and Protection Office (Protocol number 5834), 
the Johns Hopkins School of Public Health institutional review 
Board (institutional review Board number 00002484) and other 
provincial and institutional ethics committees involved in the study. 
Signed informed consent was obtained from the parents or legal 
guardians of the children for participation in this study.
RESULTS
a total of 817 iPD cases in children <5 years of age 
were screened at enhanced sites and 486 age-eligible cases were 
enrolled in the study from March 2010 through november 2012. 
Children with incomplete vaccination or HiV information (n = 24), 
those who refused consent (n = 2), as well as those who had 
received PCV-13 (n = 99) were excluded from the analysis. a 
total of 361 (74%) cases (124 HiV-infected and 237 HiV-unin-
fected) were included in the final risk factor analysis. a total of 
2037 eligible age-matched children were identified as potential 
controls. as with cases, controls lacking vaccination informa-
tion (n = 75) and those who refused consent (n = 10), were dis-
charged from hospital before enrolment (n = 17) or had received 
PCV-13 (n = 613) were excluded from the analysis. in total, 1322 
(65%) age-matched controls (394 HiV-infected and 928 HiV-
uninfected) were included in the final risk factor analysis. among 
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HiV-uninfected children, the rates of malnutrition were high in 
both cases (80/234, 34.2%) and controls (258/839, 30.8%), as 
these were mainly hospitalized children. The most common diag-
noses in our control group were acute gastroenteritis and malnu-
trition. The proportion of controls enrolled from the outpatient 
department was 3.7% (34/928) for HiV-uninfected children and 
50.2% (198/394) for HiV-infected children.
Factors Associated With IPD in HIV-uninfected 
Children
All-serotype IPD
On univariate analysis, HiV-uninfected cases differed from 
controls for many factors evaluated, including black race, some 
markers of poverty and intense exposure (Table 1). On multivari-
able analysis, siblings <5 years old, underlying medical conditions, 
preceding upper respiratory tract infections (UrTis), day-care 
attendance and HiV exposure were all associated with increased 
odds of all-serotype iPD compared with controls. Belonging to a 
household with a car or having received 2 or more doses of PCV-7 
resulted in decreased odds for all-serotype disease (Table 1). When 
we restricted our analysis to the ward control group, the results did 
not change (data not shown).
VT and NVT IPD
The analyses in HiV-uninfected children included 64 cases 
of VT iPD and 128 of nVT iPD. For VT iPD, on univariate analysis 
only, black race, previous admission in the last 12 months and cot-
rimoxazole prophylaxis use were more likely in cases than controls 
(data not shown). On multivariable analysis, lacking a flushable toilet 
and HiV exposure were associated with increased odds of having VT 
iPD, while male sex and receiving 2 or more doses of PCV-7 resulted 
in decreased odds in cases compared with controls (Table 2).
On univariate analysis, when stratified by vaccination status, 
vaccinated cases with VT iPD were more likely to have a wood fire in 
the home, malnutrition and previous admission than controls, while 
no additional variables were identified in unvaccinated cases (data 
not shown). On multivariable analysis, HiV exposure was associated 
with VT iPD [odds ratio (Or) 3.82] in vaccinated cases, while among 
unvaccinated cases having an underlying condition (Or 10.11) or 
HiV exposure (Or 8.80) was associated with VT iPD (Table 3).
TABLE 1. Univariate and Multivariable Analysis of Risk Factors for All-serotype IPD Among HIV-uninfected 
Children, South Africa, 2010–2012
Characteristics
HIV-uninfected  
Univariate Analysis*
HIV-uninfected  
Multivariable Analysis†
Cases
n/N (%)
Controls
n/N (%) OR (95% CI) P Value OR (95% CI) P Value
Demographics
  Black race 214/237 (90.3) 771/926 (83.3) 2.07 (1.22–3.50) 0.007
  Primary caregiver education level
   No secondary schooling
   Some secondary schooling
Completed secondary 
schooling
39/231 (16.9)
133/231 (57.6)  
59/231 (25.5)
127/926 (13.7) 
503/926 (54.3) 
296/926 (32.0)
Ref.
0.84 (0.54–1.30)
0.57 (0.35–0.93)
0.03
Socioeconomic characteristics
  Number of siblings <5 years of age‡
   0
   ≥1
106/230 (46.1)  
124/230 (53.9)
546/926 (59.0)  
380/926 (41.0)
Ref.
1.65 (1.22–2.24)
0.001 Ref.
1.69 (1.16–2.46)
0.007
  Wood fire in home 20/234 (8.6) 48/928 (5.2) 2.60 (1.20–5.65) 0.02
Underlying health conditions
 Underlying conditions§ 
excluding malnutrition
44/237 (18.6) 127/928 (13.7) 1.35 (0.91–2.00) 0.14 1.99 (1.22–3.22) 0.005
 Child had URTI (in  
reference period¶)
110/233 (47.2) 340/928 (36.6) 1.82 (1.30–2.54) 0.001 1.79 (1.19–2.69) 0.005
 Received antibiotic  
treatment in reference 
period
41/234 (17.5) 121/922 (13.1) 1.68 (1.11–2.55) 0.01
 Previous hospital  
admission last 12 months
66/235 (28.1) 189/928 (20.4) 1.65 (1.17–2.33) 0.005
 Day-care attendance  
(in reference period¶)
49/233 (21.0) 143/927 (15.4) 1.53 (1.05–2.24) 0.03 1.58 (1.01–2.47) 0.04
  HIV exposure 101/229 (44.1) 271/897 (30.2) 1.92 (1.40–2.63) <0.001 1.62 (1.10–2.37) 0.01
  Household has a car 28/237 (11.8) 171/928 (18.4) 0.57 (0.36–0.90) 0.02 0.45 (0.25–0.83) 0.01
Vaccination
 Received ≥3 DTP doses  
for children ≥16 weeks║
106/187 (56.7) 504/752 (67.0) 0.61 (0.41–0.90) 0.01
 Received ≥2 PCV doses  
for children ≥16 weeks║
110/187 (58.8) 509/752 (67.7) 0.67 (0.46–0.97) 0.03 0.67 (0.46–0.99) 0.05
DTP indicates diphtheria–tetanus toxoids–pertussis.
*Factors not significant on univariate analysis (>0.05) not shown (male sex, living in informal residence, building material of residence, flush toilet, crowding, smoke exposure, 
malnutrition, low birth weight, preterm birth, had ear infection in last 12 months, household member had URTI, breastfed in reference period, diagnosed with tuberculosis in 3 
months prior to reference period, received ≥3 Hep B doses for children ≥16 weeks, received influenza vaccine within last year). 
†Only factors significant on multivariable analysis shown in table.
‡Siblings: there were only 42 children in the >2 sibling group so this was combined with the ≥1 group.
§Underlying conditions included sickle cell disease, chronic kidney disease, cardiac disease, immunodeficiency conditions, chronic liver disease, asthma, neuromuscular diseases, 
connective tissue diseases, cancer, bone marrow or organ transplant, metabolic disease, chromosomal conditions, history of head injury/head surgery, hydrocephalus with ventriculo-
peritoneal shunt, burns requiring hospitalization, measles in the last month, any other chronic illness.
¶Reference period is the 1 month preceding the case pneumococcal specimen collection date.
║Only children ≥16 weeks included in the model.
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results of the analysis of factors associated with nVT 
iPD were similar to those from the analysis of all-serotype iPD 
(Table 4). On univariate analysis only, factors that differed between 
HiV-uninfected cases and controls included being admitted in the 
last year, having received antibiotics or having a car in the house-
hold. as with all-serotype disease, on multivariable analysis, hav-
ing siblings <5 years old, preceding UrTi and HiV exposure were 
2 times more common among cases with nVT iPD than among 
controls. in addition, having a wood fire in the home was also asso-
ciated with nVT disease (Table 4).
Penicillin Nonsusceptible All-serotype IPD
On univariate analysis only, having a preceding UrTi, or 
having received PCV-7 or antibiotics, was associated with penicil-
lin-non-susceptible iPD in HiV-uninfected cases. On multivariable 
analysis, factors associated with penicillin nonsusceptible all-sero-
type iPD in HiV-uninfected cases were black race, previous hospi-
tal admission in the last year, HiV exposure and day-care attend-
ance in the reference period (Table 5).
Factors Associated With IPD in HIV-infected 
Children
All-serotype IPD
Factors associated with iPD in HiV-infected cases differed 
from those factors that were identified as significant in HiV-unin-
fected cases (Table 6). On univariate analysis only, HiV-infected 
cases differed from controls for a number of factors, including having 
received antibiotics, HiV stage, CD4 count and attending HiV clinic. 
On multivariate analysis, being diagnosed with tuberculosis in the last 
3 months, preceding UrTi and the presence of malnutrition increased 
the odds of all-serotype disease in cases compared with controls. 
Using antiretroviral treatment (arT) decreased the odds of all-sero-
type iPD (Table 6). When we restricted our analysis to either ward or 
clinic control groups, the results did not change (data not shown). We 
also evaluated HiV stage and CD4 count as potential effect modifiers, 
but no statistically significant interactions were identified.
VT IPD and NVT IPD
The analysis included 46 cases of VT iPD and 49 of nVT 
iPD in HiV-infected children. For VT iPD, on univariate analysis 
only, caregiver education, previous admission in the last 12 months, 
UrTi and antibiotic use were more likely in cases than controls 
(data not shown). On multivariable analysis, the factors associated 
with VT iPD in HiV-infected cases were similar to those for all-
serotype iPD, namely having malnutrition, being diagnosed with 
tuberculosis in the 3 months prior to the reference period and use of 
arT in the reference period (Table 7).
When stratified by vaccination status, on univariate analysis, 
vaccinated cases with VT iPD were more likely to be malnourished, 
have been previously admitted, have an underlying condition and 
have a mother who was educated, compared with controls. On mul-
tivariable analysis only preceding UrTi and use of arT were asso-
ciated with HiV-infected vaccinated cases with VT iPD (n = 27) 
(Table 8). no risk factors were identified in the HiV-infected unvac-
cinated group (n = 6) on univariate or multivariable analysis, likely 
as a result of low numbers.
Similar factors were also associated with enhanced or 
reduced odds of nVT iPD in HiV-infected cases as compared with 
all-serotype iPD (Table 9). Having malnutrition was only signifi-
cant on univariate analysis.
Penicillin Nonsusceptible, All-serotype IPD
The factors associated with iPD caused by penicillin nonsus-
ceptible strains were the same as those identified for iPD caused by all 
serotypes, with similar Ors (Table 10). Use of arT was associated 
with lower odds of iPD with a penicillin nonsusceptible isolate [Or 
0.08 (95% Ci: 0.02–0.40)]. Previous antibiotic use, day-care attend-
ance and HiV stage were not significantly associated with penicillin 
nonsusceptible iPD in cases on multivariable modeling (Table 10).
DISCUSSION
This study demonstrated that, in the era of programs to 
prevent HiV transmission to newborns and arT, HiV still plays 
TABLE 2. Factors Significantly Associated with IPD on Multivariable Analysis Among HIV-uninfected Children: Risk 
Factors for VT IPD
Characteristics
Cases
n/N (%)
Controls
n/N (%)
Multivariable Analysis*
OR (95% CI) P Value
Male sex 25/64 (39.1) 143/255 (56.1) 0.30 (0.13–0.69) 0.005
No flush toilet in residence 28/63 (44.4) 90/255 (35.3) 3.33 (1.29–8.57) 0.01
HIV exposure 32/62 (51.6) 78/249 (31.3) 3.05 (1.30–7.14) 0.01
Received ≥2 doses of PCV (≥16 weeks of age)† 17/48 (35.4) 123/194 (63.4) 0.16 (0.07–0.40) <0.001
*Only factors significant on multivariable analysis shown in table.
†Only children ≥16 weeks included in model.
TABLE 3. Factors Significantly Associated with IPD on Multivariable Analysis Among HIV-uninfected Children: Risk 
Factors for VT IPD Stratified by Vaccination Status*
Unvaccinated (Number of Cases = 14) Vaccinated (Number of Cases = 17)
OR 95% CI P Value OR 95% CI P Value
Underlying conditions† (excluding 
malnutrition)
10.11 1.20–85.33 0.03 1.13 0.27–4.67 0.87
HIV exposure 8.80 1.23–62.94 0.03 3.82 1.21–12.04 0.02
*Includes contrast statement for vaccination status.
†Underlying conditions included sickle cell disease, chronic kidney disease, cardiac disease, immunodeficiency conditions, chronic liver disease, asthma, neuromuscular diseases, 
connective tissue diseases, cancer, bone marrow or organ transplant, metabolic disease, chromosomal conditions, history of head injury/head surgery, hydrocephalus with ventriculo-
peritoneal shunt, burns requiring hospitalization, measles in the last month, any other chronic illness.
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TABLE 4. Factors Significantly Associated with IPD on Multivariable Analysis Among HIV-uninfected Children: Risk 
Factors for NVT IPD
Characteristics
Cases
n/N (%)
Controls
n/N (%)
Multivariable Analysis*
OR (95% CI) P Value
  Number of siblings <5 years of age†
   0
   ≥1
56/126 (44.4)
70/126 (55.6)
302/488 (61.9)
186/488 (38.1)
Ref.
2.01 (1.29–3.15)
0.002
   Wood fire in home 9/127 (7.1) 16/488 (3.3)  4.99 (1.31–18.96) 0.02
   Had URTI (in reference period‡) 55/127 (43.3) 153/488 (31.4) 1.81 (1.10–2.96) 0.02
   HIV exposure 55/124 (44.4) 141/470 (30.0) 1.96 (1.25–3.07) 0.003
*Only factors significant on multivariable analysis shown in table.
†Siblings: There were only 26 children in the >2 sibling group so this was combined with the ≥1 group.
‡Reference period is the 1 month preceding the pneumococcal specimen collection date.
TABLE 5. Factors Significantly Associated with IPD on Multivariable Analysis Among HIV-uninfected Children: Risk 
Factors for Penicillin-resistant, All-serotype IPD
Characteristics
Cases
n/N (%)
Controls
n/N (%)
Multivariable analysis*
OR (95% CI) P Value
Black race 92/100 (92.0) 326/402 (81.1) 3.04 (1.16–8.00) 0.02
Previous hospital admission in last 12 months 28/98 (28.6) 78/402 (19.4) 2.11 (1.14–3.88) 0.02
Day-care attendance 24/98 (24.5) 54/402 (13.4) 1.91 (1.00–3.66) 0.05
HIV exposure 44/93 (47.3) 111/388 (28.6) 2.14 (1.27–3.62) 0.004
*Only factors significant on multivariable analysis shown in table.
TABLE 6. Univariate and Multivariable Analysis of Risk Factors For All-serotype IPD Among HIV-infected Children, 
South Africa, 2010–2012
Characteristics
HIV-infected  
Univariate Analysis*
HIV-infected  
Multivariable Analysis†
Cases
n/N (%)
Controls
n/N (%) OR (95% CI) P Value OR (95% CI) P Value
Underlying health conditions
  Malnutrition‡ (in reference period§) 79/120 (65.8) 124/325 (38.2) 3.23 (1.95–5.34) <0.001 2.68 (1.40–5.14) 0.003
  Child had URTI (in reference period§) 72/120 (60.0) 130/385 (33.8) 3.35 (2.03–5.53) <0.001 3.49 (1.73–7.03) <0.001
 Received antibiotic treatment in 
reference period§
26/120 (21.7) 44/394 (11.2) 2.08 (1.15–3.76) 0.02
  Breast-fed (in reference period§) 40/122 (32.8) 56/393 (14.3) 3.35 (1.91–5.86) <0.001
 Received cotrimoxazole prophylaxis in 
last 3 months
56/121 (46.3) 232/391 (59.3) 0.62 (0.39–0.98) 0.04
 Diagnosed with tuberculosis in 3 
months prior to reference period§
22/122 (18.0) 45/382 (11.8) 1.90 (1.03–3.51) 0.04 5.12 (1.69–15.50) 0.004
  ART use (in reference period§) 22/113 (19.5) 119/306 (38.9) 0.34 (0.19–0.65) 0.001 0.13 (0.05–0.38) <0.001
  HIV stage
   Stage 1
   Stage 2
   Stage 3
   Stage 4
10/119 (8.4)
6/119 (5.0)  
41/119 (34.5)
62/119 (52.1)
59/372 (15.9)
20/372 (5.4)
165/372 (44.4)  
128/372 (34.4)
Ref.
1.39 (0.41–4.66)
1.45 (0.64–3.31)
3.28 (1.44–7.43)
0.002
  Severe immunosuppression¶ 68/86 (79.1) 201/329 (61.1) 2.28 (1.23–4.22) 0.008
  Regular attendance at HIV clinic║ 23/118 (19.5) 208/383 (54.3) 0.14 (0.07–0.27) <0.001
Vaccination
 Received ≥3 DTP doses for children 
≥16 weeks
67/109 (61.5) 264/347 (76.1) 0.50 (0.30–0.85) 0.01
*Factors not significant on univariate analysis (>0.05) not shown (male sex, black race, living in informal residence, building material of residence, flush toilet, crowding, caregiver 
education level, number of siblings, smoke exposure, wood fire in the home, underlying conditions, low birth weight, preterm birth, had ear infection in last 12 months, household 
member had URTI, previous hospital admission in last 12 months, day-care attendance in reference period, household had electricity, received ≥3 Hep B doses for children ≥16 weeks, 
received ≥3 PCV doses for children ≥16 weeks, received influenza vaccine within last year).
†Only factors significant on multivariable analysis shown in table.
‡Malnutrition was classified as children with weight-for-age Z score <−2 (World Health Organization child growth standards 2009) and/or children with nutritional edema.
§Reference period is the 1 month preceding the pneumococcal specimen collection date.
¶Presence of severe immunosuppression defined as CD4% of total lymphocytes <30% for children <12 months, <25% for children 12–35 months and <20% for children 36–59 
months of age.
║Regular HIV clinic attendance defined as >2 visits in the last year.
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an important role in the risk of pneumococcal disease. among 
HiV-uninfected children, HiV exposure was associated with an 
increased risk of iPD for all endpoints, and in HiV-infected chil-
dren, risk factors for iPD were related to conditions suggesting 
more severe HiV disease, such as malnutrition16 and recent tuber-
culosis diagnosis.17 arT treatment, which is critical for maintain-
ing the health of HiV-infected children, decreased the odds of iPD, 
likely by improving the immune system and therefore reducing the 
risk of opportunistic infections.18 Unfortunately, due to the small 
numbers of HiV-infected children in our study, we could not show 
a difference in this group by degree of immunosuppression.12
although the numbers of HiV-exposed children who are 
infected annually continue to drop due to improvements in preven-
tion of mother to child transmission programs, more can still be 
done for HiV-infected and HEU children. HiV-infected children 
need to be identified as soon as possible, before they become ill, 
and be started on arT according to the current treatment guide-
line.19 HiV exposure has not been previously described as a risk 
factor for iPD. One US study did not find a difference in iPD risk 
between HEU children (n = 128) and an HiV-uninfected-unexposed 
(n = 71) control group, but the sample size was small.20 neonates 
born to HiV-infected mothers have lower levels of pneumococcal 
TABLE 7. Risk Factors for IPD on Multivariable Analysis Among HIV-infected Children: Risk Factors for VT IPD
Characteristics
Cases
n/N (%)
Controls
n/N (%)
Multivariable Analysis*
OR (95% CI) P Value
Malnutrition† (in reference period‡) 34/45 (75.6) 58/131 (44.3) 4.86 (1.25–18.86) 0.02
Diagnosed with tuberculosis in 3 months prior to reference period‡ 8/46 (17.4) 19/143 (13.3) 38.10 (2.68–541.76) 0.007
ART use (in reference period‡) 8/41 (19.5) 41/106 (38.7) 0.04 (0.003–0.46) 0.01
*Only factors significant on multivariable analysis shown in table.
†Malnutrition classified as children with weight-for-age Z score <−2 (World Health Organization child growth standards 2009) and/or children with nutritional edema.
‡Reference period is the 1 month preceding the pneumococcal specimen collection date.
TABLE 8. Risk Factors for IPD on Multivariable Analysis Among HIV-infected Children: Risk Factors for VT IPD 
Stratified by Vaccination Status*
Unvaccinated (Number of Cases = 6) Vaccinated (Number of Cases = 27)
OR 95% CI P Value OR 95% CI P Value
Child had URTI (in reference period†) 9.60 0.51–181.49 0.13 5.94 1.20–29.32 0.03
ART use (in reference period†) <0.001 Not calculated 0.99 0.14 0.02–0.88 0.04
*Includes contrast statement for vaccination status.
†Reference period is the 1 month preceding the pneumococcal specimen collection date.
TABLE 9. Risk Factors for IPD on Multivariable Analysis Among HIV-infected Children: Risk Factors for NVT IPD
Characteristics
Cases
n/N (%)
Controls
n/N (%)
Multivariable Analysis*
OR (95% CI) P Value
Diagnosed with tuberculosis in 3 months prior to reference period† 10/49 (20.4) 13/156 (8.3) 5.00 (1.44–17.43) 0.01
Child had URTI (in reference period)† 27/49 (55.1) 50/161 (31.1) 2.86 (1.24- 6.57) 0.01
HIV clinic attendance 8/48 (16.7) 72/159 (45.3) 0.13 (0.04–0.39) <0.001
*Only factors significant on multivariable analysis shown in table.
†Reference period is the 1 month preceding the pneumococcal specimen collection date.
TABLE 10. Risk Factors for IPD on Multivariable Analysis Among HIV-infected Children: Risk Factors for Penicillin-
resistant All-serotype IPD
Characteristics
Cases
n/N (%)
Controls
n/N (%)
Multivariable Analysis*
OR (95% CI) P Value
Malnutrition† (in reference period‡) 49/69 (71.0) 82/205 (40.0) 2.79 (1.17–6.68) 0.02
Diagnosed with tuberculosis in 3 months prior to reference period‡ 13/72 (18.1) 30/235 (12.8) 6.46 (1.30–32.0) 0.02
Child had URTI (in reference period‡) 45/72 (62.5) 86/232 (37.1) 4.32 (1.50–12.46) 0.007
ART use (in reference period‡) 12/65 (18.5) 74/178 (41.6) 0.08 (0.02–0.40) 0.002
*Only factors significant on multivariable analysis shown in table.
†Malnutrition classified as children with weight-for-age Z score <−2 (World Health Organization child growth standards 2009) and/or children with nutritional edema.
‡Reference period is the 1 month preceding the pneumococcal specimen collection date.
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antibodies.21 Compared with HiV-unexposed children, HEU chil-
dren have an increased risk of severe infections requiring hospitali-
zation,6 with higher odds of treatment failure and worse outcome.22 
The predisposition of HEU children to infections and their worse 
outcome is multifactorial, with factors including environmental 
conditions, feeding practices and an impaired innate immune sys-
tem all playing a role.23 This risk of invasive disease in HEU chil-
dren may persist despite vaccination, possibly due to subtle differ-
ences in qualitative antibody responses to PCV.24
in this study, factors associated with all-serotype iPD in 
HiV-uninfected children were comparable with traditional risk fac-
tors described from other countries with low HiV prevalence. The 
presence of young siblings in the household has been associated 
with disease risk, likely because children commonly carry pneu-
mococci due to a lack of serotype-specific protective antibodies, 
with the highest incidence of carriage observed during the first 2 
years of life.25 likewise, a strong association has been previously 
demonstrated between day-care attendance and pneumococcal 
infections due to crowding of young children with high levels of 
nasopharyngeal carriage.10 Underlying medical conditions are also 
well documented as risk factors for iPD.10 Vaccination with PCV26 
and improved socioeconomic status27 are associated with a reduced 
risk of pneumococcal disease. in our study, having a car, reflective 
of a higher socioeconomic status, was associated with decreased 
odds, while lacking a flush toilet, reflective of a lower socioeco-
nomic status, was associated with a higher odds of disease.
in this study, females were at increased odds for VT iPD 
among HiV-uninfected children. This is in contrast to other stud-
ies in children <5 years, which have found males to be at an 
increased risk of disease.28 The reasons for this association in our 
data are unclear. There is some evidence to suggest that the ratio 
of male:female infection varies with serotype, but sex is unlikely 
to have a significant influence on the risk of iPD with a particular 
serotype.28 in HiV-uninfected children, we identified previous hos-
pital admissions as a factor associated with penicillin nonsuscep-
tible disease; hospital admissions are often associated with antibi-
otic therapy, which affects the carriage rates of antibiotic-resistant 
strains.10,29 Having a wood fire in the home exposes children to 
particulate respiratory material, which increases the risk of acute 
respiratory tract infections.11 HiV-uninfected children who were 
of black race, possibly with lower socioeconomic status, and who 
attended day care had higher rates of antibiotic-resistant disease. 
This was possibly due to overcrowding, which facilitates respira-
tory transmission of pneumococci and additional increased anti-
biotic exposure.29 Malnourished HiV-infected children and those 
treated for tuberculosis are more likely to be admitted and exposed 
to antibiotic treatment, which increases their risk of antibiotic-
resistant disease.
recent UrTis were found to be a risk factor for iPD in both 
HiV-infected and HiV-uninfected children. While the information 
we collected on preceding UrTis was reported from parents rather 
than directly measured and therefore may be inaccurate, preceding 
upper respiratory tract viral infections have been demonstrated to 
increase susceptibility to bacterial illness. reasons for an increase 
in susceptibility to pneumococcal pneumonia following influenza 
infection30 include local respiratory epithelium changes enhanc-
ing pneumococcal invasion in colonized individuals,31 a decrease 
in mucociliary clearance and increased inflammatory responses.32
Studies from the United States reported a change in the 
factors associated with iPD following the introduction of PCV, 
with reductions in excess risk among traditional risk groups such 
as black children9,33 and day-care attendees.9 in contrast, chil-
dren with underlying conditions9,34 still remained at risk for iPD 
despite the widespread availability of PCV and the targeting of 
high risk groups for receipt of vaccination. in our study among 
HiV-uninfected unvaccinated children (n = 14), underlying condi-
tions and HiV exposure were associated with VT disease, while 
among HiV-uninfected vaccinated children (n = 17), HiV exposure 
was a risk for VT disease.
The limitations of our study include the use of controls that 
were either hospitalized or presenting to hospital outpatient depart-
ments. This choice of control group was for logistical reasons as 
study staff members were based at hospital sites and not able to 
recruit directly from the cases’ communities. if the observed preva-
lence of possible iPD risk factors were different in the control group 
than in the general population from which the cases came, then we 
may have missed some potential risk factors and overestimated oth-
ers. The majority of HiV-uninfected controls were hospitalized and 
the most common diagnoses were acute gastroenteritis and malnu-
trition. This could have masked a possible role of malnutrition as 
a risk factor for iPD in HiV-uninfected children. HiV exposure is 
a risk factor for other causes of hospitalization23 and we expected 
HiV exposure prevalence in our controls to be higher than in the 
general population. in fact, the HiV exposure prevalence among 
our control group (30.3%) was similar to the national reported per-
centage of infants exposed to HiV [32.2% (95% Ci: 30.7–33.6%)] 
in 2011.4 The advantage of using hospital controls is that their 
health-seeking behavior is likely similar to hospitalized iPD cases.
We conclude that healthcare workers should promote pneu-
mococcal vaccination in high risk groups like HEU children at rou-
tine health visits and, if doses are missed, provide catch-up vaccina-
tion at outpatient visits or when hospitalized.
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APPENDIX D: RESPONSES TO EXAMINERS’ COMMENTS: 
Responses and changes in blue text 
 
EXAMINER'S REPORT 1: 
 
The main concerns with the PhD thesis are mainly in the following areas: 
1) Justification for the study outcomes was weak in a number of places: 
I have indicated below suggested areas where the justification for the studies needs to be 
strengthened: 
a) The importance of identifying Serotype 1 outbreaks is not clear in the thesis. 
Section added to justification on page 21: 
There is conflicting data regarding whether PCV13 will result in a reduction in serotype 1 
disease and in view of its epidemic nature ongoing surveillance is important. 
Section added to page 34 and 35: 
The PCV13 vaccine has been found to induce antibodies against the serotype 1 capsule in 
children; however in two clinical trials from The Gambia and South Africa using PCV9, 
protection could not be demonstrated against serotype 1 clinical disease, although case 
numbers were small (Madhi2007,Saaka2008). In addition these two trials, which used three 
infant vaccine doses only, showed that serotype 1 vaccine failures occurred after 12 months 
of age (Klugman 2011). It was suggested that a booster dose may be necessary for protection 
against this serotype. As mentioned, the serotype 1 capsular polysaccharide is particularly 
resistant to opsonisation and it is uncertain whether protein-conjugate vaccination will be as 
effective against serotype 1 disease as against other serotypes.  
In the United Kingdom PCV13 was introduced in April 2010 in a 2+1 schedule. Annual 
serotype specific incidence rates showed a significant reduction in serotype 1 rates between 
2008-2010 and 2013-2014 in all age groups (Waight 2015). An indirect cohort study, 
including data up to 3.5 years after PCV13 introduction, showed protection against serotype 1 
with a vaccine effectiveness of 84% (95% CI 54-95) (Andrews2014).  
In South Africa a case control study demonstrated a high vaccine effectiveness point estimate 
against serotype 1 (89% [95% CI -82-100]) although the results were not statistically 
significant (Cohen 2016, submitted).  
As ST1 is an outbreak serotype with fluctuating annual cases it is important for surveillance 
programmes to monitor for increasing case numbers. The main aim of monitoring for 
outbreaks would be to determine if there are any modifiable risk factors or public health 
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changes which could be made to stop the spread of the outbreak. In addition it is important to 
determine if new serotype 1 clones are emerging as these may have different characteristics 
in terms of antibiotic resistance.     
Following the introduction of PCV13 it is assumed that serotype 1 case numbers will 
decrease although previous studies showed differing results. Our study only included data on 
ST1 up to 2 years post-PCV13 introduction. It is important to continue to monitor trends in 
outbreak prone serotypes included in PCV13 to document whether there is indeed a sustained 
reduction in these serotypes. 
 
b) The reason for identifying risk factors for pneumococcal disease. 
Added to justification on page 21: 
The identification of risk groups guides policy makers with regards to allocation of resources 
and clinical management by alerting clinicians to who may present with pneumococcal 
disease and who to treat empirically. 
Section added to page 41: 
We only had breastfeeding data for <40% of all cases and could therefore not make definite 
conclusions regarding its role as a risk factor in our population. In other studies, however, 
breastfeeding has been shown to be protective against IPD and mortality and should be 
advocated for to improve child health. HI infants who were malnourished were more likely to 
die from IPD. Improving the nutritional status of HI infants and ensuring they receive 
appropriate ART is a key part of management.  
 
c) The importance of understanding scale of serotype replacement (Page 18) - not clear what 
the implications are. 
Page 18: With the expanded use of PCV globally it is important to estimate the scale of 
serotype replacement to determine the net decline in disease and the overall benefit of 
vaccination. The magnitude of the increase in non-vaccine serotypes varies between different 
settings and is depended on host and S.pneumoniae population level characteristics.     
Page 20: There is a possibility that serotype replacement could substantially reduce the 
impact and benefits of vaccines. Replacement serotypes could be associated with antibiotic 
resistance. The amount of replacement thus far, especially with PCV13 use (which covers 
serotype 19A) is small in comparison to the overall reduction in disease. However there is a 
need for broader valency vaccines, universal vaccines and adequate surveillance (Feikin 
2013). 
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d) Justification section: needs to be strengthened to explain why it is necessary to describe 
the changes in serotypes or the risk factors for IPD 
Information added on page 21 as highlighted above in 1a and 1b. 
 
2) Interpretation of findings and recommendations from the work. There is generally a lack 
of further interpretation of findings and synthesis to determine issues arising from the work 
that would require in changes in clinical management, recommendations for guidelines or 
recommendations for further research and development in the field. I have indicated below 
suggested areas where the justification for synthesis of findings and further interpretation 
would be required: 
a) Page 34 & 36, includes detail of risk factors identified in other studies- this should have 
been covered in the literature review- also it is more important to do the comparison rather 
than state the risk factors. 
Results from other studies, “A number of factors have been proposed to contribute to the poor 
health and nutrition among HEU children: lack of parental care, infant feeding practices, 
immune abnormalities, exposure to other infections and antiretroviral drugs (Filteau 2009)” 
were moved from page 36 to the introduction (page 9). 
The comparison of risk factors with our study has been highlighted on page 38: “In our study 
these risk factors included, day care attendance which may increase IPD risk due to crowding 
which aids in transmission of pneumococci and higher pneumococcal loads, mixing of 
children with different pneumococci and possible cessation of breastfeeding (Levine 1999); 
living with siblings less than 5 years of age due to high rates of pneumococcal carriage 
(Abdullahi 2012), underlying medical conditions (Levine 1999), poor socioeconomic 
conditions which are often associated with crowding and different odds in different race 
groups and by sex.    
 
b)  In the conclusion one can indicate what kinds of interventions are recommended based on 
the risk factor analysis - mention socio-economic factors as you did in the abstract 
Page 41: Details regarding breastfeeding and malnutrition as risk factors are highlighted in 
the responses to question 1b. 
Page 42: Sentence added:  
In HU children, traditional risk factors such as poor socio-economic conditions and intense 
exposure to infection need to be addressed to reduce the burden of disease in these children. 
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c) What are the other conclusions- should there be a change in the vaccine, what kind of 
surveillance should be continued, what other questions arise from the work. 
Page 42: Laboratory-based IPD surveillance should continue unchanged to allow for 
measurement against the baseline. In addition documentation of nasopharyngeal carriage at 
defined points in time may assist with prediction of which serotypes will become most 
prominent in the post-PCV13 period. Although vaccine-serotypes continue to decrease 
globally following PCV13 introduction, some increases in non-vaccine serotypes have been 
observed. There is a limit on the number of serotypes that can be conjugated in one vaccine 
and replacement non-PCV13 serotypes vary across different countries. New universal 
protein-based vaccines are therefore in development. 
 
3) Scientific writing: a number of issues regarding the presentation of the studies especially 
in the integrative narrative were encountered, and these as well as recommendations are 
summarised below: 
a) The use of abbreviations without expansion prior to their use. A glossary of abbreviations 
was not provided and is recommended. e.g. VT-IPD and NPNM on page 2. 
A list of abbreviations has been added on page ix  
All abbreviations were described in full the first time they were used.  
 
b) Use of abbreviations should be consistent- in the pages 12 and 13- you refer to VE 
interchangeably as being vaccine efficacy and vaccine effectiveness 
This has been corrected. VE now refers to vaccine efficacy and vaccine effectiveness has 
been written out in full.  
 
c)  The flow of the integrated narrative was at times difficult to follow. 
e.g Page 1 -1st paragraph under "Burden of pneumococcal disease"- it seems it would be 
better to describe the problem of pneumococcal disease, as well as the reason for determining 
burden prior to describing all the methods for determining burden of disease. 
The paragraph has been rearranged. The description of methods has been moved to the end of 
the section.  
 
e.g. Page 6- paragraph on the serotype 1 capsule. It is not clear why this is mentioned and 
what the significance of the capsule is. 
5 
 
Details regarding the importance of the serotype 1 capsule have been added on page 6: 
The serotype 1 capsule has been shown to be more resistant to opsonisation and complement 
deposition than other serotypes, except for serotype 5; as such it is thought that the serotype 1 
capsule may function in a different way to other serotypes resulting in a difference in 
virulence. There were also differences in pneumolysin in some serotype 1 isolates, which also 
impacts colonisation and virulence. The zwitterionic polysaccharide capsule has been found 
to be related to abscess formation in animal models and thus cause empyema.  
 
e.g. Page 7- the literature on risk factors is not clear and easy to follow. It should be clearly 
stated whether findings are of HIV-infected or HIV-uninfected children, in the pre- or post 
PCV-7 vaccine era. 
Additions have been made to the risk factor section on page 7 to try and clarify which groups 
and periods the risk factors are relevant to: 
Local studies showed a significant higher risk of IPD in HIV-infected children (41-fold) with 
“paediatric” pneumococcal serotypes, than –uninfected children (Madhi 2000). HIV-infected 
children in this study had high rates of malnutrition and underlying tuberculosis. HIV-
uninfected children had underlying infections, like chronic liver and renal disease. Other 
studies from the US also showed that a higher risk of pneumococcal disease with HIV was in 
the pre-ART era. In contrast in HIV-uninfected children with IPD in South Africa had 
underlying infections, like chronic liver and renal disease in the pre-vaccine era.  
Also in the pre-vaccine era a case-control study in children <5 years of age in The Gambia 
showed…. 
 
e.g. Page 34 -limitations for interpreting surveillance data- seems to be relevant to all the 
studies and should be maybe in the discussion section rather than directly linked to one study. 
A general discussion of the limitations of surveillance data has been added on page 28: 
“Surveillance data was used as the baseline for most of our studies. There are inherent 
limitations in the use of surveillance data. Our laboratory-based surveillance programme 
underestimates the full burden of pneumococcal disease as it only includes patients who 
present to healthcare facilities and have samples taken; we aimed to address this in our 
burden model (paper I). There is often missing data associated with the use of surveillance 
programmes; we assumed that data were missing at random and imputed values for serotype 
for trend analyses. Interventions other than vaccination, for example PMTCT and ART, 
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impact IPD disease trends. It is often difficult to tease out the proportional contribution of all 
these strategies on disease reduction using surveillance data.”  
Results and discussion were combined for each study. Even though surveillance data 
limitations were applicable to all the studies, specific points were abstracted from each study 
to highlight their specific issues. For the burden paper (paper 1) the focus was on the issues 
related to burden calculations, for the risk factor paper (paper 4) issues related to case control 
studies were discussed, while for the serotype 1 paper (paper 2) considerations related to 
interpretation of cluster results were covered. Issues related to surveillance results were 
therefore explored with regards to HIV-exposed children who were discussed in the HIV-
exposure (paper 3) and risk factor paper (paper 4).   
 
c) Inconsistency in how data are presented that hinders the flow: e.g. when describing in 
pneumococcal vaccines on page 4, it is not clear when the vaccine was introduced in South 
Africa. 
The section “Pneumococcal Serotypes and Vaccines” on page 4 aimed to give a general 
overview of vaccines and serotypes globally. The first introduction date of PCV into South 
Africa is discussed on page 3 “South Africa was the first African country to introduced PCV 
into its public National Immunisation Programme in April 2009…”  
The reference to serotype 1 in South Africa on page 4 (“Serotype 1 was found to be an 
important cause of disease among older children and among HU children in the pre-PCV era 
in South Africa”) has been moved to the section discussing serotype 1 on page 6 to avoid 
confusion.    
 
d) On page 26, all results should be described first and then discussion. At the end of the 
page, results are then represented- rather keep all results in the first paragraph and then 
discuss. 
The main results of the thesis are presented in the four papers. The combined result-
discussion section in the integrating narrative aimed to synthesise the main results by 
comparing them to other data. Our results are thus related to other publications throughout 
this section. 
  
4) References to common terminology in the field without explanation of what this is: e.g. 
"meningitis belt" on page 5 
Explanation has been added for meningitis belt on page 5:  
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The African meningitis belt is a region of sub-Saharan Africa, extending from Senegal to 
Ethiopia that is characterised by hyperendemic seasonal peaks of acute bacterial meningitis 
and sporadic epidemics.  
 
5) Other issues identified (optional to address): 
a) In the abstract, the conclusion is not aligned to what is shown in the results of the abstract 
and some of the aspects mentioned are not even included in the discussion of the thesis. 
The abstract outlines the most important findings from the four manuscripts included in the 
thesis. Additions have been made to the result section to ensure that all points raised in the 
conclusion have been discussed in the abstract: 
In the pre-vaccine era (2005-2008) in South Africa, roughly 196,100 (148,000-251,000) cases 
of severe pneumococcal disease were estimated annually in children aged <5 years, an 
incidence of 3799/100,000; the rate was reduced by 67% in 2013, likely due to PCV and 
other interventions. In addition 8600 (7000-10220) pneumococcal-related annual deaths were 
estimated pre-vaccine and 3600 in 2013, a rate difference of 99/100,000 child-years.  
Over an 11-year period two clusters (2003-2004 and 2008-2012) of serotype 1 infection were 
detected in all age groups with reductions in incidence noted in 2013. 
 
b)  The importance of serotype 1 outbreaks is not clear in the thesis. The literature and data 
are adequately described but the reader is not informed on why it is important to know about 
outbreak serotypes. 
Details regarding the importance of serotype 1 and outbreaks have been added to page 34-35 
as discussed in section 1a.  
 
c) Study design- good descriptions were given in the papers about the actual surveillance 
system. How many sites involved, what information is recorded, who generally is included 
etc. these have important implications for the interpretation of your results so should be 
included in page 22 under study design. 
Additional details were added on page 25: 
Cases of IPD were considered as hospitalized individuals with S. pneumoniae cultured from 
normally sterile site specimens. The GERMS-SA programme includes over 200 
microbiological laboratories (“non-enhanced” sites) which submit isolates and basic 
demographic information (age, gender, date of specimen collection, and body fluid source of 
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isolate). Trained surveillance officers at 24 sentinel hospitals (“enhanced” sites) located in all 
nine provinces collect additional data including HIV status, discharge diagnosis and outcome. 
 
d) You mention the use of bootstrapping. Some more information about when it is usually 
used and why it is considered more accurate could be helpful (page 29). 
Additional details have been added regarding bootstrapping on pages 23 and 29:  
Page 23: Every resample has the same number of observations as the original sample, so the 
bootstrap method models the impact of the actual sample size (Fan & Wang, 1996).  
Bootstrapping allows measures of accuracy to be assigned to sample estimates, verifies 
replicability of results and allows inferences to be made regarding key parameters. 
Page 29: To account for variability and uncertainty around our estimates we used 
bootstrapping, a robust statistical method, to calculate confidence intervals.  
Bootstrapping assumes that each sample is identically and independently distributed. It draws 
many more sub-samples than other methods and provides less biased and more consistent 
results than the Jackknife method for example (Deng 2013). 
 
e) Additional analyses: Paper 1 - Figures 2a and 2b on Tornado analysis- needs further 
explanation of what a Tornado analysis is and what it is showing. 
Details regarding the use of Tornado diagrams have been added on page 24: 
Tornado diagrams were used to depict the sensitivity of the case and death estimates to 
changes in selected variables. These diagrams show the effect on the base rate by varying 
each input variable one at a time, while keeping all the other input variables at their initial 
base value. High and low values may be chosen for each input. The results are displayed as a 
bar graph with the variation for each variable from the base rate. 
 
EXAMINER'S REPORT 3: 
 
1) Methods  
a) Page 23, last paragraph: change sentence to "SatScanTM is able to detect spatial, temporal 
or spatio-temporal disease clusters and determine ... " 
Change has been made  
 
b) Page 24, second full paragraph: " ... to account for this we adjusted positively by the 
percent reduction from the pre-vaccine period". It is not clear why this was necessary for 
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detecting clusters of "cases" (i.e. serotype 1 disease) or how this was implemented 
practically. 
It was necessary to adjust controls to obtain a stable baseline by essentially removing the 
impact of PCV7 on serotypes in this group; this allowed for true increases in cases to be 
identified and not just relative case changes. 
Last sentence correct verb to "ensured". Sentence replaced by above. 
 
2) Paper 1 
a) Page 6, first paragraph: shouldn't this be "overestimation of vaccine efficacy for non-
bacteraemic pneumococcal pneumonia" as VE is 0.45 for non-bacteremic compared to 0.85 
for bacteremic pneumonia? 
To estimate the number of cases of non-bacteraemic pneumococcal pneumonia, we 
extrapolated data from PCV probe studies in South Africa by using the PCV9 vaccine 
attributable reduction (VAR) ratio of clinical pneumonia to bacteraemic pneumococcal  
pneumonia (11:1). An additional adjustment was made for the presumed underestimation of 
vaccine efficacy (VE) for non-bacteraemic pneumococcal pneumonia in this study. This 
assumption was based on a study which showed a higher pneumococcal detection rate using 
urine antigen testing in non-bacteraemic pneumonia in the elderly. The adjustment value 
(1.89) was based on the ratio of the original and inflated VE from the different studies. 
 
b) Page 6, second paragraph and page 7, second full paragraph: I assume the CRF for non-
bacteremic hospital admissions refers to admission for any disease syndrome, not just 
pneumonia. Would you expect this to lead to over- or underestimates of the non-bacteremic 
pneumonia CFR? 
A sentence has been added to the limitations section on page 13:  
For example, using a CFR for all hospitalised cases may have overestimated the CFR for 
non-bacteraemic pneumonia cases and the ratio of BPP to NBP may change by serotype 
distribution which we did not account for in our model. 
 
c) Page 9, last paragraph: add in NPNM. 
Information regarding NPNM rates have been added: 
…and 22 per 100,000 py for non-pneumonia non-meningitis pneumococcal disease (rate 
difference of 73 per 100,000, 76% reduction). 
 
10 
 
d) Page 13, second full paragraph: need to rephrase as the reductions in IPD were due to 
HAART as well as PCV. 
A sentence highlighting the fact that we did not take other interventions into account when 
exploring costs was added on page 13: “We did not account for the impact and costs of 
PMTCT and ART in these calculations.”  
 
e) Page 13, last paragraph: can you explain which assumptions may be inaccurate e.g. if the 
ratio of BPP to NBP changes by serotype distribution or HIV status.  
Details were added on page 13 regarding which assumptions may be inaccurate: 
For example, using a CFR for all hospitalised cases may have overestimated the CFR for 
non-bacteraemic pneumonia cases and the ratio of BPP to NBP may change by serotype 
distribution which we did not account for in our model. 
 
f) Page 14, first paragraph: shouldn't this be "decrease in the known vaccine efficacy" since 
VE vs. VT NBP is 0.45 compared to 0.85 for VT BPP? See comment above re: page 6. 
Perhaps I have misunderstood your point 
Page 14, first paragraph: "This study reported a higher efficacy ... " is unclear and needs to be 
rephrased. 
Page 14, last paragraph: add in "in conjunction with HAART and other interventions" to 
emphasize importance of ART. 
To address the above 3 points, changes were made to the first paragraph: 
We tried to account for this underestimate by including an adjustment for the increase in the 
known vaccine efficacy, based on more recent data, against non-bacteraemic pneumonia 
since these trials were conducted. Supporting evidence for this additional adjustment was 
seen in a recent PCV vaccine efficacy study in the elderly which used a serotype-specific 
urinary antigen detection assay to detect vaccine-type S. pneumoniae. It is possible that this 
adjustment may have overinflated our numbers as it is not clear if the magnitude of the 
difference in VE for non-bacteraemic and bacteraemic pneumonia is the same for children as 
observed in the adult study. 
 
g) Page 14: last paragraph: numbers of cases and deaths averted are "per year" and not "over 
a 5-year period" 
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The total number of cases and deaths reported were the difference between 2008 and 2013, 
thus over a 5-year period. A sentence to this effect was added on page 5: “Cases and deaths 
averted were calculated as the difference between these two periods, i.e. over 5 years.”  
 
h) Table 1a: "Adjustment factor for systematic blood culturing from South African clinical 
trial": are you assuming here that "true" BPP rates did not vary between 1998 and 2008? 
A sentence was included in the limitations section on page 13 (“In addition some estimates 
(e.g. vaccine probe study data) were only available for the pre-vaccine period and were 
assumed to be relevant to the post-PCV period”) to indicate that we used the clinical trial 
measurements for both periods which was not necessarily applicable.  
 
"Adjustment for specimen-taking practices": couldn't these differences in blood culture rates 
reflect true differences in incidence? 
A sentence has been added to the limitations section to reflect that there may be a true 
difference (page 13): “It is possible that some of the difference in incidence rates were true 
differences.” 
 
Paper 2 
I realize this paper is already published so my comments cannot be addressed in the 
manuscript, but am sharing a few thoughts nevertheless. 
Page 262, incidence estimations: There is likely to be a correlation between missing serotypes 
and antimicrobial resistance; could your assumption of randomness bias your results? 
Missing serotypes may be isolates that were not submitted by certain laboratories or non-
viable isolates due to transport issues and time delays in reaching NICD. These missing 
isolates may on occasion be non-random, for example from certain sites during certain 
periods such as outbreaks with an increased number of cases.  
There may even be an intrinsic feature of the organism that certain strains are more likely to 
autolyse than others; it has been reported that the pneumococcal capsule provides a degree of 
resistance to autolysis and this capacity varies between capsular serotypes (Kadioglu2008).  
It may be possible therefore that the difference was not completely random.  
 
It would be preferable to compare the period with clusters to the period without clusters 
rather than to the overall study period. 
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A comparison is made between the cluster period (2003-2008) and non-cluster period (2005-
2007) in the manuscript on page 264 (“Serotype 1 incidence did not differ significantly for 
2003–2008 compared with 2005–2007, when there were no clusters”) in figures 2a and 2b.  
 
Page 263, first paragraph: does the second model compare deaths (cases) to surviving patients 
(controls)? 
The second model includes only serotype 1 cases and compares surviving to non-surviving 
cases.  
 
Page 263, spatio-temporal analysis: why not look only at non-vaccine types as your control, 
to avoid the need to adjust for PCV use? 
Replacement was observed in non-vaccine type disease which would have required 
adjustment. A decision was therefore made to use all other serotypes as controls.  
 
Paper 3 
Page 1347, incidence, second paragraph: is the assumption that HIV infection and exposure 
has similar prevalence in non-enhanced sites to that in enhanced sites reasonable? Don't the 
prevalence of HIV infection and risk of HIV transmission vary across sites? 
There is likely some variation across sites, but as we had enhanced sites in each province it 
was hoped that this would account for some of the variation.  
 
Supplemental materials, page 5: can you specify the policy for cotrimoxazole prophylaxis in 
HEU and HIV-infected children? 
For all HEU infants start cotrimoxazole from 4-6 weeks of age and stop when PCR negative 
≥6 weeks after full weaning and infant is clinically HIV negative. If infant is on formula only 
cotrimoxazole can stop when PCR is negative.  
For HIV-infected infants, cotrimoxazole starts at 4-6 weeks, till child is >12 months. 
Cessation of cotrimoxazole then happens when immune reconstitution on ART occurs.  
